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Abstract 
The human immune system responds dynamically to persistent Cytomegalovirus 
(CMV) infection. Immunodeficiency following haematopoietic stem cell transplantation 
(HSCT) can lead to CMV viraemia which is an important cause of transplant-related 
morbidity and mortality. This thesis investigated the reconstitution of CMV-specific T-
cells in two cohorts of HSCT patients and studied the potential role of Tumour Necrosis 
Factor Receptor 2 (TNFR2) in regulation of CMV-specific T-cell expansion post 
HSCT. 
The first cohort included patients who participated in a randomized phase II clinical trial 
of adoptive cellular therapy for CMV-specific CD8
+
 T-cells in HSCT patients. The 
primary end point of study was reconstitution of CMV-specific CD8
+
 T-cell to 
10x10
3
/ml within 2 months post T-cell depleted matched unrelated donor HSCT. 
Reconstitution of CMV-specific CD8
+
 T-cells was monitored for up to 6 months in 17 
patients who received therapeutic T-cells and in 11 patients  who received best available  
antiviral treatment for CMV viraemia. Adoptive cellular therapy (ACT) resulted in 
earlier and greater expansion of CMV-specific CD8
+
 T cells. Within one month post 
cellular therapy, CMV-specific CD8
+ 
T-cells had greater expansion as compared to the 
control arm. Additionally, immunotherapy led to greater reconstitution of CMV-specific 
CD4
+
 and non-infused CMV-specific CD8
+
 T-cells. The number of infused therapeutic 
T-cells and circulating levels of Alemtuzumab were found as important factors 
influencing T-cell recovery after immunotherapy. 
In the second cohort of patients, reconstitution of CMV-specific CD4
+
 T-cells was 
studied using a novel HLA-class II tetramer. The aims here were to identify the 
minimum number of CD4
+
 T-cells conferring protection against CMV viraemia and 
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also, to characterise their phenotype by direct visualisation. An absolute CMV-specific 
CD4
+
 T-cell count of >0.7x10
3
/ml was found to protect from recurrent CMV 
reactivation. Approximately, one third of specific CD4
+
 T-cells were perforin and 
granzyme-B positive indicating cytotoxic potential, whilst the majority expressed T-bet 
confirming their Th1 activity. These cells were IL-2Rα negative whilst some had IL-
7Rα and the majority expressed TNFR2. Cell surface expression of CD57 molecule on 
CD4
+
 T-cells was demonstrated to be a potential universal biomarker of immune 
response to CMV infection which could be used for prediction of recurrent CMV 
viraemia in clinical practice. 
 In the final part of this PhD, the profile of cytokine receptor expression in T-cell 
subsets of healthy individuals and HSCT patients were studied. The results showed 
distinct cytokine receptor expression patterns in naïve versus memory T-cells. The most 
significant observations were: rapid decrease in expression of CD130 (gp130) (IL-6R 
signalling chain) and increase in expression of CD120b (TNFR2) after T-cell 
differentiation from naïve to effector cells. TNFR2 was present in the majority of CMV-
specific T-cells and its expression per cell increased during CMV-specific T-cell 
expansion post HSCT. Engagement of TNFR2 with a specific ligand led to the 
apoptosis of CMV-specific T-cells. This phenomenon may indicate a potential role of 
TNF/TFR2 interaction in the contraction phase of T-cell response to CMV reactivation.  
 
 
 
 
                                                                   iv 
 
Acknowledgements 
This thesis would not have been possible without the help and support of number of 
individuals. It is difficult to overstate my gratitude to my PhD supervisor, Dr Frederick 
Chen for his great insights and unwavering encouragement. His in-depth knowledge, 
dedication, and kind consideration, resulted in this work. I express my warmest thanks 
to Professor Paul Moss who strongly supported me in my research job as well as 
helping me to do PhD study with his great expertise and valuable criticism and allowing 
access to the stem cell transplant patients’samples.    
 I thank my PhD examiners Professors Antonio Pgliuca and Mark Drayson for their 
extremely valuable advice and comments. I would also like to thank Dr. Annette 
Pachnio for her great help in providing me with vital reagents for this research. I am 
deeply grateful to my colleague, Mr Guido Frumento for his wonderful technical 
guidance and help in processing of the clinical trial samples. Without his assistance, it 
was not possible to run all the samples based upon the clinical trial scheduled program. 
I also wish to thank Dr Heather Beard for her extremely valuable suggestions in 
performing experiments according to the GCLP standards. I would like to give my 
special thanks to the members of Stem Cell and Immunotherapy laboratory, NHS Blood 
and Transplant, particularly Mr Martin Cartwright, who smoothed the way for me to 
conduct most of my experiments in their GMP grade facilities. I also would like to 
thank Mr Gordon Ryan and Mrs Jasunara Begum, the research staff in the School of 
Cancer Sciences for their kind support and thank Professor Herald Wajant for providing 
me with TNFR ligand. I am deeply grateful to the Leukaemia and Lymphoma Research 
for their support and funding.   
                                                                   v 
 
Words can not express how grateful I am to my parents. Their prayer for me was what 
sustained me thus far. I owe a great deal of loving appreciation to my wife, Dr Akram 
Hosseini for all of her unlimited support and consideration during my research work. A 
very special thanks to my beloved children, Ryan and Delara for their patience and 
understanding. 
Finally I thank God (Allah). You are the one who let me finish my degree. I will keep 
on trusting You for my future. Thank you. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                   vi 
 
Table of Contents 
 
Abstract                                                                                                                            ii                                                                                                                                            
Acknowledgements                                                                                                         iv 
Table of contents                         vi  
Index of figures                         xi  
Index of tables                                                                                                                 xv  
Index of appendices                                                                                                        xvi 
Glossary                                                                                                                         xvii 
Chapter 1: Introduction                                                                                                  1                   
1.1       Cytomegalovirus                                                                                                    2 
1.1.1    CMV genome and life cycle                                                                                  2  
1.1.2    CMV encoded proteins                                                                                          6 
1.1.2A Function                                                                                                                 6 
1.1.2B  Antigenicity                                                                                                           6 
1.2       CMV infection                                                                                                     10 
1.2.1    CMV reactivation                                                                                                11 
1.3       CMV immunity                                                                                                    13 
1.3.1A  Innate immune response, production of Interferons                                           13 
1.3.1B  NK-cell response                                                                                                 14 
1.3.2     Acquired immune response                                                                                14 
1.3.2A  B-cell mediated response                                                                                    15 
1.3.2B  T-cell mediated response, role of CD8
+
 T-cells                                                  15  
1.3.2C  T-cell mediated response, CD4
+
 T-cells                                                             20 
1.3.2D  CMV-specific CD4
+
 T-cells                                                                               23                                                                                          
1.4        CMV and clinical complications                                                                        25 
1.4.1    Autoimmunity                                                                                                      25 
1.4.2    Graft rejection                                                                                                      27 
1.4.3    Mechanisms of CMV induced pathogenesis                                                       28 
1.4.3A  Humoral autoimmunity                                                                                       28 
1.4.3B  Inflammation                                                                                                       28 
1.4.3C  Vascular damage                                                                                                 29 
                                                                   vii 
 
1.4.3D Immunosuppression                                                                                             29 
1.5       CMV and Hematopoietic stem cell transplantation                                             31 
1.5.1   Reconstitution of CMV-specific T-cells post HSCT                                            33 
1.6      Adoptive cellular therapy for the prevention and treatment of CMV disease      36               
Project aims                                                                                                                    41 
Chapter 2: Material and Methods                                                                               43 
2.1      Study populations                                                                                                 44 
2.1.1   ACE-ASPECT trial patients                                                                                 44 
2.1.2   Patients studied for the characterization of CMV-specific CD4
+
 T-cells             45 
            reconstitution post  HSCT through the use of HLA class II tetramers 
2.1.3 Healthy blood donors and patients analysed for cytokine receptor expression   46 
            in T-cell subsets 
2.2       Methods used for immune monitoring of ACE-ASPECT trial patients              46 
2.2.1    Peripheral blood processing                                                                                 46 
2.2.2    Enumeration of CMV-specific CD8
+
 T-cells                                                      47 
2.2.2A  Determination of T-cell counts using Trucount tube                                          48 
2.2.2B  Detection of CMV-specific CD8
+
 T-cells                                                           48 
2.2.2C Flow cytometry analysis of T-cell counts and gating strategy                            49 
2.2.3     Functional behaviour of CMV-specific T-cells in ACE-ASPECT                    53 
             trial patients               
2.2.3A  Phenotypic analysis of CMV-specific CD8
+
 T-cells                                          53                                             
2.2.3B  Functional analysis of CMV-specific CD8
+
 T-cells through intracellular         53 
             staining           
2.2.4    Reconstitution of CMV-specific CD4
+
 T-cells in ACE-ASPECT trial               54 
            patients                
2.2.4A Flow cytometry analysis of CMV-specific T-cell phenotype and function        54                 
2.2.5    IFN-γ Elispot for analysis of CMV-specific T-cell function                               55               
2.3       Methods used for analysis of CMV-specific CD4
+
 T-cell reconstitution after   57 
            HSCT  by  HLA class II tetramers 
2.4 Methods used for analysis of cytokine receptor expression in T-cell subsets       58 
          and effect of  TNFR2 ligation on differentiated cells 
2.4.1   Flow cytometry analysis                                                                                       59 
                                                                   viii 
 
2.4.2   Detection of TNFR2 expression in CMV-specific T-cells                                 59 
2.4.3  Cell incubation with TNFR2 ligand                                                                    59 
2.5     Statistical analysis                                                                                                60 
Chapter 3: Reconstitution of CMV- specific T-cells following adoptive                66 
                   cellular therapy (ACE-ASPECT) 
 
3.1 Background                                                                                                       67 
3.1.1   Adoptive cellular therapy- Phase I clinical trial                                                 67  
3.1.2   Adoptive cellualar therapy- Phase II clinical trial                                              69 
3.1.2A Study objectives and end points                                                                        70 
3.2       Results                                                                                                               72 
3.2.1    Quality controls for quantification of T-cells                                                    72 
3.2.1A  Internal controls                                                                                                72 
3.2.1B  External controls                                                                                               74 
3.2.1C  Control of Streptamer
®
 staining                                                                        76 
3.2.2    Absolute numbers of CMV-specific CD8
+
 T-cell reconstitution following      78       
            ACT and the trial end point showed no statistically significant difference 
            between the two arms 
3.2.3    Reconstitution of total CD3
+
 and CD8
+
 T-cell populations                               81 
3.2.4    The expansion rate of CMV-specific CD8
+
 T-cells was different between      82 
            arms A and B 
3.2.5    Geometric increases in CD3
+
 and CD8
+
 T-cell populations                              84 
3.2.6    Expansion of non-infused CMV-specific T-cells in arm A patients                 86 
3.2.7    Reconstitution of CD4
+
 T-cell population                                                         88 
3.2.8    Concomitant expansion of CD4
+
 and CD8
+
 T-cells                                          89 
3.2.9    CMV-specific CD4
+
 and CD8
+
 T-cells expanded co-ordinately                      90 
3.2.10  Anti-CMV antibody response                                                                            91 
3.2.11  Functional behaviour of CMV-specific T-cells                                                 93 
3.2.11a  Elispot results                                                                                                   94 
3.2.11b Multi-functional activity of CMV-specific T-cells as detected by                   99 
             intracellular cytokine production 
3.2.12  Other results for ACE-ASPECT trial                                                                103 
3.3       Discussion                                                                                                         106 
                                                                   ix 
 
Chapter 4: Characterization of CMV- specific CD4
+
 T-cell reconstitution           113 
                   post-HSCT through the use of HLA class II-peptide tetramers 
4.1     Background                                                                                                         114 
4.2     Results                                                                                                                 116 
4.2.1  CMV reactivation was common and over 40% of patients suffered                  116 
          from multiple  episodes of viraemia  
 4.2.2 Monitoring of CMV-specific CD4
+
 T-cells using HLA-peptide tetramers        121 
          showed that CD4
+
 T- cells reconstituted with similar kinetics to virus-specific 
          CD8
+
 T-cells  
4.2.3 T-cell responses before and after clearance of viraemia indicate a minimum     123 
         threshold of CMV-specific T-cell immune response is required for viral control              
4.2.4 Expansion of CD4
+
CD57
+
 T-cells during viral reactivation indicates a              125            
         broader CMV-specific CD4
+
 T-cell response  
4.2.5 Diagnostic value of CMV-specific T-cell quantification                                     126                                         
4.2.6 CMV-specific CD4
+
 T-cells exhibit an effector phenotype                                 129                                               
4.2.7 Helper and Cytotoxic potential of CMV specific CD4
+ 
T-cells                           132  
4.2.8 Cytokine receptor expression in the reconstituting CMV-specific T-cells          134 
4.2.9 The CMV-specific humoral immune response correlates with                            136 
          the reconstitution of CMV-specific CD4
+
 T-cells  
4.3    Discussion                                                                                                            137 
Chapter 5: Cytokine receptor expression in T-cell subsets and functional           141 
                    activity of TNFR2 in effector memory subset 
5.1 Background                                                                                                         142 
5.2 Results                                                                                                                 150 
5.2.1 T-cell subset distribution and CMV infection                                                     150 
5.2.2  Expression of IL-2Rα (CD25) in T cell subsets                                                 154 
5.2.3 Expression of IL-7Rα (CD127) in T-cell subsets                                                157 
5.2.4  Expression pattern of IL-15Rα                                                                           160 
5.2.5  Expression pattern of CD130 (IL6Rα)                                                               163 
5.2.6  Expression pattern of CD120b (TNFR2)                                                           166 
5.2.7  TNFR2 expression in CMV-specific T-cells                                                      169 
5.2.8  Ligation of TNFR2 with a specific agonist caused cell apoptosis                      174 
                                                                   x 
 
5.2.8A TNFR2 ligation associated with apoptosis                                                       178 
5.2.8B Ligation of TNFR2 in CMV-specific T-cells                                                   180 
5.3      Discussion                                                                                                          181 
General Discussion                                                             189  
References                                                                                                                    199 
Appendices                                                                                                                   217                                                                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                   xi 
 
Index of Figures 
Figure 1.1: CMV virion                                                                                                    3 
Figure 1.2: Schematic map of the CMV genome                                                             4 
Figure 1.3: CMV life cycle in a host cell                                                                         5 
Figure 1.4: Immune response to CMV                                                                             8 
Figure 1.5: CD4
+
 and CD8
+
 T-cell responses to CMV proteins                                      9 
Figure 1.6: T-cell responses following primary CMV infection                                    19 
Figure 1.7: Helper function of CD4
+
 T-cells                                                                  22 
Figure 1.8: Antiviral activation of CD4
+ 
T-cells                                                            23 
Figure 1.9: Mechanisms of CMV induced immunopathology                                       30 
Figure 1.10: Strategies for adoptive cellular therapy of CMV- specific T-cells            38 
Figure 2.1: Flow cytometry gating strategy for identification of T-cells                  50-51 
Figure 3.1: ACE trial arms                                                                                              71 
Figure 3.2: Internal quality control of flow cytometry method used for T-cell              73 
                   quantification      
Figure 3.3: External quality control of flow cytometry method used for T-cell            75 
                  quantification  
Figure 3.4: Schematic picture of Streptamer® and its binding to T-cell through          77 
                   engagement of TCR and MHC molecule 
Figure 3.5: Expansion of CMV-specific CD8
+
 T-cells up to 56 days                           80 
                    post-ACT (arm A) or first detection of CMV viraemia (arm B) 
Figure 3.6: Expansion of CMV-specific CD8
+
 T-cells within one month                     83 
                   post ACT/first CMV viraemia detection 
Figure 3.7: Fold increase in the number of CMV-specific CD8
+
 T-cells                      84 
Figure 3.8: Fold increases in the numbers of CD3
+
 and CD8
+
 T-cells within               85 
                   2 months post-ACT/first CMV viraemia 
Figure 3.9: CD3
+
 and CD8
+
 T-cell expansions over one month post-ACT/first           86 
                    viraemia 
Figure 3.10: The highest and lowest median frequencies of CMV-specific                 87 
                   CD8
+
 T-cells             
Figure 3.11: Expansion of infused and non-infused CMV-specific CD8
+
 T-cells       88                   
                     post-ACT 
                                                                   xii 
 
Figure 3.12: Reconstitution of CD4
+
 T-cells in arms A and B patients                       88 
Figure 3.13: Co-expansion of CD4
+
 and CD8
+
 T-cells during immune                       89 
                     reconstitution post-ACT in arm A  
Figure 3.14: Concomitant reconstitution of CMV-specific CD4
+
 and                         90 
                     CD8
+
 T-cells post-ACT 
Figure 3.15: Co-expansion of CMV-specific CD8
+
 T-cells and                                   91 
                     CD4
+ 
CD57
+
 T-cells 
Figure 3.16: IgG response to CMV in arms A and B patients                                      92 
Figure 3.17: IFN-γ production in Elispot                                                                      93                                                        
Figure 3.18: IFN-γ response to the CMV-derived peptides as measured by Elispot    95 
Figure 3.19: Longitudinal analysis of CMV-specific T-cells with Streptamer®          96 
                     staining and Elispot assay 
Figure 3.20: Correlation between the number of CMV-specific CD8
+
 T-cells             97 
                     identified by Streptamer
®
 staining and CMV-specific IFN-γ  
                    producing   cells 
Figure 3.21: IFN-γ responses to pp65 and IE-1 peptide pools as detected by Elispot   98 
Figure 3.22: Cytokine production by CD8
+ 
T-cells following stimulation with          100 
                     CMV-derived peptides 
Figure 3.23: Intracellular cytokine production                                                      101-102 
Figure 3.24: Effects of CTL dose and Alemtuzumab level on the trial end point             104 
Figure 3.25: Combinational effects of Alemtuzumab and CTL dose on                     104 
                      reconstitution of CMV- specific CD8
+ 
T-cells  
Figure 4.1:  Pattern of reconstitution of CMV-specific CD4
+
 and CD8
+
 T-cells         120 
                    after transplantation in relation to episodes of CMV reactivation                            
Figure 4.2:  Longitudinal analysis of reconstitution of CMV-specific T-cells            122 
                    following HSCT 
Figure 4.3  Frequencies of CMV specific T-cells before and after viraemia                 
124 
                    in relation to occurrence of single or recurrent episodes of reactivations 
Figure 4.4: Correlation between the number of CMV-specific CD4
+
 T-cells and       125 
                    number of CD4
+
 CD57
+
 T-cells during T-cell reconstitution post-HSCT 
Figure 4.5: ROC analysis of CMV-specific T-cell numbers in HSCT patients with   128 
                                                                   xiii 
 
                   single or multiple episode(s) of CMV reactivation 
Figure 4.6: Immunophenotyping of CMV specific T-cells by flow cytometry           130 
Figure 4.7: Immune phenotype of reconstituting CMV-specific T-cells post-HST     131 
Figure 4.8: Expression levels of perforin, granzyme B and T-bet in CMV-specific   133 
                   T-cells     
Figure 4.9: Perforin expression in total CD4
+
 population, CD4
+
CD57
+
 and               134                             
                   CD57
+
 DYS - specific T-cells 
Figure 4.10: Flow cytometry dot plots of cytokine receptor expression in                  135 
                    CMV-specific T-cells 
Figure 4.11: TNFR2 (CD120b) expression by CMV-specific T-cells in                     136 
                     response to CMV reactivation 
Figure 4.12: Coordinated humoral and cellular immune responses to CMV              137 
                      reactivation post-HSCT  
Figure 5.1: Cytokine-receptor interactions of type I family cytokine receptors          143 
Figure 5.2: Trans-presentation of IL-15                                                                       144 
Figure 5.3: TNF/TNFR family members with co-stimulatory roles                            146 
Figure 5.4: TNF interaction with TNFR1 and TNFR2 induces two opposing            148 
                   signalling events 
Figure 5.5: Distribution of T-cell subsets in healthy individuals and                          152 
                   CMV infection 
Figure 5.6: CD25 expressions in T-cell subsets of healthy blood donors                    155                               
Figure 5.7: CD127 (IL7Rα) expression in T-cell subsets of healthy                           158 
                  blood donors   
Figure 5.8: IL15Rα expression in T-cell subsets of healthy blood donors                  161                    
Figure 5.9: CD130 (IL6Rα) expression in T-cell subsets of healthy                           164  
                  blood donors  
Figure 5.10: CD120b (TNFR2) expression in T-cell subsets of healthy                     167 
                    blood donors  
Figure 5.11: CD120b (TNFR2) expression level of CMV-specific T-cells                171 
                    in response to CMV viraemia 
Figure 5.12: Comparison of CD120b expression level in CMV-specific T-cells       173 
                    of HSCT patients 
                                                                   xiv 
 
Figure 5.13: CD120b expression and in vitro T-cell activation                                  173 
Figure 5.14: Interaction of TNFR2 and its soluble agonist                                         174 
                   (Flag-TNC- scTNF (143N/145R) which mimics TNFR2 binding to 
                   membrane TNF (main ligand for TNFR2) 
Figure 5.15: Titration of Flag-TNC-scTNF (143N/145R) for study of                       175 
                    TNFR2 ligation 
Figure 5.16: Effect of TNFR2 ligation on the frequency of CD8
+
 T-cell subsets       177 
Figure 5.17: TNFR2 ligation and cell loss in TNFR2 positive population                  178 
Figure 5.18: Induction of apoptosis following TNFR2 ligation                                  179 
                                                          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                   xv 
 
 
Index of Tables 
 
Table 1.1: List of CMV derived peptides and related HLA molecules studied in the     9 
                 current  project 
Table 1.2: Summery of published reports on adoptive cellular therapy of                    39 
                 CMV-specific T-cells  post HSCT 
Table 2.1: List of antibodies used in detection and phenotyping analysis of                 61 
                  CMV-specific CD4
+
 and CD8
+
 T-cells 
Table 2.2: List of MHC class I Streptamers
®                                                                                                 
62 
Table 2.3: List of isotype controls used in the phenotypic analysis of                           62 
                  CMV-specific T-cells 
Table 2.4: List of reagents and consumables used in the study of CMV-specific          63 
                 T-cells            
Table 2.5: Antigens and reagents used for the cell stimulation assay                            64 
Table 2.6: List of anti-cytokine receptor antibodies                                                      65 
Table 2.7: List of isotype controls used in the study of cytokine receptors                   65 
Table 3.1: Frequencies of T-cells stained with different multimers for control of        76 
                  Streptamer
®
 staining 
Table 3.2: Magnitude of CMV-specific CD8
+ 
T-cell reconstitution post ACT             78 
Table 3.3: Magnitude of CMV-specific CD8
+ 
T-cell reconstitution in arm B patients  79 
Table 3.4: Magnitude of CD3
+
 and CD8
+
 T-cell reconstitution post ACT                    80 
Table 3.5: Magnitude of CD3
+
 and CD8
+
 T-cell reconstitution post first CMV viral   81 
                  detection in arm B patients  
Table 4.1: Characteristics of HSCT patients                                                                118 
Table 4.2: Summary of CMV reactivation and magnitude of CMV specific T-cell    119 
                 responses in HSCT patients 
Table 5.1: Table 5.1 Expression properties of TNF/TNFR molecules by T-cells       145 
 Table 5.2: Frequencies of apoptotic and necrotic cells following TNFR2 ligation    180 
                  in TNFR2 positive and negative fractions of isolated CD8
+ 
cells 
 
                                                                   xvi 
 
                                                             
 
                                         Index of Appendices 
 Appendix 1: T-cell manufacturing in ACE-ASPECT trial                                        218 
Abstracts and paper published from the results of this PhD: 
Appendix 2: CMV-Specific T-Cell Therapy Improves Immune Reconstitution        219 
Following Unrelated Donor HSCT: Results of a Randomized Controlled Trial 
 
Appendix 3: Characterization Of CMV-Specific CD4
+
 T-Cell Reconstitution          220 
Following Stem Cell Transplantation Through The Use Of HLA Class II-Peptide  
Tetramers Identifies Patients At High Risk Of Recurrent CMV Reactivation 
 
Appendix 4: TNFR2 Is Expressed Preferentially By Late Differentiated                    221 
CD8 T-Cells and Can be Triggered By TNFR2-Specific Ligand to Induce Cell Death  of 
Recently  Activated Antigen-Specific T Cells: A Possible Role of TNF in T-Cell 
Deflation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                   xvii 
 
Glossary 
7-AminoactinomycinD                                                                                            7-AAD 
Activator Protein                                                                                                         AP-1 
Adoptive Cellular Therapy                                                                                          ACT 
Allophycocyanin                                                                                                          APC  
Antibody                                                                                                                         Ab 
Antibody Dependent Cell-mediated Cytotoxicity                                                    ADCC  
Antigen Presenting Cell                                                                                               APC  
Best Available Therapy                                                                                               BAT 
Becton Dickinson                                                                                                          BD 
Central Memory                                                                                                            CM 
Cluster of Differentiation                                                                                              CD 
Coefficient of Variation                                                                                                CV  
Common Variable Immunodeficiency                                                                      CVID  
Cytomegalovirus                                                                                                         CMV  
Cytotoxic T lymphocyte                                                                                               CTL  
Dendritic Cells                                                                                                               DC  
Delayed Early                                                                                                                 DE  
Donor Lymphocyte Infusion                                                                                        DLI 
Effector Memory                                                                                                           EM 
Effector Memory CD45RA
+                   
                                                                        EMRA                                                                                      
Fas ligand                                                                                                                    FasL  
Fluorescence Activated Cell Sorter                                                                           FACS  
Fluorescein Isothiocyanate                                                                                          FITC  
Glycoprotein B                                                                                                                gB 
Graft Versus Host Disease                                                                                       GVHD 
Haematopoietic Stem Cell Transplantation                                                               HSCT 
Human Immunodeficiency Virus                                                                                 HIV  
Human Leukocyte Antigen                                                                                         HLA  
Human Serum Albumin                                                                                               HSA  
Immediate Early                                                                                                               IE  
                                                                   xviii 
 
Immunoglobulin                                                                                                               Ig  
 Inflammatory Bowel Disease                                                                                      IBD 
Inflammatory Protein-10                                                                                            IP-10 
Interferon gamma                                                                                                       IFN-γ 
Interleukin                                                                                                                       IL 
Intracellular Adhesion Molecule                                                                               ICAM 
Lymphotoxin                                                                                                                   LT 
Macrophage Inflammatory Protein-1a                                                                    MIP-1a 
Major Histocompatibility Complex                                                                           MHC 
Mean Fluorescent Intensity                                                                                         MFI 
Monocyte Chemoattractant Protein-1                                                                      MCP-1 
National External Quality Assessment Service                                                      NEQAS 
Natural Killer(cell)                                                                                                        NK 
Nuclear factor kappa B                                                                                             NF-κB 
Open Reading Frame                                                                                                   ORF 
Peridinin Chlorophyll Protein                                                                                   PerCP 
Peripheral Blood Mononuclear Cell                                                                         PBMC 
Phosphate Buffered Saline                                                                                           PBS 
Phycoerythrin                                                                                                                  PE 
Quantitative Polymerase Chain Reaction                                                                  QPCR 
Regulated on Activation, Normal T-Cell Expressed and Secreted                      RANTES 
Rheumatoid  Arthritis                                                                                                    RA 
Receiver Operating Characteristic                                                                               ROC 
Staphylococcal Enterotoxin B                                                                                      SEB 
T-cell Depleted                                                                                                            TCD 
Transforming Growth Factor-b                                                                                 TGF-b 
Tumour Necrosis Factor-alpha                                                                                 TNF-α 
Tumour Necrosis Factor-receptor                                                                             TNFR 
TNF-Related Apoptosis Inducing Ligand                                                               TRAIL 
Unique Long Region                                                                                                   ULR 
Unique Short Region                                                                                                   USR  
 
  
                                                                   xix 
 
  
  
  
 
 
 
 
                                                                    1 
 
                               
 
 
Chapter 1 
INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                    2 
 
A large body of evidence exists in support of immunotherapy at both research and 
clinical levels. Much of this is focused on the clinical outcome of immunotherapy, but 
immune monitoring data is equally important as they allow us to understand the 
behaviour of infused therapeutic cells and the host’s response. The eventual success or 
failure of a particular immunotherapy approach can therefore be analysed and the 
underlying causes explored. The findings from such studies can then be used to refine or 
improve immunotherapy outcome and also lead to novel diagnostic technologies. This 
work is modelled on CMV as a target of immunotherapy, and investigated the 
reconstitution of CMV-specific T-cells in patients enrolled in a clinical trial of adoptive 
T-cell immunotherapy and in patients who received routine stem cell transplants. The 
first chapter of this thesis briefly discusses the virology and immunology of CMV 
infection and presents a summary of previously reported findings on adoptive cellular 
therapy with CMV-specific T-cells.    
1.1 Cytomegalovirus  
1.1.1 CMV genome and life cycle 
The virion of CMV is composed of a nucleocapsid surrounded by the tegument which is 
a protein field region with the phosphoprotein 65 (pp65) as the most abundant protein. 
The viral envelope, derived from host cell endoplasmic reticulum-Golgi intermediate 
compartment, cover the tegument and contains virus encoded glycoproteins such as 
glycoprotein B (gB), gH and gL (Figure 1.1). The nucleocapsid encloses a 235 kbp 
double stranded DNA with the capacity to encode in excess of 166 gene products 
(Mocarski and Pass, 2007). The genome has two regions: UL – Unique long, US – 
Unique short which are bounded by  repeat regions ; TRL (Terminal Repeat Long), IRL 
(Internal Repeat Long),  inverted repeat of TRL, TRS –Terminal Repeat Short and IRS 
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– Internal Repeat Short; inverted repeat of TRS. The repeats allow rearrangements of 
the unique regions which are sequentially transcribed in a cascade fashion (Figure 1.2). 
 CMV can replicate in many differentiated cell types which are described as permissive 
cells for viral replication. The entry to human cells is either through direct cell fusion or 
through endocytic pathway and utilises some of CMV glycoproteins such as gB (Figure 
1.3). Expression of CMV genes occurs sequentially. Intermediate-early (IE) genes are 
expressed immediately following viral entry without need for expression of other viral 
genes. These genes have vital roles in controlling viral and cellular gene expression in 
order to prepare the conditions for production of viral DNA. IE-1 and IE-2 genes 
regulate viral and host cell gene expression at transcriptional level and other IE gene 
products suppress cell death. Delayed Early (DE) genes expression depends on the 
expression of IE genes and their functional products are involved in viral DNA 
replication. Finally, Late (L) genes are expressed which encode virus structural proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.1 CMV virion. The virion is composed of envelope containing glycoproteins, 
tegument, nucleocapsid and double stranded DNA. 
 
 
Membrane 
 
 
Tegument 
Nucleocapsid and 
DNA 
 
Glycoproteins 
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Figure 1.2 Schematic map of the CMV genome.  
 
The CMV genome is around 230Kbp and includes two regions of unique sequences, 
unique long (UL) and unique short (US), bounded by two sets of inverted repeats 
(TRL/IRL) and (IRS/TRS). The positions of some important ORFs alongside 
orientation of their transcript are shown. The functional activity of CMV proteins are 
grouped and shown as well. (Boeckh and Geballe, 2011)  
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Figure 1.3 CMV life cycle in a host cell.  
 
Viral membrane glycoproteins (e.g., gB and gH) through binding to the specific surface 
receptors (e.g., platelet-derived growth factor α) facilitate attachment of virus to the cell 
which is followed by fusion of the envelope with the cellular membrane and release of 
nucleocapsid into the cytoplasm. The nucleocapsids are transferred into the nucleus 
before release of viral DNA. These events result in the expression of IE-1/IE-2 genes 
which are involved in viral replication. The synthesized DNA is encapsulated and 
transported to the cytoplasm. The endoplasmic reticulum-Golgi intermediate 
compartment is the place where the secondary envelopment occurs and finally new 
virion is released by exocytosis at the plasma membrane. (Crough and Khanna, 2009) 
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1.1.2 CMV encoded proteins 
1.1.2A Function 
The CMV genome contains 213 open reading frames (ORF) (Sylwester et al., 2005). An 
ORF is a portion of genome which includes a sequence of bases that could potentially 
encode protein. ORFs in CMV are numbered based up on their position in UL and US, 
where most of them present (Figure 1.2). Many encoded proteins of CMV ORFs have 
been characterised and their functional properties and antigenicity studied in depth. 
There are around 166 proteins encoded by ORFs, some of them are membrane, 
tegument proteins or proteins involved in gene expression. CMV produces many 
different proteins that interfere with the immune system effector functions such as 
inhibitors of NK cell activity (UL16/UL18 encoded membrane glycoprotein).In total, 
there are 7 different CMV derived proteins that suppress NK cell activity. US2/3/6 
family proteins degrade MHC class I and possibly class II molecules, inhibit their 
processing and transport and delay trafficking of MHC class I. These functions interfere 
with processing of antigens to T-cells and consequently, have negative impact on CD8
+
 
and CD4
+
 T-cell activation. CMV produces proteins which are similar to cytokines and 
chemokines. For example, cmvIL-10 is 27% identical to human IL-10 but binds to the 
same receptor and has suppressive effects such as inhibition of peripheral blood 
mononuclear cells and their cytokine production.  
  
1.1.2B Antigenicity 
CMV is a highly immunogenic complex with many different proteins capable of 
stimulating both humoral and cellular immune responses (Figure 1.4). As an example, 
the presence of neutralising Abs against glycoproteins B and H(gB, gH) have been 
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shown and gB used as a vaccine to stimulate both B cells and CD4
+
 T-cells (Sabbaj et 
al., 2011). Some other known targets of humoral immunity are proteins derived from 
UL129, UL130, and UL131A. These proteins mediate CMV entry to epithelial and 
endothelial cells. 
Picker and his team have shown that there are 151 CMV  immunogenic ORFs  for CD4
+
 
and/or CD8
+
 T-cells, and that ORF immunogenicity is influenced only slightly by ORF 
expression kinetics and function (Sylwester et al., 2005). They have found that total 
CMV-specific T-cell responses in sero-positive individuals are large, comprising on 
average approximately 10% of both the CD4
+
 and CD8
+
 memory T-cells in peripheral 
blood. Figure 1.5A shows the distribution of T-cell responses against proteins encoded 
by CMV ORFs. T-cell responses are diversely distributed against a variety of structural, 
early, late and CMV derived immunomodulator molecules including pp28, pp50, gH 
and gB. Figure 1.5B shows the strength of T-cell responses toward 10 most frequently 
recognized antigens including UL123 (IE-1), UL122 (IE-2) and UL83 (pp65). 
In the current research, CD8
+
 and CD4
+
 T-cell responses against some of the well 
known antigenic peptides of CMV were studied (Table 1.1). 
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Figure 1.4 Immune response to CMV. 
A) Primary CMV infection in immunocompetent individuals frequently starts with 
CMV replication in mucosal epithelium. B) Produced virions disseminate and infect 
CD34
+
 cells and monocytes. This is the first step in the establishment of latent infection 
and it is likely that some CMV genes are expressed and induce T-cell activation 
continuously. C) Differentiation of monocytes to activated macrophages leads to 
production of virions or virus-associated dense bodies which can be processed by 
professional APCs (e.g., DCs) and presented to CMV-specific T-cells. D) In addition, 
these DCs activated through TLRs can also secrete a range of cytokines/chemokines, 
which stimulate the innate arm of the immune system. E) Activated T-cells and NK 
cells can lyse infected cells or produce IFN-γ or TNF-α in order to block virus 
replication. F) Another important arm of adaptive immunity is the B cells that produce 
Abs which block virus dissemination (Crough and Khanna, 2009).  
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Figure 1.5 CD4
+
 and CD8
+
 T-cell responses to CMV proteins. 
 
A) Relative level of T-cell responses with regard to the expression kinetics (left) or gene 
function (right). B) Bars are schematic representative of the magnitude of CD4
+
 and 
CD8
+
 T-cell responses to ORFs of CMV (Crough and Khanna, 2009) 
 
 
Table 1.1 List of CMV derived peptides and associated HLA molecules studied in the 
current project. 
CMV genome 
region 
CMV protein Peptide sequence HLA 
presenting 
Peptide 
Recognised by  
T-cells 
UL44 
UL83 
UL83 
UL83 
UL83 
UL83 
UL123 
UL123 
UL55 
pp50 
pp65 
pp65 
pp65 
pp65 
pp65 
IE-1 
IE1 
gB 
 
VTEHDTLLY 
NLVPMVATV 
GPISSGHVLK 
QYDPVAALF 
TPRVTGGGAM 
IPSINVHHY 
VLEETSVML 
QIKVRVDMV 
DYSNTHSTRYV 
A0101 
A0201 
A1101 
A2402 
B0702 
B3501 
A0201 
B0801 
DRB1*0701 
CD8 
CD8 
CD8 
CD8 
CD8 
CD8 
CD8 
CD8 
CD4 
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1.2 CMV infection 
 
Primary CMV infection leads to lifelong latent infection which is accompanied by 
periodical reactivation. During active infection, CMV is able to replicate itself in many 
cell types such as; endothelial cells, epithelial cells, fibroblasts, neuronal cells, smooth 
muscle cells, hepatocytes, trophoblasts, monocytes and dendritic cells (Plachter, Sinzger 
and Jahn, 1996). In the latency phase of infection, virus persists in specific cells without 
detectable production of infectious virus. A few number of research groups have been 
able to find the CMV DNA in the peripheral blood of healthy CMV sero-positive 
people (Taylor-Wiedeman et al., 1991; Larsson et al., 1998). Their results show that the 
number of cells with latent CMV infection is less than 1 in 10,000 peripheral blood 
mononuclear cells. Peripheral monocytes are the major carriage site of CMV DNA in 
healthy individuals. CMV DNA also presents in the monocyte progenitor CD34
+
 stem 
cells in bone marrow. Although CD34
+
 stem cells give rise to lymphocytes and 
polymorphonuclear leukocytes, CMV genome has not been found in these cell types. It 
should be pointed out that infected monocytes in the latent phase of infection do not 
express CMV IE genes. It has been suggested that CMV may exist in certain cells with 
a low production level of virions and no visible host cell damage or lysis. Endothelial 
cells are another candidate of cells with low level of  virus production since CMV has 
been linked to atherosclerosis (Zhou et al., 1996) and CMV-specific CD8
+
 T-cells 
exclusively express a chemokine receptor (CX3CR1) (Bolovan-Fritts and Spector, 
2008) which binds to an endothelial cell surface molecule called fractalkine. There are 
also other findings supporting the role of infected endothelial cells in the activation of 
CMV-specific CD4
+
 T-cells (Walker et.al, 2009). Currently, scientific evidence shows 
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that myeloid cells are the true site of latency in CMV sero-positive immunocompetent 
carriers, with  little or no CMV gene expression. However, fully differentiated 
macrophages and dendritic cells are another possible site of continual, subclinical 
reactivation of virus with production of CMV virions (Reeves  and Sinclair, 2008). 
 
1.2.1 CMV reactivation 
CMV reactivation from latency results in serious clinical complications in 
immunocompromised individuals. The factors behind CMV reactivation have not been 
fully understood. It has been suggested that cell host differentiation causes CMV 
reactivation. Differentiation of monocyte to macrophages leads to changes in the ability 
of these cells to support viral IE gene expression (Taylor-Wiedeman et al., 1994;   
Reeves et al., 2005). Furthermore, cytokines produced following allogeneic stimulation 
of T-cells are needed for complete reactivation of CMV in differentiated monocytes 
(Söderberg-Nauclér et al.,1997). Soderberg-Naucler has shown that Tumor Necrosis 
Factor-α (TNF-α) and Interferon-γ (IFN-γ) can induce differentiation of non-permissive 
monocytes into permissive macrophages. Reactivation of latent CMV through the 
allogeneic stimulation of peripheral blood mononuclear, derived from CMV carriers, 
depends upon IE gene expression. This gene expression is controlled by 
promoter/enhancer genes which have multiple binding sites for the transcription factor 
NF-κB as well as other transcription factors such as AP-1 (Sambucetti et al.,1989). 
Activation of these transcription factors has been documented in tissues transplanted 
into allogeneic recipients. Interlukin-1(IL-1) or TNF-α signaling induces 
phosphorylation and degradation of an inhibitory factor named IκB. Following this 
event, IκB is dissociated from NF-κB and allows translocation of NF-κB to the nucleus 
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and binding to responsive genes. Some researchers have found that TNF- α alone can 
substitute for allogeneic transplantation in the induction of NF-κB activity and 
consequently CMV-IE gene expression (Hummel et al., 2001). Immune response to an 
allogeneic stimulus mimics closely an inflammatory immune response. Production of 
inflammatory cytokines such as TNF-a, Interleukin 2 (IL-2) and IFN-γ are hallmarks of 
immune system activity in an allogeneic setting or response to an infection. In both 
settings, Interleukin 8 (IL-8), MIP-1a (Macrophage Inflammatory Protein-1a), RANTES 
(Regulated on Activation, Normal T Cell Expressed and Secreted), and MCP-1 
(Monocyte Chemoattractant Protein-1) are produced and induce expression of 
endothelial cell adhesion molecules such as E-selectin and ICAM-1 (Intercellular 
Adhesion Molecule-1). These events facilitate migration of circulating lymphocytes and 
infiltration of inflammatory cells. TNF-α and IFN-γ induce expression of CD40 on 
antigen presenting cells (APC) which plays an important role in interaction between 
CD4
+
 T-cells and APCs such as B cells and endothelial cells. Activation of T-cells by 
APCs leads to the production of IL-2 which in turn induces strong T-cell proliferation 
and differentiation to cytotoxic T-cells. All of these events provide the stage for 
infiltration of immune cells to the graft and recognition of foreign cells. 
Similar events happen in a classic immune response to an infection and it is likely that 
an inflammatory response is the natural cause of CMV activation. Some investigators 
believe that CMV uses host immune system in order to reactivate its genes from latency 
(Hummel and Abecassis, 2002). 
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1.3 CMV immunity 
CMV is the biggest known antigenic complex for humans and immune system invests 
considerably in both innate and acquired immunity in order to control this virus (Figure 
1.4). As discussed earlier, CMV establishes a latent infection with possible frequent 
reactivations which constantly pressurises the immune system in the immunocompetent 
individual. This means that CMV is under constant immunesurveillance and CMV 
dissemination and clinical disease occurs when this immunity is compromised in 
conditions such as allogeneic transplantation, immunodeficiency in HIV infection or 
strong inflammatory response in the septic shock.  
 
 1.3.1A Innate immune response, production of Interferon 
Type I interferons (IFN-α/β) have important roles in the control of mouse CMV during 
acute infection and the viral spread period (Loewendorf & Benedict, 2010). MCMV 
induction of IFN-αβ is the starting point of immune response to this virus. The source of 
this interferon is splenic stromal cells which binds to B-cells expressing lymphotoxin 
(LT) α/β. In a model of CMV infection of cultured fibroblasts, LT-αβ signalling induced  
IFN-β production. In this process, NF-κB was a key component of the IFN-β gene 
transcription. The first wave of IFN-α/β production is 8 hrs post MCMV infection and is 
followed by the second wave at 36 hrs post infection. In this time point, the majority of 
interferon comes from dendritic cells activated through toll like receptor 9 (TLR9). Both 
MCMV and CMV utilise different mechanisms to suppress interferon production. In 
human, TLR2 interacts with gB/gH which triggers production of inflammatory 
cytokines through NF-κB signalling pathway (Juckem et al., 2008). 
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1.3.1B NK cell response 
Type I interferon has positive effect on NK cell cytotoxicity, and this is a primary 
mechanism by which MCMV replication is controlled at the second day of MCMV 
infection. NK-cells also produce IFN-β which restricts MCMV replication. 
In human, NK-cell activity increases in both primary and reactivated CMV infection. A 
recent study showed that 30-70% of NK-cells were proliferating cells during acute 
CMV reactivation. This study also found that a unique subset of CD57
+ 
NKG2C
high 
induced in that period and de-granulated after engagement of NKG2C molecules with 
its ligand (Foley et al., 2012). It is important to mention an interesting finding showing  
that the prevention of CMV reactivation post HSCT relates to one group of NK cell 
receptors called activating-killer immunoglobulin like receptor (KIR) (Cook et al., 
2006). 
 
1.3.2 Acquired immune response 
The establishment of sustained CMV immunity with the ability to form memory 
responses needs strong immune responses from all components of adaptive immunity. 
Innate immunity, through production of interferons and TNF-α which up-regulates HLA 
molecule expression on APCs, triggers the first signals to the adaptive immunity. NK- 
cells and activated monocytes/ macrophages produce a wide range of cytokines and 
chemokines that are involved in the recruitment of CD8
+
 T-cells from blood. Among 
these mediators, CXCL9 and CXCL10 bind to CXCR3
+
 CD8
+
 T-cells and mediate their 
recruitment to the infection site.  
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1.3.2A B-cell mediated response 
Current evidence indicates important roles of antibodies (Ab) in restricting viral spread 
and limiting the severity of CMV disease. These neutralizing Abs are mainly against 
CMV-gB which is involved in cell attachment. Another target of Abs is gH which 
facilitates integration of viral envelope with the host cell membrane. 
In humans, the transfer of antibodies from a CMV-seropositive mother protects 
newborn infant from CMV infection (Fowler et al., 1992). The avidity of these 
neutralizing Abs are not the same and transfer of low avidity Abs increases significantly 
the probability of the transmission of viral infection from mother to foetus (Boppana 
and Britt, 1995). There are documented data on vaccine development for CMV using 
gB as an immunogen which decreases incident cases of maternal and congenital CMV 
infection (Pass et al., 2009). 
 
 1.3.2B T-cell mediated immune response, role of CD8
+
 T-cells 
T-cells play a profound central role in the control of CMV reactivation. Deficiency of 
cellular immunity is strongly related to CMV disease with the exception of congenital 
CMV related disease. 
CD8
+
 T-cells are in the front-line of cellular immunity against intracellular pathogens. 
Antigen presentation by HLA-class I molecules with the help of cytokines and cell 
surface co-stimulatory molecules, induce CD8
+
 T-cell activation. The main function of 
activated CD8
+
 T-cells is destroying target cells (harbouring pathogen) through their 
cytotoxic mediators such as perforin and granzyme. CD8
+
 T-cells also produce high 
levels of inflammatory cytokines mainly TNF-α, IFN-γ and MIP-10. These cytokines 
can restrict CMV proliferation and make a cytokine milieu that supports recruitment 
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and activation of other effector cells e.g.; macrophages and NK cells. In the peripheral 
blood of healthy CMV-seropositive carriers, frequency of viral specific CD8
+
 T-cells is 
surprisingly high and it can even rise to 23% of all peripheral CD8
+
 T-cells (Khan et al., 
2002). These cells are oligoclonal with restricted TCR usage and can be toward 
different CMV peptides. 
Quantitative changes in CD8
+
 population. CMV infection has a major impact on CD8
+
 
T-cell repertoire in the peripheral blood. The number of CMV-specific CD8
+
 T-cells 
increases gradually and can lead to low or even inverted CD4/CD8 ratio in the 
peripheral blood. The possible mechanism behind this change in the peripheral T-cells 
is persistent stimulation of CD8
+
 T-cell repertoire by subclinical reactivation of CMV 
during latency. It has been found that CD8
+
 T-cells block progression of MCMV gene 
expression during reactivation (Kurz et al., 1999; Balthesen et al., 1994). These data 
indicate that MCMV establishes a latent infection with frequent reactivations but the 
full process of virion production is aborted or blocked by T-cell surveillance.  
The increase in the number of CMV or MCMV-specific T-cells over time has been 
referred to as memory inflation (Snyder et al., 2009). The result of inflationary memory 
is accumulation of effector T-cells (discussed below). Acute infection leads to the 
generation of T-cells specific for a wide range of antigens, followed by disappearance of 
most of these cells in the latency phase. The surviving cells are non-inflationary T-cells 
with a memory phenotype which is mainly characterised by the expression of IL-7 
receptor (van Leeuwen et al., 2005). The current understanding is that non-inflationary 
cells have a strong proliferation capacity. It has been documented that the presence of 
non-inflationary T-cells in the stem cell graft, identified by low CD57 expression, 
confers better CMV immunity post HSCT (Scheinberg et al., 2009). One of the 
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controversies surrounding accumulation of inflationary T-cells is their proliferative 
capacity. Some recent findings suggest absence of substantial proliferation within these 
cells, in contrast to non-inflationary T-cells  (Hertoghs et al., 2010). There are two 
possible mechanisms, one describes CMV-specific inflationary T-cells as long lived, 
resting effector cells with an estimated half life of 55 days in human (Wallace et al., 
2010). The alternative explanation is that these cells are dynamic, comprising mostly 
short lived cells that are replaced as they die. Mice model studies support the second 
explanation since transfer of inflationary MCMV-specific T-cells lead to the rapid 
disappearance of them even in the presence of virus. These cells have low level Bcl-2 
expression (anti apoptotic molecule). The source of these cells might be more memory 
like T-cells (IL-7R
+
 T-cells) and not naïve cells. It has been shown that T-cell clones 
derived from memory like T-cells but not more differentiated effector memory subsets 
persist after adoptive immunotherapy in non-human primate model of CMV infection 
(Berger et al., 2008). Another important fact is the functional ability of inflationary T-
cells in terms of cytotoxicity and strong production of inflammatory cytokines. It has 
been suggested that encounter with CMV antigens does not drive inflationary T-cells to 
cell division but is enough to stimulate their functional ability (Snyder et al., 2011). 
In regard to the proliferation ability of inflationary T-cells, it should be noted that there 
are important data obtained from in vitro studies showing proliferative capacity of this 
type of T-cells. Wills and his team studied proliferation requirement of effector cells 
with the phenotype of CD45RA
+ 
CD28
-
 (see below). They found that these cells were 
able to proliferate if appropriate co-stimulatory signals are provided. The fully 
differentiated effector cells are CD28 negative but this team showed that another co-
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stimulatory molecule named 4-1BB could induce proliferation signals to  CD8
+ 
T-cells 
stimulated with CMV antigens (Waller et al., 2007). 
Qualitative changes in CD8
+
 T-cell population. CMV infection does dramatically 
change the phenotype of CMV-specific T-cells toward effector/highly differentiated 
cells which is unique to CMV infection amongst other viral infections (Appay et al., 
2002). Peripheral blood T-cells have been classified based upon expression of some cell 
surface molecules. The most appreciated classification is based upon the presence or 
absence of a chemokine receptor called CCR7 and CD45RA molecule (Sallusto et al., 
2000). T-cells with expression of both CCR7 and CD45RA are called ‘naïve’ T-cells. 
CCR7
+
 CD45RA
-
 cells are central memory (CM) cells. CCR7
-
 CD45RA
- 
and CCR7
-
 
CD45RA
+ 
T-cells are effector memory (EM) and effector/memory CD45RA
+
 (EMRA) 
T-cells, respectively. Antigenic stimulation of T-cells, drive them toward a memory 
phenotype and response to CMV pushes these changes further. CMV-specific CD4
+
 or 
CD8
+
 T-cells have mainly effector memory and effector RA
+
 phenotype, respectively. 
Central memory T-cells migrate to lymph nodes and after encounter with antigen, 
become effector T-cells with profound cytotoxicity and cytokine production ability. The 
phenotype of inflationary T-cells is mainly differentiated effector T-cells expressing 
CD45RA. CD45 molecule has two isoforms; CD45RO and CD45RA. CD45RO isoform 
is expressed following antigenic stimulation of naïve T-cells and presents mainly in 
memory T-cells, but effector cells down regulate CD45RO and re-express CD45RA 
isoform. Among other widely studied membrane markers are co-stimulatory CD27 and 
CD28 molecules which are expressed by naïve T-cells. Cell stimulation leads to the 
gradual down regulation of these molecules, resulting in the appearance of T-cells with 
CCR7
-
 CD45RA
+ 
CD27
-
 CD28
- 
phenotype which is the signature of inflationary T-cells. 
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CD57 is another well discussed molecule in CMV infection. This surface glycoprotein 
is not present in naïve and nearly all of CM cells but appears in EM cells and its 
expression increases in EMRA cells. In this regard, CD57 positive cells are 
representative of fully differentiated EMRA cells with strong cytotoxic ability 
(Chattopadhyay et al., 2009). T-cell response following primary CMV infection has 
been summarized in Figure 1.6.  
 
 
 
 
Figure 1.6 T-cell responses following primary CMV infection. 
 
 Polyclonal cytotoxic T-cells are generated following primary infection. CMV virion production 
and spread are controlled within a few weeks and many clones of specific T-cells disappear. An 
oligoclonal population of cells is selected to memory with re-expression of CD45RA molecule 
and losing CD27 and CD28. The selected clones into memory pool are very stable and stay for 
years but their frequency increases with time (memory inflation) (Crough and Khanna, 2009). 
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1.3.2C T-cell mediated immune response, CD4
+
 T-cells 
CD4
+
 T-cell functional activity against viruses is less characterized. CD4
+
 T-cells are 
usually considered as T-cells providing help for B-cell and CD8
+
 T-cell responses to 
pathogens. New evidence has uncovered additional roles for CD4
+
 T-cells which 
includes direct antiviral roles and helping innate immune cells (Swain et al., 2012). 
Virus specific CD4
+
 T-cells have mainly a Th1 phenotype which is characterised by the 
expression of transcription factor; T-bet which regulates IFN-γ production. Type I 
interferon and IL-12 have major impacts on the generation of Th1 cells. IFN-γ not only 
augments cytotoxic activity and cell division of T-cells but induces immunoglobulin 
class switching and production of neutralizing IgG2a Abs. CD40L in CD4
+
 T-cells, is 
one of the well known co-stimulatory molecules which binds to CD40 molecule in B 
and CD8
+
 cells and sends stimulatory signals to them. CD4
+
 T-cells also down regulate 
expression of two inhibitory cell surface molecules called; programmed cell death-1 
(PD-1) and TNF-related apoptosis-inducing ligand (TRAIL). These activities make 
CD8
+
 T-cells less prone to apoptosis and increase their functional activity. CD4
+
 T-cells 
promote the generation of effector CD8
+
 T-cells through different mechanisms 
including production of IL-2, IL-15 and TNF (Oh et al., 2008). Figure 1.7, illustrates 
CD4
+
 T-cell helper roles in survival, activation and differentiation of B and CD8
+
 T-
cells. 
CD4
+
 T-cells have also direct engagement with virally infected cells. Following contact 
with professional APCs, CD4
+
 T-cells can act as effector cells by producing a wide 
range of pro-inflammatory cytokines such as IFN-γ and TNF-α (Figure 1.8A, B). CD4+ 
T-cells also produce anti-inflammatory cytokine IL-10 which may be involved in the 
control of inflammatory response to viruses. Recent findings indicate the presence of 
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cytotoxic molecules such as perforin and granzyme B and also FAS in CD4
+
 T-cells 
which enable them to directly kill target cells (Figure 1.8C). It is important to mention 
that cytotoxic activity of CD4
+
 T-cells does not depend upon the presence of 
transcription factor T-bet which is the main known transcription factor for Th1 cells. 
The vital transcription factor for cytotoxic activity of CD4
+
 T-cells is EOMES 
(Eomesodermin) which regulates IFN-γ and granzyme B gene expression in T and NK 
cells (Qui et al., 2011). 
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Figure 1.7 Helper functions of CD4
+
 T-cells.  
 
A) Follicular helper T-cells (TFH) are a subset of CD4
+
 T-cells that interact with B-cells 
through CD40L-CD40 binding and other co-stimulatory molecules and release of 
cytokines. CD4
+
 T -cell response leads to production of neutralizing antibodies which is 
the ultimate goal of many vaccines. B) CD4
+
 T-cells provide help to CD8 
+
 T-cells 
directly by release of cytokines such as IL-2 and indirectly by interaction with DCs. 
CD4
+
 T-cell’s help generate cytotoxic T-cells and down regulation of TNF-related 
apoptosis-inducing ligand (TRAIL).These activity facilitates robust response of CD8
+
 
T-cells during secondary infection (Swain et al., 2012)    
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Figure 1.8 Antiviral activities of CD4
+
 T-cells that involve direct contact with target 
infected cells. 
 
A) CD4
+
 T-cells recognize viral Ags presented by APCs and produce an array of 
effector cytokines. Some products of activated effector cells such as IL-10 dampen 
inflammation. B) CD4
+
 T-cells produce IFN-γ and TNF-α that make an antiviral state in 
tissues. C) Cytotoxic CD4
+
 T-cells can directly kill infected cells through perforin and 
granzyme release or FAS dependent cell lysis (Swain et al., 2012) 
 
 
1.3.2D CMV-specific CD4
+
 T-cells 
CD4
+
 T-cell responses to CMV have not been as well studied as CD8
+
 T-cell responses, 
due to the lack of appropriate experimental tools. Picker’s team showed that in healthy 
CMV carriers, immune system devotes a median of 9% of its CD4
+
 repertoire to this 
virus and that CD4
+
 T-cells recognize a median of 21 different ORFs (Figure 1.5) 
(Sylwester et al., 2005). There are ORFs that induce potent CD8
+
 and CD4
+
 T-cell 
responses, although CD8
+
 T-cells recognize more CMV-ORFs. Glycoprotein B is the 
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most frequently detected antigens for CD4
+
 T-cells but in around 5% of healthy 
individuals, high frequency of CD4
+
 specific for TRL14 and UL16 exist. As mentioned 
in the above section, the role of CD4
+
 T-cells is not only restricted to providing help to 
the other immune cells. gB specific peripheral blood CD4
+
 T-cells with cytotoxic 
function have been expanded in vitro (Hopkins et al., 1996). Researchers have been able 
to isolate gB specific CD4
+
 CTL with the ability to release granzyme from peripheral 
blood (Hegde et al., 2005). These CTLs recognize an immune dominant epitope 
DYSNTHSTRYV from gB which is restricted through HLA DRB1
* 
0701 (Elkington et 
al., 2004). It has been shown that CD4
+
 T-cells in large granular lymphocytosis are 
oligoclonal expansion of HLA-DR7 restricted DYS specific T-cells (Crompton et al., 
2008). Similar to CMV-specific CD8
+
 T-cells, CD4
+
 T-cells specific for CMV proteins 
such as pp65 are oligoclonal and use restricted and stable T-cell receptors. Gamadia and 
colleagues (2004) showed that CMV-specific CD4
+
 T-cells had effector-memory 
phenotype in healthy individuals and renal transplant recipients and produced Th1 
related cytokines. These cells were granzyme B positive and their response occurred 
before CD8
+
 T-cells in the peripheral blood of asymptomatic renal transplant patients. 
They also found that during latency, CD4
+
 T-cells were CCR7
-
 CD45RA
-
 (CD45RO
+
) 
CD27
-
. During both latency and primary infection, CMV-specific CD4
+
 T-cells 
expressed CD40L and produced IFN-γ, TNF-α but not IL-2 and IL-4 (Gamadia et al., 
2004). Other groups have shown that CD4
+ 
CD28
-
 T-cells exist almost exclusively in 
CMV infected individuals (van Leeuwen et al., 2004).                                                                                                                                                                                                                                            
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1.4 CMV and clinical complications  
 
CMV causes severe disease when the immune system is immature or impaired. CMV 
infected patients during active infection, display signs of immune dysfunction such as 
immunosuppression and autoimmunity. CMV infection has been linked to the allograft 
rejection and graft-versus-host disease in solid organ and bone marrow transplant 
recipients, respectively. Active viral infection takes place in several autoimmune 
diseases (Varani and Landini, 2011 ). Active forms of CMV infection are: a) primary 
infection of a CMV- naïve host; b) endogenous infection in CMV positive individuals 
who suffers reactivation from latency; c) exogenous re-infection by a different strain. 
Active and latent infection induces Th1 type inflammatory cytokines (van de Berg et al., 
2010). As discussed above, initiation of viral replication can be triggered by 
inflammatory conditions. For example, TNF-α binds to TNF receptor on latently 
infected cells, inducing signals that activate NF-κB. The activated NF-κB trans-locates 
into the nucleus and binds to the IE enhancer region of CMV, which leads to the viral 
replication (Hummel et al., 2002). There are published data that correlate high serum 
level of TNF and CMV reactivation and clinical complications such as atopic 
dermatitis, sepsis and acute graft-versus-host disease in the bone marrow transplant 
patients (Cantoni et al., 2010). 
 
1.4.1 Autoimmunity 
Anti-phospholipids and anti-CD13 auto-antibodies have been detected in CMV infected 
bone marrow transplant recipients and anti-CD13 has been linked to the development of 
chronic GVHD in these patients (Larsson et al., 1998). Auto-antibodies against 
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endothelial cell, smooth muscle cell and anti-nucleus are associated with CMV infection 
in solid organ transplant recipients. It is likely that these Abs increase the risk for 
humoral and chronic allograft rejection. In addition, hyper-gammaglobulinemia, 
cryoglobulinemia and autoantibody production are features of CMV related 
mononucleosis (Varani et al., 2002). Active CMV infection has been observed in 
cutaneous vasculitis and SLE associated vasculitis (Pérez-Mercado et al., 2010). CMV 
infection and CMV disease are risk factors for early-onset diabetes mellitus in the renal 
transplant patients (Hjelmesaeth et al., 2004) and incidence of this disease has declined 
following the introduction of pre-emptive anti viral treatments. CMV infection can 
damage β-cells directly or indirectly through the cytotoxic effects of activated 
lymphocytes or production of pro-inflammatory cytokines (Kamalkumar et al.,2009).  
There are some autoimmune conditions that may lead to CMV reactivation from 
latency. As it was mentioned before, CMV reactivation in monocytes can happen during 
differentiation of monocytes to macrophages after stimulation with IFN-γ or TNF-α. 
Thus it is likely that chronic inflammation in autoimmune diseases provide the ideal 
microenvironment in which latent CMV can be reactivated in macrophages. One 
example of chronic inflammation is inflammatory bowel disease (IBD) that has 
attracted attention of different research groups to study possible involvement of CMV in 
IBD. CMV antigens have been detected in biopsies from patients with IBD. Patients 
with inactive or mild ulcerative colitis (UC) rarely suffer from CMV replication, 
whereas active CMV infection exists in 20% to 40% of steroid refractory UC, indicating 
the possible role of the virus in severity of inflammation. Active CMV infection occurs 
in colon where CMV-DNA has been detected by PCR, whereas blood analysis shows 
low or no viral load. All patients with steroid refractory UC and active CMV infection 
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have been CMV-seropositive, suggesting reactivation of latent virus at the site of 
inflammation (Domènech et al., 2008). CMV has also been related to the vascular 
damage in systemic sclerosis (Lunardi et al., 2006). There are auto-antibodies that are 
specific for systemic sclerosis and bind the late CMV protein UL94. These Abs induce 
apoptosis in endothelial cells and dermal fibroblasts in vitro. In systemic sclerosis, 
vascular damage and fibrosis are two main clinical complications. CMV-DNA can be 
detected in gastrointestinal tract of CVID patients (Common Variable 
Immunodeficiency) who suffer from inflammatory granulomatosis. This inflammation 
has been related to an exaggerated T-cell response to CMV (Marashi et al., 2011 and 
2012). 
 
1.4.2 Graft rejection 
Several studies have shown that CMV infection is associated with an increased risk of 
graft rejection in liver, lung and renal transplantation (Varani and Landini, 2011). 
Randomized trials of antiviral prophylaxis and pre-emptive therapy have shown that 
antivirals significantly provide protection against CMV related graft rejection (Slifkin. 
et al., 2005). In bone marrow transplant patients, graft versus host disease and its 
treatment increase the risk of CMV replication (Cantoni et al., 2010). The role of CMV 
replication as a causative agent in development of GVHD is controversial since 
randomized studies of prophylaxis with antiviral drugs have not shown any impact on 
the risk for GVHD. 
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1.4.3 Mechanisms of CMV- induced pathogenesis 
1.4.3A Humoral autoimmunity  
Some of CMV genes are homologous to cellular genes and it may lead to cross reaction 
between viral and host proteins. Humoral autoimmunity can also be triggered by non-
specific B-cell activation induced by CMV. CMV is a polyclonal B cell activator in 
vitro and in addition, CMV interacts with toll-like receptor (TLR) 7 and 9 in human 
plasmocytoid dendritic cells leading to IFN-α production and B-cell proliferation 
(Figure 1.9A). In clinical settings, hyper-activation of B-cells is important since auto-
antibodies contribute to the development of GVHD in CMV-infected HSCT patients 
and graft rejection in solid organ recipients. 
 
1.4.3B Inflammation 
Active and latent CMV infections induce systemic type 1 inflammatory response (Van 
de Berg et al., 2010).This condition can augment alloimmune responses by enhancing 
the expansion of alloreactive T-cells. High level of IFN-γ can increase major 
histocompatibility complex (MHC) expression on graft T-cells and as a result, 
recognition of these cells by alloreactive T-cells is enhanced. Association of Th1 related 
molecules: IFN-γ, T-bet and granzyme B with transplant glomerulopathy, a risk factor 
for chronic graft rejection, has been shown (Homs et al., 2009). In autoimmune diseases 
including RA, Wegener’s granulomatosis, dermatomyositis, polymyositis, multiple 
sclerosis and IBD, CD4
+ 
CD28
-
 T-cells expand. These cells are Th1 cells and produce 
inflammatory cytokines in lesions in Wegener’s graulomatosis (Komocsi et al., 2002). 
The predominant T-cells infiltrate inflamed muscles in patients with dermatomyositis 
and polymyositis, are CD4
+ 
CD28
-
 and CD8
+ 
CD28
- 
T-cells which secrets IFN- γ after 
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CMV stimulation. In healthy controls and RA patients, CD4
+ 
CD28
-
 T-cells respond to 
several CMV antigens (Figure 1.9B) (Thewissen et al., 2007). CMV can stimulate the 
translocation of NF-κB into the nucleus, which then up-regulates TNF-α production. 
This leads to the further activation of latent CMV and inflammatory responses. 
 
1.4.3C Vascular damage  
CMV can infect endothelial cells in vitro and infected cells are dysfunctional. These 
cells produce more IL-8, Il-1 and some adhesion molecules. IFN-γ and TNF-α up-
regulate the expression of fractalkine in the endothelial cells. CMV-specific T-cells 
exclusively express CX3CR1 which binds to fractalkine. It seems that CMV induced 
endothelial cell inflammation and damage results from chemokine-mediated 
pathogenesis (Figure 1.9C). 
 
1.4.3D Immunosuppression 
CMV has evolved different mechanisms to suppress immune response and persist in the 
host. CMV infection in vivo and in vitro reduces proliferative ability of T-cells, inhibits 
NK cell cytotoxicity, suppresses myelopoiesis, and impairs APC function and 
maturation of DC. The secretion of CMV encoded IL-10 might help the virus in the 
inhibition of DCs (Figure 1.9D). Immune suppression by CMV may cause a generalised 
immune defect which might be responsible for increased risk of secondary bacterial and 
fungal infection post stem cell transplantation. 
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Figure 1.9 Mechanisms of CMV induced immunopathology. 
 
 A) CMV induce auto-Ab production. B) Inflammation caused by the virus. C) CMV- 
induced vascular damage. D) CMV and immunosuppression. PDC; plasmacytoid 
dendritic cells, SMC; smooth muscle cells, 5-LO: 5-lypooxygenase, cox-2, 
cyclooxygenase2, PGE2; prostaglandinE2, LTB4; leukotriene B4, MIF; macrophage 
migration inhibitory factor, MIP-1α; macrophage inflammatory protein 1-α, MIP-1β; 
macrophage inflammatory protein 1-β, VCAM-1; vascular cell adhesion molecule-1, 
PDGF; platelet-derived-growth factor, vIL-10; virally encoded IL-10. (Varani and 
Landini ,2011)    
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1.5 CMV and hematopoietic stem cell transplantation 
 
 Following hematopoietic stem cell transplantation, uncontrolled CMV reactivation can 
cause gastroenteritis, interstitial pneumonitis, hepatitis, retinitis and encephalitis. CMV 
reactivation and associated diseases post HSCT can occur early or late after 
transplantation (Boeckh et al., 2003). Many research studies have shown vital role of 
immune cell reconstitution in the control of reactivated CMV post HSCT. 
HSCT is the transplantation of multi-potent hematopoietic stem cells, usually derived 
from bone marrow, peripheral blood, or umbilical cord blood. Prior to the transplant 
procedure, conditioning chemotherapy and/or irradiation treatment is given to the 
transplant recipients in order to eradicate their tumor cells and to suppress immune 
reactions. These types of conditioning therapies are classified in two groups; 
myeloablative which ablates bone marrow cells and non-myeloablative which is less 
aggressive and does not eradicate all the bone marrow cells. Among drugs used in non-
myloablative treatments, is Alemtuzumab (marketed as Campath-H), a monoclonal Ab 
which binds to pan lymphocyte marker CD52. 
The mechanism(s) of Alemtuzumab action is not fully understood and  recent evidence 
from  a human CD52 transgenic mouse model suggests that neutrophils and NK cells 
through ADCC deplete lymphocytes attached to anti-CD52 Ab (Hu et al., 2009).   
Following the HSCT procedure and engraftment of stem cells in the bone marrow, 
blood cells are generated and normalise the blood cell count. Post HSCT, there is the 
aplastic phase (neutropenia) until recovery of neutrophils at 14 days post peripheral 
blood stem cell transplantation. This is followed by recovery of other cells of innate 
immunity including NK cells. Adaptive immune cells recovery starts within 100 days 
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post HSCT and CD8
+
 T-cells appear before CD4
+ 
T-cells. Homeostatic expansion of T-
cells results from peripheral memory T-cell expansion in response to cytokines plus 
alloantigens and from production of naïve T-cells which happens later and in the 
thymus. CD4
+
 T-cell recovery is more dependant upon thymic production of naïve T-
cells and as a result, CD4/CD8 ratio is inverted early post HSCT. The lack of enough  
T-cells with broad antigen specificity causes susceptibility to viral and fungal 
infections. The reconstitution of B-cells takes place much later, up to 2 years after 
HSCT. The low frequency of memory B-cells and impaired immunoglobulin class 
switching lead to susceptibility to the encapsulated bacteria. 
HSCT is associated with significant changes in the levels of a variety of cytokines in the 
peripheral blood. This so called ‘cytokine storm’ is caused by different events such as 
conditioning regimen, donor engraftment, infections and GVHD. Results from animal 
models and human studies show the production of inflammatory cytokines such as IL-1 
and TNF-α following myeloablative conditioning regimen which lead to a cycle of 
lymphocyte activation and contribution to the development of GVHD. There are also 
reports on increase in the levels of non-inflammatory cytokines such as G-CSF, IL-15, 
and IL-7 during period of cytopenia and GVHD. A recent study on the levels of 33 
cytokines pre and post HSCT in patients receiving T-cell depleted CD34
+
 cells 
following a myeloablative treatment,  showed two cytokine storms (Melenhorst et al., 
2012 ). The first happened during pancytopenia and peaked in week 1 post HSCT then 
declined as granulocytes returned ( 14 days post HSCT). This cytokine storm included 
hematopoietic and lymphopoietic cytokines such as IL-6 and G-CSF and IL-15. The 
second storm coincided with leukocyte reconstitution and was made up of 
                                                                    33 
 
inflammatory, anti-inflammatory and chemokines such as IP-10, IL-1β, LIF, IL-17, 
IFN-γ and TNF-α. 
 
1.5.1 Reconstitution of CMV-specific T-cells post HSCT 
CMV reactivation is one of the major obstacles after HSCT due to the lack of 
appropriate T-cell mediated immune surveillance. Joe Meyers (1980) and his team 
studied for the first time, cellular immune response to CMV in the bone marrow of 
transplant patients. Using a proliferation assay in response to CMV stimulation, they 
found that the presence of proliferative response protected patients from CMV disease. 
The fundamental role of cytotoxic cells was unravelled by Quinnan and his colleagues 
(1982) who showed HLA-restricted T-cells and non-T-cell cytotoxicity correlated with 
recovery from CMV infection in both bone marrow and kidney transplantation. Later, it 
was documented that CD8
+
 T-cells were the main component of cytotoxic T-cells 
(Reusser et al., 1991) and for the first time, adoptive transfer of CMV-specific CD8
+
 T-
cell clones in 3 patients was performed successfully (Riddell et al., 1992). Evaluation of 
immune response to CMV revealed that restoration of cytotoxic response was related to 
CD4
+
 T-cell recovery (Li et al., 1994; Walter et al., 1995). These original studies 
indicate that reconstitution of CMV-specific CD4
+
 and CD8
+
 T-cells is essential for 
controlling CMV reactivation post HSCT. Since then, our knowledge of CMV-specific 
T-cells has advanced rapidly following development of 3 new experimental techniques; 
intracellular staining of cytokines, detection of released cytokines and cell staining with 
HLA-peptide multimer/tetramer complex. Using HLA-peptide tetramer reagents, it was 
shown that recovery of CMV-specific CD8
+
 T-cells to levels greater than 10x10
3
/ml 
provided protection from CMV reactivation (Cwynarski et al., 2001). Later, another 
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research group showed that functional ability of CMV-specific CD4
+
 and CD8
+
 T-cells 
were also important in controlling CMV reactivation following HSCT (Ozdemir et al., 
2002). Using TNF-α production as read out of cell activity, HSCT patients with or 
without CMV reactivation were compared. This group found that patients suffering 
from CMV reactivation, had higher numbers of CMV-specific T-cells but the 
percentage of functional cells was lower compared to the patients with no reactivation.  
Another research group studied 137 patients who received non-T-cell-depleted 
allogeneic peripheral blood stem cell or bone marrow transplantation and found that 
high dose steroids and CD4
+
 T-cell count less than 100x10
9 
/L strongly predicted 
impaired functional activity of CD4
+
 T-cells (Hakki et al., 2003). This study also found 
that total peripheral blood CD8
+
 T-cell number should be around 50x10
9 
/L to provide 
immune protection. In an attempt to clarify the importance of quality versus quantity of 
CMV-specific T-cells, a study investigated simultaneously intracellular cytokine 
production by specific T-cells and the number of tetramer binding cells (Morita-Hoshi 
et al., 2008). This study demonstrated that 67% of patients had more than 10x10
3 
/ml 
CMV-specific CD8
+
 T-cells at the onset of disease. Intracellular staining upon 
stimulation by CMV lysate and peptide in patients with CMV colitis showed that the 
number of IFN-γ producing CD4+ and CD8+ T-cells were smaller at the time of colitis 
but increased with recovery of the disease. At the end, the investigators suggested that 
prediction of viral reactivation solely based upon quantification of CMV-specific T-cell 
number was difficult and additional functional analysis was needed. In the recent years, 
other research groups have focused on functional behaviour of T-cells  and studied 
multiple aspect of their function (Stuchly et al., 2011; Costa et al., 2011; Zhou et al., 
2009; Lilleri et al., 2009; Pourgheysari et al., 2008). These groups investigated 
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production of cytokines; IFN-γ, TNF-α and IL-2 plus up-regulation of co-stimulatory 
molecule; CD40L and de-granulation marker; CD107. One of these studies showed that 
CMV-specific CD8
+
 T-cells producing both IFN-γ and IL-2 were present in patients 
controlling viral reactivation and cells producing only IFN-γ were non-protective T-
cells. CD4
+
 CD40L
+
 IFN-γ+  T-cells were the most frequent CD4+ cells in both patients 
controlling or not controlling CMV reactivation, therefore, the authors did not find a 
subset representing protective CD4
+
 T-cells (Stuchly et al, 2011). Lilleri (2009) reported 
a protective role for IFN-γ + IL-2+ CD8+ T-cell population. These findings are in 
accordance with results of studies on Human Immunodeficiency Virus (HIV) and  
Leishmania  major vaccine showing importance of multifunctional compare to 
monofunctional T-cells in the control of infection (Zimmerli et al., 2005; Darrah et al., 
2007) . It should be mentioned that most of studies on the quality of CMV-specific T-
cells post HSCT have not analysed quantity of these cells and vice versa, so there is still 
need for detailed studies on large cohort of patients looking for both quality and 
quantity aspects of CMV-specific T-cells. These studies will be beneficial for clinicians 
to predict viral reactivation and more importantly decide on management of patients 
during reconstitution of immunity to CMV. 
There are also multiple studies on CMV-specific T-cells post solid organ 
transplantation. Results of those studies are similar to data obtained from stem cell 
transplant patients and in addition provide information on immune response in primary 
CMV infection. Molecular profiling of CMV-specific CD8
+
 T-cells post primary 
infection in kidney transplant patients has shown that very early after infection, CD8
+
 T-
cells expressed  the T1 related transcription factors T-bet and EOMES in parallel with 
continuous expression of IFNG mRNA and IFN-γ–regulated genes (Hertoghs et al., 
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2010). During acute and latency phase, CMV-specific T-cells expressed perforin, 
granzyme B and CX3CR1 and down regulated IL-7R with no changes in expression of 
IL2Rα (CD25) but increased IL2Rβ (CD122). 
 
1.6 Adoptive cellular therapy for the prevention and treatment of 
CMV disease  
 
The vital role of protective CMV-specific T-cells in HSCT has led to several attempts to 
passively restore CMV cellular immunity by transferring cells to immune compromised 
patients. Different strategies have been developed to obtain enough number of CMV-
specific cells which some of them are presented in Figure 1.10. Riddell and colleagues 
(1992) pioneered the adoptive cellular therapy for the prevention of CMV disease by 
cloning CMV-specific CD8
+
 T-cells derived from bone marrow donors. They 
transferred CD8
+
 T-cells to 14 patients in 4 intravenous infusions 30 to 40 days after 
marrow transplantation and found that infused cells were able to expand in all the 
patients and provided protection against CMV reactivation and disease without any 
toxic effects. They also found that CMV-specific CD4
+
 T-cells were required to 
maintain long term CD8
+
 T-cell response (Table 1.2). In other study, K.Peggs and his 
team (2003) generated autologous CMV-specific T-cells by stimulation with DCs 
presenting CMV antigens and treated 16 patients with those cells. They observed 
massive expansion of transferred T-cells and there was no need for antiviral drugs in 8 
patients. In another study, 10
7 
/m
2 
CMV-specific T-cell lines (mainly CD4
+
 T-cells) 
were transferred  into HSCT patients at a median of 120 days after transplantation 
(Einsele et al., 2002). In the absence of antiviral drugs, CMV viral load dropped at a 
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median of 20 days and cell therapy was successful in 5 out of 7 patients. Interestingly, 
they recorded an increase in CMV-specific CD4
+
 T-cells in 5 patients in addition to 
increase in CD8
+
 T-cells. In 2 out of 7 patients who were under strong immune 
suppression at the time or after cell infusion, only transient decrease in viral load 
occurred. In this study, CMV-specific T-cells with broad antigen specificity were 
produced since the cells had been stimulated with CMV or CMV lysate. In order to 
reduce the risk of live virus, Micklethwaite and colleagues (2008) used DCs sensitized 
with HLA- class I restricted epitopes to stimulate T-cells. This method increased the 
precursor frequency of CMV-specific T-cells but it limited its use only to patients who 
carry that particular HLA. M. Cobbold and his team (2005) used a completely different 
strategy to obtain viral specific T-cells. They isolated CMV-specific T-cells from 
peripheral blood using MHC-peptide multimer complexes and without any in vitro 
manipulation, isolated cells were transferred into patients which resulted in clearance of 
viraemia in 8 of 9 patients. Some groups have successfully generated and clinically used 
multi-specific T-cell lines targeting CMV, EBV and adenovirus (Leen et al., 2006). 
Table 1.2 lists the published reports and their important findings on adoptive cellular 
therapy for CMV. In addition to the listed papers, a recent study showed the possibility 
of generating CMV specific T –cells from the naïve T-cells of CMV seronegative 
individuals or from cord blood. These cells were able to protect 2 out of 3 patients  
received cord blood transplants from CMV reactivation and helped the third patients in 
the control of reactivation (Hanley et al., 2015). Taken together, these results 
demonstrate the ability of T-cell therapy in restoring CMV-specific immunity without  
significant toxicity and with a low risk of GVHD induction.   
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Figure 1.10 Strategies for adoptive cellular therapy of CMV-specific T-cells.  
 
Different methods have been explored to obtain enough number of CMV-specific T-
cells which includes enrichment of CMV-specific T-cells using MHC-peptide 
multimer/tetramer and in vitro T-cell stimulation with DCs sensitized with a range of 
CMV derived antigens. (Crough and Khanna, 2009) 
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Table 1.2 Summary of published reports on adoptive cellular therapy of CMV-specific 
T-cells post-HSCT. 
 
Study / 
Year 
Number 
of 
patients 
Pre-emptive 
therapy or 
Prophylaxis 
T-cell 
source / 
Antigenic 
Stim. 
Number of Infused cells 
/ Days post HSCT 
Method of 
Immune-
monitoring 
Peak CMV- 
CD4/ CD8 
counts post 
cell 
infusion 
Results 
Walter, 
1995 
14 
Prophylaxis 
      
Allogeneic 
(donor-
derived) 
CD8 T 
clones 
stimulated 
with CMV 
infected 
fibroblasts 
Cells given in 4 weeks 
as 
33,100,330,1000x103/m2 
first infusion at day: 0 
Cytotoxic 
activity of 
cells 
against 
CMV 
NA 
Reconstitution 
of CMV 
immunity in all 
patients 
Einsele, 
2002 
 
8 Pre-
emptive 
therapy 
 
 
 
 
 
Allogeneic  
CTL 
stimulated 
with CMV  
lystae 
10x107/m2 
median infusion day: 
120 
Analysis 
of IFN-γ 
response  
or 
multimer 
staining 
CD4: 
7.9x103 
/ml 
CD8: 
42X103 
/ml 
 
Clearance of 
infection in 
5/7 evaluable 
patients 
 
 
 
 
 
Peggs, 
2003 
16 
Pre-emptive 
therapy 
  Allogeneic       
CMV-CTL 
 1x105/kg, median 
infusion day: 36 
 
Multimer 
staining 
CD4:NA 
CD8: 
570X103/ml 
Reconstitution 
of viral 
immunity  
 Cobbold  
2005 
      9 
 Pre-emptive                        
therapy 
     
Allogeneic 
CMV 
tetramer 
selected T- 
cells 
 
 8.6X103/kg 
 
 
Multimer 
staining 
CD4:NA 
CD8: 
156x103 /ml 
8/9 cleared 
infection 
Mickleth 
-waite, 
2008 
 
12 
Prophylaxis 
Allogeneic 
CMV-CTL 
generated 
by 
stimulation 
of DC with  
pp65 vector   
 
2X107/m2 
infusion at day: 56 
 
Analysis 
of IFN-γ 
response, 
Multimer 
staining  
 
CD4:NA 
CD8: 
280x103 /ml 
Increase in 
NLV-tetramer 
binding T cells 
in 6 recipients, 
reduced 
antiviral 
therapy 
Peggs, 
2009 
30 Pre-emptive          
therapy  &  
Prophylaxis 
T- cell lines 
generated 
by CMV 
lystae 
stimulation 
1x105/Kg cultured 
cells(78% CD4, 28% 
CD8) 
 Infusion at day: 28 
Analysis 
of IFN-γ 
response  
and 
multimer 
staining 
CD4:NA 
CD8: 
110x103/ml 
CMV-specific 
T cell therapy 
effectively 
prevents the 
requirement for 
recurrent 
treatment and 
the occurrence 
of late CMV 
disease 
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Feuchtin-
ger 
2010 
   18 Pre-
emptive 
therapy 
IFN-γ 
capture 
selection 
of pp65 
specific  
cells  
 
50x103/kg T-cells : 
21x103/kg CD4 and 
6.7x103/kg CD8  
Infusion at day: 118 
IFN-γ 
response 
to pp65 
NA Clearance or  
> 1 log 
reduction in 
viral load in 
15 patients 
Schmitt, 
2011 
   2 Therapy/ 
Recurrent 
viraemia 
Streptam-
er 
selection 
2.2x105/kg isolated 
T-cells with purity of 
97% 
Multimer 
staining 
CD4:NA   
CD8: 
400x103        
/ml 
Discontinued 
antiviral in 
recurrent 
reactivations 
without 
further high 
titre viraemia 
Peggs, 
2011 
  18 Therapy 
(11 patient) 
Prophylax.-
is (7 
patients) 
IFN-γ 
capture 
selection 
of  pp65 
specific T-
cells 
 
10x103/kg T-cells:  
2.8x103/kg 
CD4,0.63x103/kg 
CD8 infusion: d42 
 
IFN-γ 
response 
to pp65 
CD4:   5x 
103 /ml  
CD8:   17 
x103 /ml 
No patient 
treated 
prophylactica-
lly required 
antivirals; 2 
patients 
treated pre-
emptively 
required no 
antivirals and 
7 had a single 
episode 
Blyth, 
2013 
 50 Prophylax-
is 
 
T-cell 
lines after 
21 days 
stimulati-
on by 
dendritic 
cells 
loaded 
with CMV 
antigens 
 
2x107/m2 CTL 
including : mean 
CD4:26% mean 
CD8:68% 
Infusion: day 45 
IFN-γ 
response 
to pp65 
NA 
There was no 
significant 
difference in 
the incidences 
of CMV 
viraemia, but 
the CMV 
peak titre, the 
number of 
patients 
needed  anti-
CMV drugs 
,the number 
of treatment 
days per 
patient and 
the number of 
patients with 
late CMV 
viraemia were 
significantly 
lower in ACT  
patients   
Koehne/ 
2015 
17 Pre-
emptive 
therapy 
p65 
stimulated  
allogeneic 
T-cells 
0.5-2x106/kg 
including mainly 
CD8 and some CD4 
T-cells 
- - 
15 cleared 
viraemia 
including 3 
out of 5 with 
overt  disease  
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Project aims 
This thesis studied the reconstitution of CMV-specific T-cell responses following 
HSCT and investigated cytokine receptor expression in these cells. The reconstitution of 
T-cell immunity against CMV viraemia was studied in two HSCT patient cohorts: a) 
patients enrolled in a phase II randomised controlled study of adoptive immunotherapy 
for CMV reactivation using ex-vivo HLA-multimer selected donor CMV-specific CD8
+ 
T-cells, and b) non-trial CMV sero-positive HLA-DRB1*0701 HSCT patients. 
The objectives of the clinical trial study were: i) to analyse the reconstitution of CMV-
specific CD8
+
 T cells post immunotherapy and compare with the reconstitution of these 
cells in patients who did not receive cell therapy (control group). ii) to evaluate  the trial 
end point achievement  which defined as reconstitution of 10x10
4
/ml CMV-specific 
CD8
+ 
T-cells within a period of 2 months post-cellular therapy and iii)  to study the 
reconstitution of  non-infused CMV-specific CD8
+ 
and CD4
+
 T-cells in patients who 
received cell therapy in comparison with the control group. 
In the second cohort of HSCT patients, the objective was to explore CMV-specific 
CD4
+ 
T-cell reconstitution following HSCT. For the first time, a novel HLA-class II 
tetramer  was used  i) to analyse the kinetics of CMV-specific CD4
+ 
T-cell 
reconstitution and their phenotypes in relation to CMV-specific CD8
+ 
T-cell 
reconstitution, and ii) to assess the clinical utility of immune monitoring using both 
HLA-class I and II multimers for risk stratification of patients. A further objective of the 
study was to introduce a novel putative HLA-independent marker for monitoring CD4 
immunity against CMV. 
In the final part of this thesis, the expression pattern of receptors to the cytokines 
involved in the cell expansion following HSCT was studied in normal healthy 
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individuals and HSCT patients. Because of the unusual pattern of expression, TNF 
receptor was studied in CMV-specific T cells to explore the functional activity of this 
receptor and its potential role in the contraction of expanded CMV-specific T-cells. 
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Chapter 2 
 
MATERIALS AND METHODS
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 2.1 Study populations  
 
 
2.1.1 ACE-ASPECT trial patients  
 
The clinical trial ACE-ASPECT (Adoptive CMV immunotherapy-Alternate Donor 
Study of Pre-Emptive Cellular Therapy), sponsored by Cell Medica Ltd with 
ClinicalTrials.gov Identifier NCT01220895, was a multi-centre phase II randomised 
controlled trial. The trial had two arms with a randomisation ratio of 2:1 of CMV-
specific CD8
+
 T-cell therapy with best available therapy (BAT) versus BAT only. Nine 
centres recruited patients to the trial (University College London Hospital, Queen 
Elizabeth Hospital, Birmingham, Churchill Hospital, Oxford, City Hospital, 
Nottingham, Manchester Royal Infirmary and the Christie Hospital, Manchester, King’s 
College Hospital, London, Royal Free Hospital, London and University Hospitals 
Bristol NHS Trust). 
The CMV-specific CD8
+ 
T-cells used for ACT were manufactured under the 
sponsorship of Cell Medica by the GMP facilities of the Royal Free Hospital, London 
and NHS Blood and Transplant, Birmingham. 
Eligibility 
The trial was designed for patients undergoing allogeneic stem cell transplant who were 
CMV sero-positive and who received HSCT from HLA-matched CMV sero-positive 
unrelated donors. Patients were 16 years or older and were T-cell depleted in vivo with 
Alemtuzumab incorporated into the conditioning regimen. All patients and donors 
consented to the trial. Patients had also given consent to additional study procedures as 
per study schedule. Donors consented to the use of their harvested stem cells that were 
in excess to what was required for transplantation for selection of CMV-specific T cells. 
Other inclusion criteria included donor engraftment (neutrophils >0.5x10
9
/ml) prior to 
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the cell therapy. Recipients and donors must had to have negative serology for Human 
immunodeficiency virus (HIV), Hepatitis B and C, HTLV 1 and 2, and syphilis. Patients 
and transplant donors shared one or more of the following HLA-class I alleles: A
*
0101, 
A
*
0201, A
*
2402, B
*
0702 and B
*
0801. The following patients were excluded: pregnant 
or lactating women, co-existing medical problems that would place the patient at 
significant risk of death due to GVHD or its sequela, active GVHD > grade I prior to 
CMV-specific T-cell infusion, concurrent use of systemic corticosteroids prior to CMV-
specific T- cell infusion, organ dysfunction to ( prior to cell infusion ) as measured by: 
creatinine > 200 μmol/l, bilirubin > 50 μmol/l alanine transferase > 3x upper limit of 
normal, and donors with less than 50x10
9
/L platelets. 
All patients received Alemtuzumab (Campath-1H) for in vivo T-cell depletion, a 
humanized IgG1 anti CD52 monoclonal antibody that targets lymphocytes and other 
immune cells. Therapeutic CMV-specific CD8
+
 T- cells were infused at the time of 
CMV reactivation  but beyond 28 days post HSCT, to minimise the anti-lymphocyte 
activity of Alemtuzumab which has been shown to remain in the recipient’s circulation 
for at least 28 days post transplant (Morris et al., 2003).  
 
2.1.2 Patients studied for the characterization of CMV-specific CD4
+
 T-cell 
reconstitution post HSCT through the use of HLA-class II tetramers 
Detailed descriptions of 20 CMV sero-positive HLA-DRB1*0701 HSCT patients 
participated in this study are documented in chapter 4. This chapter also contains 
demographics data on studied patients. 
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2.1.3 Healthy blood donors and patients analysed for cytokine receptor expression 
in T-cell subsets 
In order to study the normal pattern of cytokine receptor expression in the peripheral 
blood T-cell subsets and CMV-specific cells, 10 ml heparinised bloods from 27 healthy 
platelet donors (mean age +/- SD: 43 +/- 11.9) were studied following peripheral blood 
mononuclear cells (PBMC) isolation by Ficoll density gradient centrifugation. Freshly 
isolated cells were used to study cytokine receptor expression in T-cell subsets and 
analyse the effect of TNF-receptor ligation. In addition, fresh or frozen PBMC from 5 
non-clinical trial HSCT patients were used to study TNFR in CMV-specific T-cells. The 
patients were under care of transplant unit of Haematology department, Queen Elizabeth 
Hospital, Birmingham and all the patients and healthy blood donors had agreed to 
participate in the study and signed the consent form. 
  
 
2.2 Methods used for immune monitoring of ACE-ASPECT trial 
patients 
 
2.2.1 Peripheral blood processing  
For immune monitoring of CMV-specific immunity after CMV reactivation, peripheral 
blood samples were obtained from 13 patient visits. The first peripheral blood sample 
was taken before the cellular therapy or at the beginning of CMV reactivation in the 
control patients. This was followed by weekly peripheral blood collection for 8 weeks 
and then monthly for 4 months. In total, 13 longitudinal blood sample collections were 
planned for each patient. The blood samples included 16-20 ml blood in heparin and 4-5 
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ml in EDTA tubes. Royal Mail’s first class delivery service was used for the posting of 
blood samples which in most cases, reached to the centralised research laboratory (Stem 
Cell and Immunotherapy, NHSBT Birmingham) for processing and immune monitoring 
within 24 hrs of venesection. 
Heparinised whole blood samples were first centrifuged at 2000 rpm (MSE-Harrier 
18/80R) for 5 min. in order to collect up to 3 ml plasma which was frozen immediately 
at -20 C. The remaining blood was resuspended and mixed at ratio of 1:1 in CliniMACS 
EDTA/PBS buffer (Miltenyi Biotec Ltd) containing 0.5% human serum albumin 
(HAS). This mixture was carefully overlaid onto Lymphoprep (Axis-Shield) at a ratio of 
2:1 in 50 ml sterile Falcon
®
 tubes and centrifuged at 2000 rpm for 20 min at room 
temperature. Following centrifugation, the mononuclear layer was collected with a 
Pasteur pipette and transferred into a fresh 50 ml Falcon
®
 tube and the volume topped-
up to 50 ml with 0.5% HAS-CliniMACS buffer and centrifuged at 1500 rpm for 10 min 
(RT) in order to remove any residual Lymphoprep. The resultant PBMC pellet was re-
suspended in 30 ml 0.5% HAS-CliniMACS and centrifuged at 1200 rpm for another 5 
min. Following the final wash, the PBMC pellet was re-suspended in 1 ml 0.5% HAS-
CliniMACS buffer. Afterward, the cells were counted using a ABX Pentra (Horiba 
Medical) cell counter. The cells were then placed on ice for subsequent staining. To 
determine the total whole blood count, blood from the EDTA tube was diluted 1:10 with 
PBS and analysed with the ABX Pentra cell counter. 
 
2.2.2 Enumeration of CMV-specific CD8
+
 T-cells 
In order to quantify ex vivo CMV-specific CD8
+
 T-cells in the peripheral blood, a dual 
platform flow cytometry assay was used. In the first  staining platform, whole blood 
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was transferred into a Trucount tube (BD Biosciences) in order to enumerate the 
absolute CD3
+
, CD4
+
 and CD8
+
 T-cell numbers, and for the second platform, ficoll 
gradient-separated PBMCs were stained with PE-conjugated Streptamers
®
 (IBA, 
GmbH) and anti-CD3 and CD8 fluorochrome-conjugated antibodies in order to 
determine the frequency of CMV-specific CD8
+
 T-cells. The number of CMV-specific 
CD8
+
 T-cells was then calculated by multiplying the frequency of these cells with the 
absolute count of CD8
+
 T-cells.   
 
2.2.2A Determination of T-cell counts using Trucount tube 
The number of T-cells was determined by using Trucount tubes. 100 µl of blood from 
the EDTA tube was taken by reverse pipetting and transferred into a Trucount tube. 
Next, the following antibodies were added at 5 µl each: anti-CD45-FITC, anti-CD3-
APCH7, anti-CD8-APC and anti-CD4-PECy7 (all from BD Biosciences) (Table 2.1). 
To exclude dead cells, 5 µl of 7-AAD was also added. This mixture was then incubated 
for 30 min at RT in the dark. This was a no wash staining method and prior to FACS 
analysis, RBCs were lysed by 10 min incubation with 1 ml of diluted Pharmlyse ( 1 to 
10 dilution with DDW) (BD Biosciences). The stained cells were analysed by FACS-
Canto II (BD) within 45 min. 
 
2.2.2B Detection of CMV-specific CD8
+
 T-cells 
CMV-specific CD8
+
 T-cells were identified using HLA-class I restricted Streptamers
®
 
(Table 2.2). This was a 2 step procedure and the manufacturer’s recommendation was 
followed. In the first step, 4 µl HLA-class I Streptamer
®
 was mixed with 5 µl 
Streptactin PE (IBA, GmbH) and 41 ml cold 0.5% HAS–CliniMACS buffer. This 
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mixture incubated 45 min on ice in the dark. Following the incubation, PE-conjugated 
Streptamer
®
 was added to up to 5x10
6
/ml PBMCs (kept already on ice) and incubated 
for 45 min on ice in the dark. It was followed by 2 cell washes with 2 ml 0.5% HAS-
CliniMACS buffer (1500 rpm, 5min). Then, cells were stained with the same antibodies 
used for the enumeration of T-cell counts in Trucount tube. SOP (standard operating 
procedure) 2144/3.1, prepared in NHS Blood and Transplant, Birmingham, was the 
SOP for the analysis of CMV-specific CD8
+
 T-cells. 
2.2.2C Flow cytometry analysis of T-cell counts and gating strategy 
For determination of blue and red lasers voltages and compensation values, first a 
compensation set up was established by using PBMCs. BD CompBeads were not used 
since the flow cytometry panel included 7-AAD. Therefore, cells were used and to 
obtain dead cells (7-AAD positive), cells were killed by ethanol. Since Trucount tubes 
contained very small beads labelled with fluorochromes, it was necessary to set a 
threshold on one of fluorescent channels instead of forward scatter (FSC) channel. In 
this regard, threshold of 1200 FITC was chosen for acquiring stained cells. The gating 
steps included: plotting 7-AAD versus side scatter (SSC) in order to exclude dead cells, 
then plotted FSC versus SSC for lymphocyte gating which then followed by plotting 
CD3-APCH7 against SSC which allowed detection of CD3
+
 T-cells and then by 
selecting this population, a plot for CD4-PECy7 versus CD8-APC was made in order to 
identify CD4
+
 and CD8
+
 populations (Figure 2.1A). To detect the population of 
counting beads, APC or APCH7 against SSC channel was plotted and a very bright 
population of events with high FCS and SSC classified as beads. The number of events 
in the beads population was used in the following equation to obtain cell counts: 
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CD8
+
cell number/µl= number of cell events X beads count/ number of beads event X test 
volume(100µl) 
Figure 2.1A Flow cytometry gating strategy for identification of T-cells and counting 
beads. 
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In the first staining platform, whole blood cells were stained in BD-Trucount tubes in 
order to calculate the number of CD8
+
 T-cells in the peripheral blood. Gating strategy 
included identification of the beads region, viable lymphocytes and their T-cell subsets. 
This tube did not include Streptamers
®
. 
 
Figure 2.1B Flow cytometry gating strategy for identification of T-cells and counting  
beads. 
 
In the second platform, Streptamer® staining was performed to obtain the frequency of 
viable CMV-specific CD3
+
 CD8
+
 T-cells. This staining tube did not include the 
counting beads, but the FACS voltages and compensation settings were the same as the 
first staining tube. 
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In order to have reliable results, at least 100,000 events were collected in Trucount tubes 
and if the patient was lymphopenic, all of the lysed blood sample was acquired. Due to 
very low lymphocyte count in some cases, up to 400 µl blood (instead of routine 100 µl 
blood) was added to Trucount tubes and the volume of Pharmlyse adjusted accordingly.  
The flow cytometry gating strategy was the same for both platforms (tubes) with the 
exception that  the second tube with Streptamer
®
 had no counting beads and cells 
stained with Streptamer
®
 were gated out from CD8
+
 T-cells to obtain their frequency 
(Figure 2.1B) and consequently their number using the following formula: 
 
CMV-specific CD8
+
 T-cell number/ µl = percent of CMV-specific cells in CD8
+ 
population X CD8
+ 
T-cell number in 1µl /100 
 
The detection limit of CMV-specific T-cells was set up as 0.10% of CD8
+
 T-cells 
following a series of preliminary experiments and previous findings (Yao et al., 2008). 
This was due to non-specific staining of cells by Streptamer
®
 in some samples which 
could be up to 0.07% of CD8
+
 T-cells. In addition, only clustered and not scattered dots 
were accepted as positive Streptamer
®
-PE stained cells. 
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2.2.3 Functional behaviour of CMV-specific T-cells in ACE-ASPECT trial patients 
2.2.3A Phenotypic analysis of CMV-specific CD8
+
 T-cells 
Phenotypic analysis of CMV-specific CD8
+
 T-cells was carried out in some patients 
who were not as lymphopenic and from whom we had extra cells for this study. 
Following Streptamer
®
 staining, PBMCs were stained with anti-CCR7-FITC (10 µl) 
(R&D Systems) and 5 µl of the following antibodies: anti-CD45RA-PECy7 (BD 
Biosciences), anti-CD57-APC (Biolegend), anti-CD8-APCeflour 870 (eBiosciences) 
and 7-AAD. The incubation time was 30 min at 4C which was followed by one cell 
wash with PBS. 
 
2.2.3B Functional analysis of CMV-specific CD8
+
 T-cells through flow cytometry  
Functional behaviour of CMV-specific CD8
+
 T-cells was studied using intracellular 
cytokine staining method (Lachmann et al, 2012). Freshly isolated PBMCs were 
suspended in RPMI-1640 with 10% heat inactivated human AB serum (Biosera) at 
density of 0.5x10
6 
cells/0.5 ml in sterile capped 12x75 mm propylene tubes (Table 2.4). 
Cells were stimulated with 1 µg/ml of viral peptides (Table 2.5) or stimulated with 
peptide dissolvent as a negative control in the presence of 5 µg/ml anti-CD28/CD49d 
antibody (BD Biosciences) as a co-stimulatory molecule. PBMCs stimulated with SEB 
(Sigma) (0.5 µg/ml) served as positive control for this assay.  Following one hour 
incubation of cells in a humidified incubator at 37C with 5% CO2, freshly thawed 
Brefeldin A (Sigma) at concentration of 5 µg/ml was added to the cell culture and cells 
were incubated for an extra 14 hours at 37C, 5% CO2. After the incubation period, tubes 
were vortexed to mix, centrifuged at 1500 rpm for 5 min at RT and the cell pellet re-
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suspended in 1 ml PBS before cell wash (1500 rpm, 5min). The supernatant was 
completely discarded and 100 µl fixation solution (Caltag A medium, Invitrogen) was 
added. This mixture was incubated for 20 min at RT in the dark before addition of PBS 
for cell wash. After that, the supernatant was completely removed and 80 µl 
permeabilization solution (Caltag B medium) was added. Then the following antibodies 
for cell surface and intracellular staining were added at 5 µl: anti-CD8-APC-efluore780 
(eBiosciences), anti-CD3-PE (R&D systems), anti-TNFα-PECy7, anti-IL2-FITC, 7-
AAD and anti-INFγ-APC (2 µl) (all from BD Biosciences). Stained cells were then 
incubated for 25 min at RT (protected from light) and after that, washed as before and 
analysed by flow cytometry (FACSCanto-II) immediately after final wash. The details 
of antibodies and isotype controls are listed in Table 2.1 and Table 2.3.  
 
2.2.4 Reconstitution of CMV-specific CD4
+
 T-cells in ACE-ASPECT trial patients 
Due to lack of relevant HLA-class II specific Streptamers
®
 or tetramers, CMV-specific 
CD4
+
 T-cells were detected using intracellular cytokine staining after cell stimulation 
with CMV lysate (provided by Professor Moss group). PBMCs at concentration of 
0.5x10
6
/ml in RPMI plus 10% heat inactivated human AB serum were stimulated with 5 
µl of CMV lysate and anti-CD28/CD49d antibody (5 µg/ml) (BD Biosciences) for 1 
hour at 37C in 5% CO2 incubator before adding Brefeldin A. After further 14 hours 
incubation, the procedure mentioned in the section 2.2.3B was followed with the 
exception of adding anti-CD4-APCefluor780 (5 µl) (eBiosciences) instead of adding 
anti-CD8 antibody. 
 
2.2.4A Flow cytometry analysis of CMV-specific T-cell phenotype and function 
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Different compensation set ups were prepared for FACS analysis of different staining  
panels. Flow cytometry threshold was set as FSC 20000. For phenotypic analysis, up to 
200,000 lymphocytes were acquired and then a plot for CCR7-FITC versus CD45RA-
PECy7 was prepared. For functional studies, CD3
+ 
T-cells were gated out from the 
lymphocyte population and then, CD4
+
 or CD8
+
 T-cells were identified. To obtain final 
frequencies of cytokine producing cells, background subtraction was performed by 
deducting frequency of cytokine producing cells in unstimulated PBMC from cells 
producing the same cytokine after antigenic stimulation. For determination of cells 
producing different combination of cytokines, the Boolean gating strategy was adopted. 
In all cases, IFN-γ producing cells had the highest frequencies. Therefore, CD4+ or 
CD8
+ 
T-cells producing IFN-γ were first identified and amongst them, cells producing 
either IL-2, TNF-α or both were then determined. This method measured the 
frequencies of different expression profiles corresponding to single, double and triple 
cytokine producing cells. 
In all the flow cytometry assays, FACS-Diva software version 6.3 (BD) was used for 
cell acquisition and data analysis.  
 
2.2.5 IFN-γ Elispot for analysis of CMV-specific T-cell function 
 Functional activity of CMV-specific T-cells was analysed by Elispot method as well. In 
the first day of experiment, PVDF membrane in non-sterile 96 wells plate (MAIPN45) 
(Milllipore) was activated by adding 15 µl 35% Ethanol in distilled water for maximum 
1 min. During this step, extra care was carried in order to cover all membrane area with 
Ethanol. After removing Ethanol by flicking out, the plate was washed 5 times with 200 
µl distilled water. It was followed by adding 50 µl anti-IFN-γ (1-D1K) (Mabtech) at 15 
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µg/ml (67 fold dilution) in PBS in order to coat the plate. Following overnight 
incubation at 4C, the plate was washed 5 times with 200 µl sterile PBS and blocked 
with 50 µl RPMI with 10% human serum for at least one hour at 37C. Then, the 
blocking solution was removed and without any wash, cell suspension at concentration 
of 2.5x10
5
 in 100 µl RPMI+10% human AB serum was added. PBMCs were stimulated 
with two CMV peptide pools; CMV pp65 and CMV IE-1 PepTivator Peptide Pool 
(Miltenyi Biotec). These peptide pools contained 15-mer peptides with 11 amino acid 
overlap. Manufacturer’s recommended working concentration of these antigens was 
used which gave a final concentration of 1µg/ml for each peptide in the pool. In 
addition, PBMCs were stimulated with individual CMV derived peptides (Proimmune) 
(1 µg/ml) based on the HLA type of patients (Table 2.5). As positive control, cells were 
incubated with SEB (0.5 µg/ml) and all stimulations were performed in triplicate. In 
order to obtain background response, cells were stimulated with the peptide diluents and 
the plate was incubated overnight (37C, 5% CO2). Following incubation, cells were 
removed and Elispot plate was washed 5 times with 200 µl PBS. It was followed by 
adding 50 µl of the secondary anti-IFN-γ antibody conjugated with biotin (7-B6-1) 
(Mabtech). The final concentration of this antibody was 1 µg/ml and prepared by 1000 
fold dilution of original concentration in PBS+0.5% FCS. The incubation time was 2 hrs 
at RT which was followed by 5 times wash with 200 µl PBS. Then 50 µl Streptavidin-
Alkaline Phosphatase (diluted 1:1000 in PBS with 0.5%FCS) was added for 1 hr at RT. 
After 4 times wash with PBS and once with distilled water, 50 µl BIO-RAD detection 
solution was added. For 5 ml of this solution, 200 µl AP buffer (BIORAD), 50 µl 
BIORAD-reagent A and 50 µl reagent B were added to 4.7 ml distilled water. This was 
incubated at RT until enzymatic reaction developed in the format of visible spots (30 to 
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60 min). When spots became visible, the front and back of plate were thoroughly 
washed with tap water and left at RT to be air dried. The number of spots in each well 
was enumerated using the AID Elispot- reader and mean numbers of dots (in triplicate 
wells) were reported following deduction of background dots in negative control wells. 
 
2.3 Methods used for the analysis of CMV-specific CD4
+
 T-cell 
reconstitution after HSCT by HLA-class II restricted tetramers 
 
Characterisation of reconstituting CMV-specific CD4
+
 T-cells in non-clinical trial 
HSCT patients was conducted through usage of a novel HLA-class II tetramer. The 
HLA-class II tetramer was consist of HLA-DRB1*0701 and CMV glycoprotein B-
derived peptide DYSNTHSTRYV (DYS) and custom made by Benaroya Research 
Institute, WA. For detection of CMV-specific CD8
+
 T-cells, Streptamers
®
 were used 
(Table 2.1). To obtain frequencies of CMV-specific T-cells, the second flow cytometry 
panel described in section 2.2 was used which contained anti-CD45-FITC, anti-CD3-
APCH7, anti-CD8-APC and anti-CD4-PECy7 and 7-AAD (all at 5 µl each) (Table 2.1).  
Total lymphocyte count reported in routine monitoring of haematological parameters 
(Clinical Haematology Service, Queen Elizabeth Hospital) was considered for 
enumeration of total and CMV-specific T-cells. This method may underestimate the 
actual number of cells since some of them die during PBMC isolation or cell freezing 
process. In this study, different flow cytometry panels were designed in order to 
characterise the phenotype of T-cells which included T-cell subset phenotypes, cytokine 
receptor expression and staining for intracellular perforin, granzyme B and T-bet. In 
order to detect intracellular expression of above mentioned molecules, cells were first 
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stained with multimers as described before and then fixed with Caltag A reagent (100 
µl/RT/20 min), washed with PBS and 80 µl Caltag B reagent was added with antibodies 
against perforin, granzyme B and T-bet for 20 min at RT and in dark. Stained cells were 
analysed immediately.  
Tables 2.1 and 2.3 list the detail of antibodies and isotype controls used in this study. In 
all flow cytometry analysis, appropriate isotype controls with the same concentrations 
as the main antibodies were used to discriminate positive from negative population. 
 
2.4 Methods used for analysis of cytokine receptor expression in T-cell 
subsets and effects of TNFR2 on differentiated T-cells 
 
 Analysis of cytokine receptor expression and effects of TNFR2 ligation was performed 
on healthy blood donors and HSCT patients. In order to study the results of TNFR2 
ligation in recently activated CMV-specific T-cells, PBMCs from HSCT patients were 
used.  
Detection of cytokine receptor expressing cells was dependent on using isotype controls 
in order to distinguish between negative and positive cells. Detailed information on anti-
cytokine receptor antibodies and their isotype controls are presented in Tables 2.6 and 
2.7. In addition, the following antibodies were used: anti-CD4 and anti-CD8-APC-
eFlour 780 (e-Biosciences, UK), anti-CCR7- FITC (R&D Systems, UK), anti CD45RA-
PE-Cy7, anti CD3-Percp, and 7-AAD (all from BD Biosciences, UK), anti CD57-APC 
(Biolegend, San Diego). CMV specific CD8
+ 
T-cells were identified by using HLA-
class I Streptamers
®
.
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CMV-specific CD4
+ 
T-cells were identified through usage of HLA-DRB1*0701 
restricted DYS tetramer. 
2.4.1 Flow cytometry analysis 
Following blocking of immunoglobulin receptors with 1ul human IgG, PBMCs in 
phosphate buffered saline (PBS) were incubated with 10ul of PE conjugated anti 
cytokine receptor antibodies for 35 min at RT. After two washes, cells were incubated 
for 30 min in RT with the rest of antibodies including anti-CCR7, CD45RA, either CD4 
or CD8, CD3 and CD57 molecules. After final wash, cells were immediately acquired 
by FACS-Canto II flow cytometry (BD) and data analysed with FACS-Diva software 
(version 6.2, BD). In order to discriminate cytokine receptor positive cells from 
negative population, isotype control was used at similar concentration to anti cytokine 
receptor antibodies.  
 
2.4.2 Detection of TNFR2 expression in CMV-specific CD8
+ 
T-cells 
Streptamers
®
 were incubated with up to 1x10
6
/ml PBMC for 45 min on ice. Following two 
washes, 3 ul of anti TNFR2–biotin (BD Pharmingen) was added to the cells (30 min at 4◦C) and  
after wash, cells were incubated with APC-Streptavidin (BD Pharmingen) for 15 min at 4
◦
C, 
washed and stained with anti-CD3 and CD8 antibodies. 
 
2.4.3 Cell incubation with TNFR2 ligand 
PBMC at concentration of 1x10
5
/ml in 200ul of RPMI with 10% FCS were incubated 
with 50,100 and 200 ng/ml of TNFR2 ligand (Flag-TNC-scTNF (143N/145R)) (a 
courtesy gift from Professor Harald Wajant, Division of Molecular Internal Medicine, 
Würzburg University Clinics, Wuerzburg, Germany) for 3 days. Following incubation 
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period, cells were washed, re-suspended in100ul of PBS and transferred to the Trucount 
tubes (BD). Then, anti CD3, CD4, CD8 antibodies and 7-AAD were added in order to 
quantify the number of viable T cells.  For the measurement of CMV-specific T cells, 
incubated cells were first stained with the Streptamer
® 
as mentioned before and then 
transferred to the Trucount tubes. The cell numbers after incubation with the ligand 
were compared with the number of un-stimulated cells (without ligand) in order to 
detect any change in the cell number. For the detection of apoptotic cells after 
incubation with TNFR2 ligand, Annexin V-FITC kit (Trevigen, Gaithersburg, MD) was 
used to discriminate apoptotic from necrotic CD8
+ 
T-cells. For this experiment, CD8
+
 
T-cells were isolated from PBMCs of a healthy blood donor by using CD8
+
 isolation kit 
(Miltenyi Biotec). Then, cells were labelled with anti-TNFR2-PE and TNFR2 positive 
cells were separated from TNFR2 negative CD8
+
 T-cells through usage of anti-PE 
MicroBeads (Miltenyi Biotec). Following manufacturing recommendations, cells from 
positive (TNFR2
+
) and negative (TNF2
-
) were collected and cultured at 1x10
5
 
cells/100µl RPMI with 10%FCS. Flag-TNC-scTNF (143N/145R) at concentrations of 
50, 100 and 200ng/ml were incubated with the isolated cells for 21 hrs at 37C, 5% Co2. 
This was followed by cell staining with Annexin V-FITC kit and analysis of stained 
cells by flow cytometry method. 
 
2.5 Statistical analysis 
Non-parametrical Mann-Whitney test and parametrical t-test were used for statistical 
comparison between two groups of data. For correlation analysis, non-parametrical 
Spearman’s rank coefficient correlation test was used. All statistical analysis and graph 
preparations were made through GraphPad Prism software version 5 (La Jolla, USA). 
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Table2.1 List of antibodies used in detection and phenotypic analysis of CMV-specific 
CD4
+
 and CD8
+
 T-cells. 
 
Antibody 
 
 
Fluorophore Source Catalogue 
number 
 
Isotype* Volume 
(µl) 
 
 
 
 
 
 
(µl) 
 
CD3 APC-H7 BD Biosciences 641397 IgG1,κ 5 
CD4 PE-Cy7 BD Pharmingen 557852 IgG1, κ 5 
CD8 APC BD Pharmingen 555369 IgG1, κ 5 
CD45 FITC BD Biosciences 345808 IgG1, κ 5 
CD45RA PE-Cy7 BD Pharmingen 560675 IgG2b, κ 5 
CCR7 FITC R&D Systems FAB197F IgG2a 10 
CD8 APC-eFluor 780 eBiosciences 47-0087-42 IgG1, κ 5 
CD4 APC-eFluor 780 eBiosciences 47-0049-42 IgG1, κ 5 
CD57 APC Biolegend 322314 IgM 7 
Perforin FITC eBiosciences 11-9994-42 IgG2b, κ 5 
Granzyme b FITC BD Biosciences 560211 IgG1,κ 20 
T-bet PerCP-Cy5.5 BD Biosciences 561316 IgG1, κ 5 
CD25 PE-Cy7 BD Biosciences 557741 IgG1, κ 5 
CD127 FITC eBiosciences 11-1278-42 IgG1, κ 5 
IL-2 FITC BD Biosciences 340448 IgG1, κ 20 
IFN-γ APC BD Biosciences 554702 IgG1, κ 3 
TNF-α PE-Cy7 BD Biosciences 557647 IgG1, κ 5 
CD3 PE R&D systems FAB100P IgG1 5 
*All the monoclonal antibodies are mouse immunoglobulin   
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Table 2.2 List of MHC class I Streptamers® ( IBA, BioTagnology GmbH). 
 
Streptamer Catalogue number 
 
MHC I-Strep HLA-A*0101; CMV pp50; VTEHDTLLY 
 
6-7024-005 
MHC I Strep HLA-A*0201; CMV pp65; NLVPMVATV 
 
6-7001-005 
MHC I Strep HLA-A*0201; CMV IE1;  VLEETSVML 
 
6-7041-005 
MHC I Strep HLA-A*2402; CMVpp 65; QYDPVAALFL 
 
6-7028-005 
MHC I Strep HLA-B*0702; CMVpp65; TPRVTGGGAM 
 
6-7027-005 
 MHC I Strep HLA-B*0801; CMV IE1;  QIKVRVDMV 
 
6-7017-005 
  MHC I Strep HLA-B*3501; CMV pp65; IPSINVHHY 
 
6-7048-005 
 
 
 
 
Table 2.3 List of isotype controls used in the phenotypic analysis of CMV-specific T-
cells.  
 
Fluorophore* Isotype Source Catalogue 
number 
Volume 
(µl) 
FITC IgG2b,κ eBiosciences 11-4732 0.6 
FITC IgG1,κ BD Biosciences 551954 3 
PerCP-Cy5.5 IgG1, κ BD Biosciences 550795 1 
PE-Cy7 IgG1, κ BDBiosciences 557872 1 
FITC IgG1, κ eBiosciences 11-4714-73 0.6 
* These isotype controls were used for perforin, granzyme B, T-bet, CD25 and CD127 
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Table 2.4 Reagents and consumables used in the study of CMV-specific T-cells. 
 
Reagents/Consumable Source Catalogue number 
 
Trucount tube 
 
BD Biosciences 340334 
BD Pharm Lyse 
 
BD Biosciences 555899 
Lymphoprep 
 
Axis-Sheild PoC AS 1114545 
CliniMACS PBS/EDTA 
buffer 
Miltenyi Biotec GmbH 700-25 
RPMI-1640 
 
Sigma R8758 
Human Serum Albumin 
(Zenalb 20) 
Bio Products Laboratory - 
Centrifuge tube(50 ml) 
 
Corning 430921 
Centrifuge tube(15 ml) 
 
Corning 430791 
FALCON  tubes 
(5 ml sterile) 
FALCON 352054 
Sterile water 
 
Baxter UKF7114 
Vacutainer- 9ml 
(lithium Heparin) 
BD 455084 
Vacutainer- 4 ml 
(EDTA) 
BD 454021 
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Table 2.5 Antigens and reagents used for the cell stimulation assay. 
 
Antigens/ 
Reagents 
Source Catalogue 
number 
Concentration 
(µg/ml) 
CMV /peptide 
NLVPMVATV 
Proimmune CPD7383 
 
1 
CMV/peptide 
VTEHDTLLY 
Proimmune CPD7384 1 
CMV/peptide 
TPRVTGGGAM 
Proimmune CPD7385 1 
CMV/peptide 
QIKVRVDMV 
Proimmune CPD7386 1 
CMV/peptide 
QYDPVAALF 
Proimmune CPD7388 1 
SEB 
 
Sigma S0812 0.5 
Brefeldin A 
 
Sigma 37651 5 
Anti 
CD28/CD49d 
 
BD Biosciences 347690 5µl 
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Table 2.6 List of  anti- cytokine receptor antibodies. 
 
Antibody 
 
 
Fluorophore/ 
Conjugate 
Source Catalogue 
number 
 
Isotype* Volume 
(µl) 
 
CD25(IL2Ra) 
 
PE AbD 
serotec 
MCA2127PE IgG1 5 
CD127(IL7Ra) 
 
PerCP/Cy5.5 Biolegend A019D5 IgG1 5 
CD130(gp130) 
 
PE R&D 
Systems 
FAB228P IgG1 10 
CD120a(TNFRI) 
 
PE R&D 
Systems 
FAB225P IgG1 10 
CD120b(TNFRII) 
 
PE R&D 
Systems 
FAB226P IgG2a 10 
IL15Ra 
 
PE R&D 
Systems 
FAB1471P IgG2b 10 
CD120b(TNFRII) 
 
Biotin BD 
Biosciences 
552477 IgG2b 3 
*All monoclonal antibodies are mouse immunoglobulin with exception of anti -
CD120b-biotin which is rat IgG2b 
 
 
 
Table 2.7 Isotype controls used in the cytokine receptor study. 
 
Fluorophore* Isotype Source Catalogue 
number 
Volume 
(µl) 
 
PE IgG1 AbD 
serotec 
MCA928PE 5 
PerCP/Cy5.5 IgG1 Biolegend 
 
MOPC-21 2 
PE IgG1 R&D Systems 
 
IC002P 10 
PE 
 
IgG2a R&D systems IC003P 10 
PE 
 
IgG2b R&D systems IC0041P 10 
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                                     Chapter 3  
 
RECONSTITUTION OF CMV-
SPECIFIC T-CELLS FOLLOWING  
CELLULAR THERAPY 
(Phase II trial: ACE (Adoptive Cellular Immunotherapy)- 
ASPECT (Alternate Donor Study of Pre-emptive Cellular 
Therapy ) 
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3.1 Background 
3.1.1 Adoptive cellular therapy- Phase I clinical trial 
Consistent immune control of lifelong CMV infection is required for protection against 
overt replication of the virus. Immune suppression in the transplant setting leads to the 
reactivation of CMV and CMV DNAaemia, associated with considerable morbidity and 
mortality. CMV reactivation can cause multiorgan disease in HSCT patients, including 
pneumonia, hepatitis, gastroenteritis, retinitis, and encephalitis, and the disease can 
develop both early and late after the transplantation procedure (Boeckh and Ljungman, 
2009). Adoptive cellular therapy with CMV-specific CD8
+ 
T-cells is a promising 
strategy for accelerating immunity against CMV post transplantation. One of the 
methods for the generation of CMV- reactive cells is direct T-cell isolation by means of 
magnetic beads. This method allows rapid access to the T-cells without need for labour-
intense and prolonged in vitro culture. In addition, because ex vivo selection does not 
alter the function and identity of cells, it is considered as minimally manipulated and 
therefore not considered as an investigative advanced therapeutic medicinal product 
(ATMP). Compared to in vitro cell expansion, direct cell selection is easier to achieve 
GMP-compliance (Sellar et al., 2014). In a phase I clinical trial conducted in 
collaboration between the University of Birmingham and NHS Blood and Transplant, 
CMV-specific CD8
+  
T-cells from stem cell donors were isolated using a GMP-grade 
immunomagnetic column (cliniMACS
®
) with HLA-class I tetramers labelled with PE 
fluorophore and a secondary anti-PE magnetic beads (Cobbold et al., 2005). Transfer of 
isolated cells with median cell dosage of 8.6x10
3
/kg (median total 0.5 x 10
6
) into 9 
HSCT patients showed persistence of therapeutic cells in the treated patients and 
clearance CMV infection in 8 out of 9 including one patient with a history of prolonged 
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CMV infection. Seven of these 9 patients, received CTLs after the first episode of 
viraemia and 2 patients were treated for persistent viraemia. CTLs were infused within 4 
hrs of selection and had a median T-cell purity of 95.6%. CMV-specific CD8
+
 T-cells 
were detectable within a median of 10 days after cell therapy and their presence was 
maintained during the follow-up period of up to 24 months. The number of CMV-
specific CD8
+
 T-cells reached its peak level between 12 and 30 days post T-cell 
infusion with a range of 1-156 cells/µl of blood. It was also shown that CTLs were 
functional and able to produce IFN-γ. 89% of patients controlled CMV viraemia and 
there was a reduction in the use of ganciclovir by 48%. Three out of nine patients in this 
phase I trial had received stem cell transplant from unrelated donors which is considered 
a high risk factor for CMV reactivation. One of these 3 patients experienced 4 months 
of persistent CMV reactivation with no detectable CMV-specific CD8
+
 T-cells prior to 
cell therapy. Four days after infusion of therapeutic cells, CMV-specific CD8
+
 T-cells 
were detectable and the CMV viraemia was cleared at 11 days after infusion. The 
second patient with unrelated stem cell transplant had no CMV-specific immunity 
before cell infusion and was able to control the viraemia after that. The third patient also 
cleared viraemia following cell therapy. These results and lack of significant GVHD in 
patients, clearly demonstrated the safety and tolerability of adoptive cell therapy, with 
preliminary evidence of efficacy.  
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3.1.2 Adoptive cellular therapy- Phase II clinical trial  
Following the successful conclusion of the phase I trial, a randomised phase II clinical 
trial named ACE-ASPECT was conducted, a collaboration between Cell Medica, Ltd as 
sponsor, University of Birmingham and NHS Blood and Transplant. The primary 
objective of this study was to evaluate the immunological efficacy of pre-emptive 
CMV- specific adoptive cellular therapy following T-cell depleted allogeneic HSCT in 
terms of the peak number of circulating CMV-reactive CD8
+
 T-cells within the first 2 
months post-ACT. The trial had two arms: arm A enrolled patients for cell therapy plus 
antiviral treatment and arm B enrolled patients who received best available therapy 
(BAT) using standard of care antiviral drugs alone for the treatment of CMV 
reactivation. The CMV-specific CD8
+ 
T-cells were selected from the original donor 
stem cell harvest, using excess cells that were not required for transplantation and DLI 
storage. Selection of CMV-specific T-cells were immunomagnetically performed from 
these fresh harvests using a GMP grade magnetic column CliniMACS after incubating 
the cells with novel commercially available CMV-specific  HLA-multimers 
(Streptamers
®
) that were directly linked to magnetic beads by Stage Cell Therpeutics, 
GmbH (Gottingen, Germany) (Figure 3.1). After isolation and further processing, cells 
were transferred to a cryobag or cryovial at a maximum cell number of 3x10
4 
CD3
+
 T-
cells per kg of recipient body weight. Following CMV reactivation, the cryopreserved 
cell product was released from the laboratory and transported to the patient’s bedside, 
thawed rapidly at 37°C and infused intravenously. 
A total of 52 CMV sero-positive patients undergoing T-cell depleted allogeneic HSCT 
using CMV sero-positive donors were recruited to the ACE-ASPECT. 24 patients 
(46%) were withdrawn from the study due to GVHD, leukaemia relapse and other 
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reasons and did not complete the immune assessment programme. The immune 
reconstitution was analysed in the remaining 28 evaluable patients. 17 patients were 
randomised to receive CMV-specific CD8
+
 T-cells plus antiviral treatment (arm A). 11 
patients were randomised to the BAT group to receive only antiviral drug for the 
treatment of CMV viraemia (arm B) and among them, 10 had evaluable immune 
monitoring data.  
 
3.1.2A Study objectives and endpoints 
The primary objective of this study was to evaluate the efficacy of immune 
reconstitution of pre-emptive CMV-specific adoptive cellular therapy following T-cell 
depleted allogeneic HSCT in terms of the peak number of circulating CMV-reactive 
CD8
+
 T-cells within the first 2 months post-ACT. The secondary objectives included: 
the incidence and severity of GVHD, the time to detection of CMV-reactive T-cells post 
ACT, evaluation of the potential clinical benefit of cell therapy following T-cell 
depleted allogeneic HSCT as measured by reduction in CMV anti-viral drug treatment 
and number of in-patient days and investigate the feasibility of use of ACT generated 
from G-CSF mobilised peripheral blood. The primary endpoint was the percentage of 
patients with a peak number of circulating CMV-reactive T-cells above 10x10
3
/ml 
within the first two months post single positive PCR result (or ACT infusion).  
The reconstitution of CMV- specific CD8
+
 T-cells were monitored using HLA-class I 
restricted Streptamers
®
, weekly for the first 56 days post cell therapy and then monthly 
for 4 months up to a total of 6 months post CTL infusion/ first viral detection (control 
group).  
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Arm A: Antiviral therapy + pre-emptive ACT 
using HLA Multimer Selection 
Arm B: Best available antiviral drug therapy 
RCT- 2:1 randomisation
Inclusion criteria                                              Exclusion criteria
• Unrelated Donors                                                         GVHD II or systemic steroids
• High CMV risk: CMV D/R+/+; -/+ Alemtuzumab T Cell Depletion
• Selection from Stem Cell Harvest
• Donor >0.1% streptamer detectable CMV-CTL
ACE – ASPECT
Adoptive CMV ImmunmothErapy - Alternate Donor Study of Pre-Emptive Cellular Therapy
Phase II randomised controlled trial of pre-emptive CMV adoptive CTL immunotherapy for patients 
receiving HSCT from unrelated donor. Total: 52 patients recruited. Study completed Feb 2014
Endpoint:
Reconst. of CMV-CTL 
to 10x106/L by D56
 
Figure 3.1 ACE Trial arms (ACT and control arms) and cell therapy plan for ACT 
arm 
                                                                    72 
 
3.2 Results 
 
3.2.1 Quality controls for the quantification of T-cells 
3.2.1A Internal controls  
In order to perform T-cell staining with internal controls in place, BD™ Multi-Check 
Control was used. This is a stabilized preparation of normal peripheral blood which is 
used for control of immunophenotyping by flow cytometry. The BD™ Multi-Check is 
a control for antibody staining, red blood cell lysis, instrument setup and performance, 
and data analysis. Figure 3.2 shows the CD3
+
, CD4
+
 and CD8
+
 T-cell counts of BD™ 
Multi-Check samples obtained in our assay and reported by BD. T-cell counts 
obtained by our flow cytometry method were in close match with the counts given by 
BD. The coefficient of variations (CV) of the cell counts obtained by our method and 
reported by BD were less than 10% in all cases. As an example, the following cell 
counts were calculated by our assay: 1330/µl, 845/µl and 364/µl for CD3
+
, CD4
+
 and 
CD8
+
 T-cells in BD™ Multi-Check with Lot Number: BM072N. The reported cell 
counts by BD were: 1210/µl, 776/µl and 365/µl for CD3
+
, CD4
+
 and CD8
+
 T-cells, 
respectively. The resulted CVs for these cell counts of CD3
+
, CD4
+
 and CD8
+
 T-cells 
were 7.4%, 8.9% and 0.2% , respectively. 
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Figure 3.2 Internal quality control of flow cytometry method used for T-cell 
quantification.  
Cell counts of BD™ Multi-Check samples, calculated by our assay (blue bars) in comparison to 
the cell counts reported by BD (grey bars). The X axis shows five different BD™ Multi-Check 
samples with the following Lot numbers: BM112N, BM082N, BM072N, BM100N and BM068. 
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3.2.1B External quality control 
 
National External Quality Assurance Scheme (NEQAS) samples were used to check the 
quantification of CD3
+
, CD4
+
 and CD8
+ 
T-cells using established flow cytometry settings and 
panels. The results were compared with the mean consensus results reported for NEQAS blood 
samples. Figure 3.2 shows the results of T-cell counts of the NEQAS blood samples calculated 
by our assay (bright brown bars) in comparison to the cell numbers reported by NEQAS (bright 
red bars). In each case, the experiments were performed in duplicate and the mean of cell counts 
documented. In all the tested samples, CVs between calculated CD4
+
 and CD8
+ 
T-cell counts and 
cell counts reported by NEQAS were less than 10%. This was within acceptable range according 
to the NEQAS reports (Figure 3.3). The CVs for CD3
+
 counts were above 10%, averaging 11.1% 
above mean consensus counts reported by NEQAS. This was found to be due to the degradation 
of fluorochrome bound to anti-CD3. This fluorochrome was a tandem dye named APC-H7 which 
degraded and produced non-specific signals in APC channel (Le Roy et al., 2009). In order to 
minimize the consequences of this problem, a tight CD3 gate in FACS plots was chosen to 
include only bright clustered cell population. However, it should be mentioned that the CD3 
count was not a vital parameter in this study and CD3 staining was mainly used to identify CD8
+
 
CD3
+
 T-cell population. The CD8 count determined by our flow cytometry was however, in 
close accordance with NEQAS counts. 
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Figure 3.3 External quality control of flow cytometry method used for T-cell 
quantification.  
 
The numbers of CD3
+
, CD4
+
 and CD8
+
 T–cells in the NEQAS blood samples, calculated by 
used method in this thesis (bright brown bars) in comparison to the cell counts reported by 
NEQAS (pink bars). The X axis shows identification numbers of 10 different blood samples 
provided by NEQAS and used for the comparison analysis. 
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3.2.1C Control of Streptamer
®
 staining 
CMV-specific T-cell numbers were quantified by staining of PBMCs with HLA-class I 
Streptamers
®
. Streptamers
®
 are complexes of HLA-class I molecules, antigenic peptide 
and Strep-Tactin conjugated to a fluorochrome (Figure 3.4). In order to control the 
staining with this reagent, a series of experiments were performed. First, staining with 
Streptamers
®
 was compared with HLA-class I tetramer staining. HLA-class I tetramers 
are the original and most used reagent for staining specific T-cells through interaction of 
TCR and HLA-class I molecule. 
In these experiments, PBMCs from CMV sero-positive HSCT patients and healthy 
blood donors with different types of HLA-class I molecules were stained in parallel 
with Streptamers
®
 and tetramers. In the next step and to check non-specific staining 
properties of Streptamers
®
, PBMCs of donors with HLA types different from HLA 
molecules of Streptamers
®
, used for T-cell staining. For example, HLA-A*0201/NLV 
Streptamer which binds TCR of HLA-A*0201 donor was used to stain PBMCs of HLA-
B*0701 donor. In addition, we checked non-specific bindings of Streptamers
®
 to CD3
+ 
CD4
+
 T-cells in CMV sero-positive donors. The results showed that both Streptamers
®
 
and tetramers detect similar frequencies of CMV-specific T-cells and in some cases, 
there were a low no non-specific binding of Streptamers
®
 to PBMCs from a donor with 
non-relevant HLA-types (Table 3.1). There were also low frequencies of non-specific 
binding to CD4
+ 
cells in some cases. In order to reduce background staining, a step 
including three washes after cell staining was introduced and a threshold level of 0.10% 
CD3
+ 
CD8
+
 Streptamers
®+
 cells was determined as cut off. Streptamer
®
 positive cells 
with the frequency of less than 0.10% of CD8
+
 T-cells were not reported as CMV-
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specific T-cells. Frequencies of above this level and if the stained cells had a 
demarcated population (not scattered staining) were considered as positive staining.  
 
 
 
Figure 3.4 Schematic picture of Streptamer
® 
and its binding to T-cell through 
engagement of TCR and MHC molecule (modified from IBA, GmbH) 
 
 
 
Table 3.1 Frequencies of T-cells stained with different multimers for control of 
Streptamer
®
 staining. 
 
HLA restriction 
and Ag specificity 
 of multimers 
Patient 1* 
HLA:A1,A2,B8 
Patient 2 
HLA:A2,B7 
Healthy donor 1 
HLA:A1 
Health donor 2 
HLA:B7 
Strept. Tet, Strept. Tet, Strept. Tet, Strept. Tet, 
HLA-A2/NLV 21.94** 22.00 1.56 1.48 0.00 0.00 0.00 0.00 
HLA-B8/QIK 0.88 0.96 0.01 0.00 0.00 0.00 0.01 0.00 
HLA-A1/VTE 1.96 2.00 0.00 0.00 0.58 0.56 0.00 0.00 
HLA-B7/TPR 0.01 0.00 2.15 2.25 0.02 0.01 1.78 1.90 
 
* HLA typing of patients and controls, ** frequencies of CD3
+ 
CD8
+ 
T-cells stained 
either with Streptamer
®
 (Strept) or tetramer (Tet). Frequencies of multimer binding 
CD3
+ 
CD4
+
 T-cells in these samples were 0.02, 0.00, 0.02 and 0.03 percent, 
respectively. 
 
 
 
 
 
 
 
 
                                                                    78 
 
3.2.2 Absolute CMV-specific CD8
+
 T-cell numbers following ACT and the trial end 
point showed no statistically significant difference between the two arms of trial 
 
The trial end point (reconstitution of 10x10
3
/ml CMV-specific CD8
+
T-cells in up to 2 
months post-ACT) was achieved in 8 out of 17 patients who had cell therapy. In one 
patient, the number of CMV-specific cells was higher than the trial end point at the time 
of cell infusion and  in the rest of patients (n=8), the frequency of these cells stayed 
below  10x10
3
/ml in 2 months post-ACT (Table 3.2). At 2 months post-ACT, the 
highest numbers for CMV-specific CD8
+
 T-cells ranged from 0.2-147x10
3
/ml with 
mean
+
/-SD: 35
+
/-47 x10
3
/ml. In 11 out of 17 patients, cell expansion continued after 2 
months and reached to the higher levels (range:5-528x10
3
/ml, mean
+
/-SD:91
+
/-
150x10
3
/ml) (Table 3.2). 
 Among 10 patients of control group (arm B), two patients (02/23 and 03/43) had higher 
than 10x10
3
/ml CMV-specific T-cells at the beginning of CMV viraemia. In the 
remaining arm B patients, the trial end point was observed in 3 patients. The peak 
number of CMV-specific CD8
+
 T-cells ranged from 0.003-121x10
3
/ml with mean
+
/-SD: 
25
+
/-40x10
3
/ml within 2 months post first CMV
+
 PCR and continued to rise after this 
period in 8 out of 10 patients (range:16-111x10
3
/ml, mean
+
/-SD:54
+
/-38x10
3
/ml) (Table 
3.3). Therefore, after exclusion of patients who had more than10x10
3
/ml cells at the 
beginning of study,  the trial end point was achieved in 8 out of 16 (50%) in arm A and 
in 3 out of 8 patients in arm B (37.5%). This difference was not statistically significant 
(p=0.67). Additionally, analysis of the peak CMV-specific CD8
+
 T-cell numbers either 
in the period of 2 months or after that (up to 6 months as the study scheduled program) 
revealed no difference between the two study arms (p=0.57 and 0.51, respectively). 
Figure 3.5 illustrates the overall reconstitution of CMV-specific CD8
+
 T-cells in  both 
arms of trial in up to 2 months post-ACT/first viral detection. Although numerically 
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there was no statistical difference in the reconstitution of CMV specific CD8
+
 T-cells  
between arms A and B, a difference in the rate of reconstitution early post cell 
therapy/first CMV
+
 PCR was detected (discussed later).  
 
 
 
 
Table 3.2 Magnitude of CMV-specific CD8
+ 
T-cell reconstitution post ACT.  
 
Patient code End point 
at day 
Peak cell  
number*  
up to 2 
months  
at day 
Peak cell 
number up 
to 2 months 
(x10
3
/ml) 
Peak cell  
number  
after 2 
months  
at day 
Peak cell  
number  
after 2 
months  
(x10
3
/ml) 
01/01 7 14 109 140 112 
01/02 7 21 147 -** -** 
08/04 21 21 12 170 14 
02/06 NR 35 6 - - 
11/07 NR 56 6 140 34 
11/08 NR 56 4 170 36 
09/09 NR 56 0.2 112 37 
08/13 21 21 36 - - 
01/15 0 28 101 - - 
01/16 21 28 16 - - 
08/20 14 35 18 84 528 
06/29 NR 49 0.9 170 5 
05/36 NR 35 7 140 27 
09/41 56 56 26 - - 
01/44 NR 56 3 170 58 
08/46 NR 56 2 140 16 
01/49 21 28 105 112 124 
 
 
 
The table shows the day at which the trial end point reached and days that the maximum cell 
numbers were recorded during and beyond the period of 2 months post ACT. The maximum 
cell numbers (x10
3
/ml) also reported.*The peak cell number shows the frequency of CMV-
specific CD8
+
 T-cells with the same specificity as the infused cells. **-, There was not any cell 
expansion after 2 months. NR; the trial endpoint not reached. 
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Table 3.3 Magnitude of CMV-specific CD8
+ 
T-cell reconstitution in arm B patients. 
 
Patient code End point 
at day 
Peak cell * 
number  
within 2 
months  
at day 
Peak cell 
number 
within 2 
months 
(x10
3
/ml) 
Peak cell  
number  
after 2 
months  
at day 
Peak cell  
number  
after 2 
months  
(x10
3
/ml) 
02/03 7 7 28 84 30 
06/22 35 35 11 112 20 
02/23 0 0 121 -** - 
05/25 NR 56 0.003 112 63 
04/32 42 42 12 - - 
08/37 NR 49 2 170 16 
05/40 NR 56 0.7 170 111 
03/43 0 14 70 112 92 
05/47 NR 14 4.6 112 79 
09/50 NR 56 0.6 84 18 
 
The table shows the day at which the trial end point reached and days that the maximum cell 
numbers were recorded during and beyond the period of 2 months post ACT. The maximum 
cell numbers(x10
3
/ml) also reported.* The peak cell number shows the frequency of dominant 
CMV-specific CD8
+
 T-cells. **-, There was no further cell expansion after 2 months. NR; the 
trial endpoint not reached. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Expansion of CMV-specific CD8
+
 T-cells up to 2 months post-ACT (arm A) or 
first detection of CMV viraemia (arm B).  
The means of cell numbers from all the patients of arms A and B in each time point are plotted 
against the time to show the overall expansion patterns of CMV-specific T-cells during the 
study period (this figure was presented by Professor K.Peggs at BTM Tandem meeting, 2014). 
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3.2.3 Reconstitution of total CD3
+ 
and CD8
+
 T- lymphocyte populations 
 In order to have a broader picture of T-cell reconstitution, the frequencies of total CD3
+
 
and CD8
+
 T-cells at their peaks were analysed. There were no statistically significant 
differences in the peak levels of CD3
+
 T-cells within 2 months post ACT/first viral 
detection or beyond  that between the two arms of trial (p=0.68). This was true for the 
CD8
+
 T-cells, as well (p=0.73) (Tables 3.4 and 3.5). 
 
Table 3.4 Magnitude of CD3
+
 and CD8
+
 T-cell reconstitution post ACT. 
 
Patient 
code 
Peak 
CD3
+
  
number  
within 2 
months  
at day 
Peak CD3
+
 
number 
within 2 
months 
(x10
3
/ml) 
Peak 
CD3
+
 
number  
after 2 
months  
at day 
Peak CD3
+
 
number  
after 2 
months  
(x10
3
/ml) 
Peak 
CD8
+
  
number  
within 
2 
months  
at day 
Peak 
CD8
+
 
number 
within 2 
months 
(x10
3
/ml) 
Peak 
CD8
+
 
number  
after 2 
months  
at day 
Peak 
CD8
+
  
number  
after 2 
months  
(x10
3
/ml) 
01/01 35 343 112 1164 21 266 140 594 
01/02 21 1444 -* - 21 991 - - 
08/04 56 284 170 583 21 77 170 242 
02/06 56 582 - - 49 710 - - 
11/07 56 181 170 292 56 33 170 160 
11/08 56 139 170 1234 56 70 170 996 
09/09 56 62 112 3538 56 14 112 2996 
08/13 21 393 - - 21 248 - - 
01/15 56 950 84 1305 21 690 84 1048 
01/16 14 466 - - 14 386 - - 
08/20 56 243 112 1640 14 160 84 1337 
06/29 49 1405 - - 49 1164 - - 
05/36 7 87 140 1050 14 75 140 909 
09/41 42 92 - - 56 34 - - 
01/44 56 130 112 541 56 114 112 284 
08/46 56 350 140 747 56 139 140 503 
01/49 21 185 170 927 21 122 112 500 
 
 
The figures show the highest detected levels of CD3
+
 and CD8
+
 T-cells within and beyond 2 
months post-ACT.*- There was no further cell expansion beyond 2 months. 
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Table 3.5 Magnitude of CD3
+
 and CD8
+
 T-cell reconstitution post first CMV viral 
detection in arm B patients. 
 
 
Patient 
code 
Peak 
CD3
+
  
number  
within 2 
months  
at day 
Peak 
CD3
+
 
number 
within 2 
months 
(x10
3
/ml) 
Peak 
CD3
+
 
number  
after 2 
months  
at day 
Peak 
CD3
+
 
number  
after 2 
months  
(x10
3
/ml) 
Peak 
CD8
+
  
number  
within 2 
months  
at day 
Peak 
CD8
+
 
number 
within 2 
months 
(x10
3
/ml) 
Peak 
CD8
+
 
number  
after 2 
months  
at day 
Peak 
CD8
+
  
number  
after 2 
months  
(x10
3
/ml) 
02/03 0 184 140 262 0 110 140 158 
06/22 56 198 84 648 14 153 112 642 
02/23 0 268 - * -  0 171 -  -  
05/25 56 10 140 1048 56 4 140 870 
04/32 56 1024 112 2555 56 838 112 2186 
08/37 56 847 -  -  56 688 -  -  
05/40 56 166 170 2234 49 45 170 2024 
03/43 56 471 112 1142 14 361 112 984 
05/7 35 100 112 764 28 37 112 477 
09/50 56 109 84 254 56 80 84 211 
 
The figures show the highest detected levels of CD3
+
 and CD8
+
 T- cells within and beyond 2 
months post viral detection. 
*- There was no further cell expansion. 
 
 
 
   3.2.4 The expansion rate of CMV-specific CD8
+
 T-cells was different between  
     arms A and B patients 
 
           The expansion of CMV-specific T-cells post-HSCT is time-dependent. This 
relationship can be quantified by correlating CMV-specific T-cell levels with time (the 
period of study). By comparing the correlation lines between cell numbers and time 
(one month post-ACT/first viral detection) in arm A and B, a difference in the slope of 
the 2 arms was observed (Figure 3.6). Cell expansion in arm A patients demonstrated a 
considerably closer correlation with time than arm B (r=0.91, p=0.01 versus r=0.31, 
p=0.61, respectively). This suggests a ‘faster’ reconstitution amongst patients who 
received cell therapy which happened within 1 month post-ACT. By analysing the cell 
numbers in the first month post-ACT, a clear difference in the expansion rate of CMV-
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specific CD8
+
 T-cells between the two cohorts was seen (Figure 3.6), where patients in 
arm A experienced a considerably greater cell expansion than in arm B.  
           This differential effect between the two arms was further strengthened by comparing 
the geometric increase in the number of CMV-specific T-cells within the first 2 
months. The fold increase was calculated by comparing the highest expanded level of 
T-cells to the baseline level (day 0 which was the day of cell infusion). As Figure 3.7A 
shows, the bigger fold increase of CMV-specific CD8
+
 T-cells occurred in arm A in 
comparison to arm B within 2 months post-ACT (p=0.002). However, when the data 
was analysed over 6 months, the fold increases of CMV-specific CD8
+
 T-cells were 
similar in arms A and B patients (Figure 3.7B). 
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Figure 3.6 Expansion of CMV-specific CD8
+
 T-cells within one month post ACT/first  
CMV viraemia detection. 
 
There was a greater cell expansion in the first month post ACT in arm A than in arm B patients. 
The numbers show the mean frequencies of cells in each time point. 
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Figure 3.7 Fold increase in the number of CMV-specific CD8
+
 T-cells. 
 
This figure shows the higher fold increases in the frequencies of CMV-specific T-cells (A) within 
first 2 months post-ACT in arm A when compared to arm B patients. (B)  In both groups, fold 
increases in the frequencies of these cells over the total period of study were similar. Bars show 
the median fold increases. 
 
 
3.2.5 Geometric increases in CD3
+
 and CD8
+
 T-cell populations 
In the next step, fold increases in the number of total CD3
+
 and CD8
+
 T-cells were 
analysed. Similar to the previous finding for CMV-specific CD8
+
 T-cells, fold increases 
of total CD3
+
 and CD8
+
 T-cells within the first 2 months post ACT were also found to 
be higher in arm A than B (Figure 3.8) but not when analysed for the whole 6 month 
period post-ACT. 
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  Figure 3.8 Fold increases in the numbers of CD3
+
 and CD8
+
 T-cells within 2 
  months   post-ACT/first CMV viraemia. 
 
(A)Higher CD3+ and (B) CD8+ T-cell expansions in arm A compared to arm B patients 
occurred within 2 months post-ACT/first detected viraemia. Bars show the median fold  
increases. 
 
Following transplantation, CD3
+
 and CD8
+
 T-cells expanded rapidly within the first 
month in patients who received cell therapy (arm A), compared to those who did not 
(Figure 3.9). 
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Figure 3.9 CD3
+
 and CD8
+
 T-cell expansions over one month post-ACT/first 
viraemia. There were higher cell expansions in CD3+ (A) and (B) CD8+ T-cells in arm A 
patients in one month post-ACT. 
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3.2.6 Expansion of non-infused CMV-specific T-cells in arm A patients  
In 10 out of 17 patients in arm A, it was possible to study the reconstitution of CMV-
specific CD8
+
 T-cells targeted against CMV peptides different from the specificity of 
infused T-cells. Depending on the availability of Streptamer
®
 specificities, 
reconstitutions of T-cell responses specific for up to three CMV derived epitopes were 
analysed. The results showed that in all of these patients, the dominant response 
belonged to the infused cells. Figure 3.10 shows the lowest and highest level of infused 
(dominant response) and three non-infused cells (sub-dominant) during 6 month period 
of study. Analysis of the second biggest response in those 10 patients revealed their 
parallel expansion with the infused cells which increased rapidly over 1 month. Figure 
3.10 shows increase in the number of the sub-dominant non-infused CMV-specific T-
cells in comparison to the infused cells in one months period post- ACT. 
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Figure 3.10 The highest and lowest median frequencies of different CMV-specific 
CD8
+
 T-cells.  
 
The figure shows the frequencies of (a) infused, (b-d) the first, second and third sub-
dominant non-infused CMV-specific CD8
+
 T-cells in arm A patients. 
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Figure 3.11 Expansion of infused and non-infused CMV-specific CD8
+
 T-cells post-
ACT.  
Similar to the infused cells, non-infused CMV-specific CD8
+
 T-cells expanded rapidly 
over 1 month post- ACT in arm A patients. The non-infused cell is the first sub-
dominant CMV-specific T-cell response. 
 
In 6 out of 10 arm B patients, depending on the availability of Streptamers
®
, up to 3 
different CMV-specific CD8
+
 T-cells were analysed. The mean frequency of dominant 
CMV-specific T-cell response increase from 9.6 to 40.0x10
3
/ml. The sub-dominant 
response increased from 0 to 5.8x10
3
/ml. 
 In both arms, patients’ immune system produced T-cells with diverse epitope 
specificities. Therefore, the expansion of CMV-specific T-cells other than the infused 
cells was a natural phenomenon. The important finding was the rapid expansion of non-
infused CMV-specific CD8
+
 T-cells alongside the infused T-cells in arm A patients 
(Figure 3.11). This observation was not seen in arm B patients and both the dominant 
(Figure 3.6) and sub-dominant responses developed slowly in the first month post CMV 
reactivation. These results and properties of CD4
+
 T-cell reconstitution in arm A 
(discussed below), show that cellular therapy had a global positive effect on T-cell 
reconstitution. 
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3.2.7 Reconstitution of CD4
+
 T-cell population  
In the next step, the reconstitution of CD4
+ 
T-cells was analysed. The data showed that 
the increase in the number of these cells from base line to the highest level within 2 
months post-ACT was higher in arm A compared to arm B patients (p=0.008, Figure 
3.12A). In addition, CD4
+
 T-cells also expanded rapidly in arm A during the first month 
post ACT whilst their number in arm B declined (Figure 3.12B). For the overall period 
of study, there was not any statistically significant difference in median fold increases 
between arm A (13.1) and arm B (16.0) patients (p=0.45). 
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Figure 3.12 Reconstitution of CD4
+
 T-cells in arms A and B patients. 
(A) The fold increase in the number of CD4
+
 T-cells was higher in arm A patients during the 
first 2 months post ACT.(B) The mean number of  CD4
+
 T-cells increased over one month post 
ACT in arm A whilst their number in arm B patients, experienced a decline.  
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3.2.8 Concomitant expansion of CD4
+
 and CD8
+
 T-cells 
In both arm A and B patients, concomitant reconstitution of CD4
+
 and CD8
+
 T-cells 
was observed. Figure 3.13 shows a strong correlation between the frequencies of these 
cells post-ACT in all arm A patients. The correlation between expansion of CD4
+
 and 
CD8
+
 T-cells in arm B was also statistically significant (r=0.59, p=0.0001).   
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Figure 3.13 Co-expansion of CD4
+
 and CD8
+
 T-cells during immune reconstitution 
post-ACT in arm A. 
 
There was a strong correlation between the numbers of peripheral blood CD4
+
 and 
CD8
+
 T-cells in arm A patients during the period of study. 
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3.2.9 CMV-specific CD4
+
 and CD8
+
 T-cells expanded co-ordinately 
In order to study CMV-specific CD4
+
 T-cells, and due to lack of appropriate multimers, 
a cell stimulation method with CMV lysate was performed to detect specific CD4
+
 T-
cell responses. After the incubation, CMV-specific CD4
+
 T-cells were identified as 
IFN-γ producing cells. Analysis of IFN-γ production by CD4+ T-cells in 40 samples 
collected from 9 arm A patients demonstrated a correlation between the number of 
CMV–specific CD4+ T-cells (CD4+ IFN-γ+) and CMV-specific CD8+ T-cells (detected 
by Streptamer
®
 staining) (r=0.41, p=0.008) (Figure 3.14). 
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     Figure 3.14 Concomitant reconstitution of CMV-specific CD4
+
 and  
     CD8
+
 T-cells   post-ACT. 
 
    CMV-specific T-cells expanded in parallel in 9 studied arm A patients. 
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Also as discussed in the next chapters, analysis of CMV-specific CD4
+
 T-cells showed 
that CD57 co-expressed by most of these cells and CD4
+ 
CD57
+
 T-cells were present 
only in CMV infected individuals. In this regard, reconstitution of these cells was 
studied in 8 arm A patients and correlated with the number of CMV-specific CD8
+
 T-
cells. Results showed a statistically significant correlation between the number of 
CMV-specific CD8
+
 T-cells and the frequency of CD4
+ 
CD57
+
 T-cells post-ACT 
(Figure 3.15). 
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Figure 3.15 Co-expansion of CMV-specific CD8
+
 T-cells and CD4
+ 
CD57
+
 T-cells. 
During immune response to CMV-reactivation, the frequency of CD4
+
 CD57
+ 
T-cells 
increased in parallel with CMV-specific CD8
+
 T-cells. 
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3.2.10 CMV specific antibody response 
The IgG antibody response to CMV was measured using an in-house ELISA assay in 10 
arm A and 5 arm B patients. In response to CMV reactivation, levels of anti-CMV 
antibody gradually increased over time in both groups. There was not any correlation 
between this increase and the time of study (Figure 3.16). The lowest detected Ab levels 
early post CMV reactivation were 176 and 226 units which increased to 309 and 406 
units in arms A and B patients, respectively. This possibly reflects the fact that during 
the short period of this study, anti-CMV Abs were of recipient origin and synthesis of 
new Abs occurs late following HSCT.  
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Figure 3.16 IgG response to CMV in arms A and B patients. 
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3.2.11 Functional behaviour of CMV-specific T-cells 
3.2.11a Elispot results 
In addition to the frequency of CMV-specific T-cells, assaying the functional activity of 
them is important for assessing the capacity of the cells to control CMV reactivation. 
Cytokine production following antigenic stimulation was studied using Elispot and 
intracellular staining methods. In Elispot, PBMCs were stimulated with CMV-derived 
epitopes consisting of 9 amino acids which stimulated CD8
+
 T-cell responses. 
Following cell stimulation, IFN-γ response was analysed by counting the number of 
spots, representing individual cytokine producing cells (Figure 3.17). 
 
 
 
 
 
 
 
Figure 3.17 IFN-γ production in Elispot.  
The left picture shows negative control for the assay and the right picture shows 
response of 1x10
5 
PBMC/well to the antigenic stimulation with CMV-derived antigens 
after overnight incubation as described in the method section. The number of dots was 
counted using AID Elispot reader. 
 
 
Longitudinal analysis of  56 blood samples from 6 patients (05/36, 08/37, 03/43, 08/46, 
05/40 and 05/47) demonstrated IFN-γ production in response to CMV derived epitopes 
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which fluctuated in accordance with the number of CMV-specific CD8
+
 T-cells over 
time. Figure 3.18 shows the reconstitution of CMV-specific CD8
+
 T-cells identified by 
Streptamers
®
 and IFN- γ response (number of dots in Elispot plates). 
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Figure 3.18 IFN-γ response to the CMV-derived peptides as measured by Elispot.  
The figure shows Elispot responses (number of Elispot dots) and number of CMV-
specific CD8
+
 cells as determined by Streptamers® in 6 patients. Strept/peptide and 
IFN-γ/peptide represent the number of specific CD8+ T-cells and Elispot dots in 
response to a particular peptide, respectively.  
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In the next step, the number of Elispot dots was converted to the number of CMV-
specific IFN- γ producing cells/ml. To perform this, the number of dots were divided by 
the number of CD8
+
 T-cells per 100µl of cell culture and then multiplied by the number 
of CD8
+
 T-cells/ml. In all 6 patients, only a fraction of Streptamer
®+
 cells made IFN-γ 
as the number of IFN- γ+ cells were at range of 10 to 65% of Streptamer®+ cells. Figure 
3.18 represents the number of cells measured by Streptamer
®
 staining and IFN-γ 
production in 2 patients. The ratio of IFN-γ+/ Streptamer®+ cells was in the range of 10-
17% and 20-65% in these 2 patients (Figure 3.19 A and B, respectively). The red filled 
area in this figure was used for the better demonstration of these ratios. 
Overall, there was a strong correlation between the number of CMV-specific CD8
+
IFN-
γ+ cells/ml with the number of CMV-specific T-cells identified by Streptamer® staining 
(Figure 3.20, r=0.72, p<0.0001). These observations indicated functional activity of 
CMV–specific T-cells in the trial patients. However, it is very likely that due to the age 
of blood samples at the time of processing, the functional activity of T-cells was 
underestimated. 
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Figure 3.19 Longitudinal analysis of CMV-specific T-cells with Streptamer
® 
staining 
and Elispot assay. 
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Figure 3.19 (continued). The frequency of CMV-specific CD8
+
 T-cells by Streptamer
®
 
staining (black line) and IFN-γ production (red filled line). (A) and (B) represent 2 
patients with low or high ratios of IFN-γ producing cells among CMV-specific CD8+ T-
cells. 
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Figure 3.20 Correlation between the number of CMV-specific CD8
+
 T-cells identified 
by Streptamer
® 
staining and CMV-specific IFN-γ producing cells(r=0.72, p<0.0001). 
 
 
IFN-γ production in response to the pooled peptides: pp65 and IE-1 was also analysed 
by Elispot. Longitudinal analysis showed changes in response to these peptides pools 
during the period of study which had some similarities with fluctuation of CMV-
specific CD8
+
 T-cell responses, as illustrated in Figure 3.21. It should be mentioned that 
pp65 and IE-1 contain antigenic epitopes for both CD4
+
 and CD8
+
 T-cells. In 3 patients, 
the CMV-specific CD8
+ 
T-cells, measured by Streptamer
®
 staining, were specific for 
VTE peptide which is not present in pp65 or IE-1 (Figure 3.21).  
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Figure 3.21 IFN-γ responses to pp65 and IE-1 peptide pools as detected by Elispot. 
The figure shows the number of Elispot dots (IFN- γ response to pp65&IE-1) and 
number of CMV-specific CD8
+
 T-cells as determined by Streptamers
®
 in 5 patients. 
Strept/peptide represents the number of specific CD8
+
 T-cells. Peptides: TPR and QIK 
belong to pp65 and IE-1 peptide pools, respectively (full list of CMV-derived peptide 
pools are in Table 2.2) 
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3.2.11b Multi-functional activity of CMV-specific T-cells as detected by 
intracellular cytokine production 
Multiple cytokine production in response to antigens is an important indicator of 
functional properties of T-cells (Nebbia et al., 2008; Lichterfeld et al., 2004). In viral 
immunity, functional T-cells producing different cytokines have vital roles in control of 
viruses. Betts (2006) showed a strong association between the presence of 
multifunctional HIV-specific CD8
+
 T-cells and control of HIV. In order to investigate 
the quality of CMV-specific T-cells, a flow cytometry-based intracellular staining of 
IFN-γ, IL-2 and TNF-α was conducted for 4 patients. PBMCs were stimulated in the 
presence of Brefeldin A in an overnight incubation with CMV-derived nanomeric 
peptides and CMV-lysate for stimulation of CD8
+
 and CD4
+
 T-cells, respectively. After 
cell surface and intracellular staining, flow cytometry based Boolean gating strategy 
was used to identify cytokine expression profiles of T-cells (Seder et al., 2008).This 
included analysis of cells producing all three cytokines (triple producers, TP) (IL-2
+
 
TNF
+
 IFN- γ+ ) or different combinations of two cytokines (double producers, DP) 
(TNF-α+ IL-2+, TNF-α + IFN- γ+ , IL-2+ IFN- γ+) or only one cytokine (single producers, 
SP). In total, seven different conditions are possible: one TP, three DP and 3 SP cells. 
As mentioned, the ACE trial blood samples were 24 hrs old at the time of cell 
processing and our preliminary experiments showed a negative effect of blood age on 
ability of cells to produce cytokines. Therefore, the quality of T-cells was 
underestimated in this study and in this regard, the assay did not continue beyond the 4 
patients.Following subtracting the background values (from un-stimulated cells), the 
proportion of each of the seven subsets was expressed as a percentage of total cytokine 
producing cells. In overall, IFN- γ was the main produced cytokine during longitudinal 
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analysis of samples. Figure 3.22 represents cytokine production profile of CMV-
specific T-cells in one patient during the period of study. In all four patients, IFN- γ was 
the main produced cytokine by both CD4
+
 and CD8
+
 T-cells and the frequency of IFN-
γ+ was much higher than the other two cytokines. This phenomenon was stable during 
the period of study.  
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Figure 3.22 Cytokine production by CD8
+ 
T-cells following stimulation with CMV-
derived peptides.  
 
In the next step, the frequencies of SP, DP and TP cells were analysed. In CD8
+
 
population, the frequency of SP cells producing only IFN-γ (76%) was more than the 
other cells which was followed by TP (14%) and TNF-α + IFN-γ+ (10%). There were no 
detection of cells making only TNF-α or IL-2 or both and IL-2+ IFN-γ+ cells. 
In CD4
+
 T-cells, SP cells making IFN-γ had higher frequency (72%). The other cells 
were: TP (15%), TNF-α + IFN- γ+ (7%) and only IL-2+ cells (6%). 
Figure 3.23A is an example of flow cytometry panels used for the analysis of cytokine 
producing cells in response to CMV lysate in order to detect CMV-specific CD4
+ 
T-
cells producing different cytokines. Figure 3.23B is an example of negative control for 
the cell stimulation with a cell lysate without CMV antigens. 
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Figure 3.23A Intracellular cytokine production. 
Production of IFN-γ, TNF-α and IL-2 in response to CMV antigens. The gating strategy 
was first to identify CD4+ CD3+ cells (third panel in the first row). Then, IFN-γ/TNF- α 
producing cells were identified (the forth panel) (double positive cells). This was 
followed by identification of IL-2 producing cells among IFN-γ and TNF-α positive 
cells  (triple positive cells making all the three cytokines) (6
th
 panel). Other possible 
double producing cells were also identified (5
th
, 7
th
 and 8
th
 panels). 
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Figure 3.23B Intracellular cytokine production. 
FACS panels show lack of cytokine response in the negative control for the cell 
stimulation assay. 
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3.2.12 Other results for ACE-ASPECT trial 
At the time of writing this thesis, there was no access to full  CMV virology data, 
circulating levels of Alemtuzumab, frequency of CMV-specific CD8
 +  
T-cells in the  
donors, dose of infused cells and anti-viral treatment duration. Some data on these 
parameters were orally presented at BMT Tandem meeting, Texas in 2014 and 
published as an abstract (Chen et al., 2014, Appendix 2A). The following results have 
been released so far: 
a) Alemtuzumab concentration; higher concentration of Alemtuzumab at the time 
of cell infusion led to a statistically significant lower number of reconstituting 
CMV-specific CD8
+  
T-cells (Figure 3.24). This figure shows that patients in 
arm A who did not reach to the trial end point (10
4 
cells/ml) had higher levels of 
circulating Alemtuzumab in comparison to the patients who reached to this point 
(p=0.0076). Therefore, Alemtuzumab level has direct effect on CMV-specific T-
cell reconstitution.  
b) Cell dose: number of infused cells had positive effect on reaching to the trial end 
point (Figure 3.24). Arm A patients who reached to the trial end point, on 
average, received 18x10
3
/kg CTLs whilst patients who did not, received around 
four times less specific cells (5x10
3
/kg ) (p=0.0215). 
c) Donor CTL frequency: the frequency of CMV-specific CTLs in the donors had 
no effect on achieving the trial end point. 
By considering a cut off level of  Alemtuzumab at 0.15 mg/ml and cell dose of 1000/kg, 
patients who had less than this level of Alemtuzumab and received more than 1000 
cells/kg, experienced bigger cell expansion following cell therapy (p=0.0413) (Figure 
3.25).  
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Figure 3.24 Effects of CTL dose and Alemtuzumab level on achieving the trial 
end point. (from Dr K.Peggs presentation, BMT Tandem meeting, 2014) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.25 Combinational effects of Alemtuzumab level and CTL dose on 
reconstitution of CMV-specific CD8
+
 T-cells. (Dr K.Peggs, BMT Tandem meeting, 
2014) 
 
As it is demonstrated in the above figure, the trial end point (10
4
 cells/ml) was achieved 
in 8 out of 10 patients  with baseline Alemtuzumab <0.15 mg/ml and CTL dose 
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>1000/kg and in 1/7 of those with either baseline Alemtuzumab >0.15 mg/ml or CTL 
dose <1000/kg (p = 0.0134).  
It was also reported that incidence of new onset grade II-IV GVHD post ACT did not 
differ significantly between the cellular therapy and control arm (17.6% vs 27.3% 
respectively).The frequencies of new GVHD in the cellular therapy arm were: 1 Grade 
II and 2 Grade III and in arm B were: 2 Grade II and 1 Grade III (BMT Tandem 
meeting, 2014). 
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3.3 Discussion 
 
 
This chapter presented the results of CMV-specific T-cell reconstitution in ACE-
ASPECT trial patients. In this first randomized trial of adoptive immunotherapy of 
CMV-specific CD8
+
 T-cells in T-cell depleted unrelated donor allogeneic HSCT 
patients, the primary end point was the reconstitution of CMV-specific T-cells above 
1x10
4
/ml within two months post-ACT (or first positive CMV-PCR result in the control 
group).  
In both therapeutic and control groups, the trial end point at 2 months was achieved in 
considerable numbers of patients and consequently, no statistically significant 
difference between these two groups was observed. However, a number of patients in 
the ACT group had low recovery of adoptively transferred T-cells, and this was found 
to be associated with the serum level of Alemtuzumab and the dose of infused cells. 
Patients who received on average 18x10
3
/kg CMV-specific CD8
+
 T-cells and had lower 
level of Alemtuzumab at the time of cell infusion (below 0.15 mg/ml) were able to 
reconstitute more CMV-specific T-cells and reach to the trial end point. 
 It has been shown that Alemtuzumab remains in the circulation of HSCT patients in up 
to 56 days post-HSCT at the concentration above lympholytic level (> 0.1 µg/ml) 
(Morris et al., 2003). ACE-ASPECT trial patients received therapeutic cells at 28 days 
post-HSCT when residual Alentuzumab was still in circulation, which may explain the 
poor reconstitution of of the infused cells. The reported concentration of Alemtuzumab 
in ACE-ASPECT trial (Figure 3.23) at around day 28 post-HSCT is in the range of 100-
400 µg/ml which is much higher than the level reported by Morris (2003). At the time 
of writing this thesis, the method used for measuring Alemtuzumab was still been 
reviewed. The mean number of cells infused cells into patients who did not reach to the 
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trial end point was less than 3x10
3
/kg. In the phase I CMV specific T-cell therapy trial, 
the lowest number of infused cells was around 1.5x10
3
/kg and interestingly, these 
patients had the lowest number of reconstituting CTLs at their peak level (Cobbold et 
al., 2005). However, these patients were able to produce CTLs above 10x10
3 
cells/ml. It 
is therefore important that both cell dose and Alemtuzumab should be considered as 
contributing factors to the efficacy of the ACT. As revealed by the data, 80% of patients 
with Alemtuzumab level <0.15 mg/ml and CTL dose >10
3
/kg, reached the trial end 
point whilst only 14% of patients with Alemtuzumab level >0.15 mg/ml and CTL dose 
<10
3
/kg did. 
The mean peak numbers of CTLs in ACT patients and the control group within 2 
months post-ACT/viraemia were around 3 times higher than the trial end point (35 and 
25x10
3 
/ml, respectively). This indicates that some of HSCT patients were able to 
produce appropriate number of CMV-specific CD8
+
 T-cells, regardless of 
immunotherapy. As discussed in the next chapter, half of HSCT patients receiving 
Alemtuzumab-containing conditioning chemotherapy experience only one episode of 
CMV viraemia and these patients were able to mount sufficient number of CTLs to 
control the viraemia. The minimum protective level of CTLs reported by this thesis 
(next chapter) and other studies range from 7 to 20x10
3
/ml (Gratama et al., 2010; 
Cwynarski et al., 2001; Aubert et al., 2001). In this regard, CMV specific T-cell therapy 
may not be necessary for boosting CMV immunity in patients who rapidly expand 
sufficient CMV-specific T-cells in response to the first CMV reactivation. In the next 
chapter we will discuss how patients could be stratified based on CMV-specific T-cell 
levels to help identify patients who could benefit most from immunotherapy. 
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Despite the presence of similar results in the patients of both arms in regard to the trial 
end point, the fold increase in CTL numbers from baseline to the peak within 2 months 
post-ACT was higher in ACT arm. This indicates that cellular therapy resulted in a 
greater CMV-specific CD8
+ 
T-cell expansion in response to CMV viraemia. Detailed 
analysis of the kinetics of response showed that this greater cell expansion in the cell 
therapy arm occurs only during the first month post-ACT. In this time period, there was 
a clear statistically significant difference between the 2 arms, with CTLs expanding 
exponentially in the ACT arm. However, over the whole 6 month of immune 
monitoring, both groups experienced similar overall degree of cell expansion. In other 
words, cell expansion in ACT patients was more rapid only at the beginning of cell 
therapy. In accordance with the bigger CTL expansion in a short time period post-ACT, 
patients also experienced bigger increase in their total CD3
+
 and CD8
+
 counts.  
Interestingly, CMV-specific T-cells that had antigen specificities other than the infused 
cells, also co-expanded rapidly in parallel with the infused CMV-specific T-cells. 
Expansion of CD4
+ 
T-cells was also positively influenced by ACT. This means that 
during the first month post-ACT of CMV-specific CD8
+
 T-cells, both CD8
+ 
and CD4
+ 
populations expanded in parallel and that their fold increases from baseline to the peak 
were higher in comparison to the control group. It should be noted that the co-expansion 
of CD4
+ 
and CD8
+ 
T-cells is a feature of T-cell reconstitution which was also observed 
in the control group and non-trial HSCT patients (next chapter). 
These findings suggest that adoptively transferred CD8
+ 
T-cells have a non-specific 
boosting effect on concomitant reconstitution of T-cell immunity shortly post-ACT. 
This impact of ACT might become less effective as time passes. This thesis did not 
have opportunity to explore some of physiological mechanisms behind the boosting 
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effect of T-cell therapy. Based up on the well documented data on T-cell reconstitution 
post-HSCT, it is possible to speculate involvement of different factors especially 
cytokines and co-stimulatory molecules in the rapid cell expansion in ACT patients.  T-
cell reconstitution after HSCT relies on thymopoiesis and expansion of mature T-cells. 
Thymopoiesis is a delayed process which occurs 1 up to 2 years post-HSCT (Krenger et 
al., 2011) and initial T-cell reconstitution depends on proliferation of mature T-cells 
derived from the donor infusion and driven by high homeostatic cytokine levels and 
antigen exposure, in a process called homeostatic peripheral expansion (HPE). 
IL-7 and IL-15 are two important HPE cytokines that induce naïve and memory T-cell 
proliferation post-HSCT, respectively. However, HPE can also be constrained by 
regulatory T-cells and cytokines such as TGF-β. It has been shown that following 
lymphocyte depletion, there is an increase in the level of IL-7 possibly due to the less 
consumption of this cytokine. This high level of IL-7 leads to the considerable increase 
in the number of naïve T-cells (Fry and Mackall, 2001). As shown in chapter 5, naïve T-
cells express IL-7Rα and following cell differentiation, frequency of IL-7Rα positive 
cells decreases.   
In opposing pattern, expression of IL-15Rα increases following antigenic exposure 
(Chapter 5) (Geginat etal., 2003). IL-15 is produced constitutively by tissues and 
antigen-presenting cells and its level increases after severe lymphocyte depletion. 
Different studies have shown the important role of IL-15 in expanding of 
memory/effector memory T-cells. Proliferation of effector memory CD8
+ 
CD28
- 
T-cells 
depends on IL-15 and its induced cytokines such as TNF-α (Chiu et al., 2006). 
Concomitant TCR engagement and IL-15 stimulation induce CD4
+ 
T-cell proliferation 
(Van Belle, et al., 2012). Interestingly, IL-15 is also a potent inducer of CD4
+
 FOXP3
+ 
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T-cells that are involved in the control of homeostatic lymphocyte expansion post-
HSCT (Imamichi et al., 2008). Human and animal studies have shown that initial period 
post-HSCT with high levels of IL-7 and IL-15 provides an optimal milieu for T-cell 
immunotherapy (William and Gress, 2008). In this period, transferred cells consume 
cytokines and out-compete T-reg cells. Rapid increase in the number of CTLs within 1 
month post-ACT may be a result of CTL response to antigenic stimulation and presence 
of cytokines such as IL-15. In this short time period, the number of transferred cells is 
initially greater than other cells including T-reg. This phase of immune response is 
followed by gradual proliferation of T-reg that can compete with CTLs and control their 
proliferation. The initial cytokine milieu and antigenic stimulation are similar in both 
arms of the trial and the only difference is the transfer of CTLs in ACT group. It is 
possible that the initial expansion of infused cells lead to greater consumption and 
competition for the cytokines by the infused CMV-specific CD8
+ 
T cells, thus 
outcompeting the T-regs. We can further speculate that these activated CTLs influence 
CD4
+ 
T-cell reconstitution through release of cytokines and expression of co-
stimulatory molecules (such as CD40L). It has been shown that co-culture of effector 
memory CD4
+ 
and CD8
+ 
T-cells induces expression of CD40 and CD40L in both of 
these cells. Consequently, CD40/CD40L interaction causes a bi-directional stimulation 
of effector memory CD40
+ 
CD4
+ 
T-cells by effector memory CD40L
+ 
CD8
+ 
T-cells and 
of CD40
+ 
CD8
+ 
T (EM) by CD40L
+ 
CD4
+ 
T (EM) (Xydia et al., 2011). As 
demonstrated, CTLs were able to produce cytokines such as IFN-γ and IL-2. IFN-γ is a 
potent inducer of HLA-class II expression on APC. This facilitates more antigenic 
exposure for CD4
+ 
T-cells and leads to their augmented activation and proliferation. 
Murine CD8
+
 T-cells do not transcribe MHC class II (MHC-II) genes, however it has 
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been reported that MHC-II molecules present on activated murine CD8
+
 T-cells in vitro 
as well as in vivo. These MHC-II molecules are acquired via trogocytosis by CD8
+
 T-
cells from their activating APCs, particularly CD11c positive dendritic cells (DCs). 
These transferred MHC-II molecules on activated murine CD8
+
 T-cells were 
functionally competent in stimulating specific CD4
+
 T-cells to proliferate and produce 
high levels of Th1 cytokines. These CD4
+
 T-cells in return help CD8
+
 T-cells 
(Romagnoli et al., 2013). One of these cytokines is IFN-γ that activates IL-15 
production by monocytes and DCs which in return induce T-cell proliferation (Perera et 
al., 2012). Therefore, activation of higher number of CTLs in ACT patients, in 
comparison to the control group, set the stage for augmented stimulation and activity of 
other cells such APCs and CD4
+ 
T-cells. One month after rapid and enhanced 
proliferation of CMV-specific T-cells in ACT patients, a decline in this process 
occurred and cell expansion became similar to the control group. These results may also 
provide evidence for a best time frame for immunotherapy. As it was shown, in one 
month post-ACT, cell expansion was greater and the biggest fold increase in T-cell 
counts occurred.  
Functional behaviour of CMV-specific T-cells is also an important factor in control of 
viraemia (Seder et al., 2008). By using 2 different methods of Elispot and intracellular 
staining, the ability of reconstituting CMV-specific T-cells in producing IFN-γ was 
shown. The main challenge was the age of blood samples which were at least 24 hrs 
old, and our preliminary experiments showed the detrimental effect of age on cytokine 
production. Therefore, cytokine production was likely underestimated in our 
experiments. IFN- γ was the main cytokine produced and depending on the patient, 10 
to 65% of CTLs (measured by Streptamer® staining) were able to make this cytokine. 
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Despite the considerable frequency of IFN-γ producing cells, production of TNF-α and 
IL-2 were low which may be related to the age of blood at the time of functional 
analysis. 
In conclusion, the current data from the first randomised adoptive immunotherapy of 
CMV-specific CD8
+
 T-cells indicated rapid and greater reconstitution of CMV-specific 
T-cells in patients who received ACT. Although there was no difference in reaching to 
the trial end point between ACT group and the control, immunotherapy not only led to 
early expansion of infused cells, but also induced bigger expansion of non-infused 
CD4
+ 
T-cells. The presented data also indicated that the infusion of antigen-specific 
therapeutic cells led to a general boost of T-cell immune reconstitution. Immunotherapy 
might not be necessary for patients who are able to produce enough CMV-specific T-
cells and in this regard, CMV-specific T-cells quantification prior to the cell therapy 
could potentially identify high risk patients at need of T-cell immunity. This issue will 
be discussed in more detail in the next chapter. 
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Chapter 4 
CHARACTERIZATION OF CMV- SPECIFIC 
CD4
+
 T-CELL RECONSTITUTION POST- 
  HSCT THROUGH THE USE OF  
HLA-CLASS II-TETRAMERS 
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4.1 Background   
 
CMV infection is generally well controlled in the immunocompetent host, but viral 
reactivation may occur during immunosuppressive treatment following HSCT 
(Ljungman et al., 2011). CMV reactivation remains very common after T-cell depleted 
or allogenic transplants in which either the patient or donor are CMV sero-positive and 
up to half of such patients suffer from recurrent or late episodes of reactivation with 
impaired clinical outcome (Chakrabarti et al.,2002:, Boeckh et al., 2003). 
Several studies have focussed on the role of CD8
+ 
T-cells in controlling CMV 
reactivation (Quinnan et al., 1982; Reusser et al., 1991, Li et al., 1994; Walter et al. 
1995).  Using HLA-multimers to enumerate CMV-specific CD8
+ 
T-cells permitted a 
rapid assessment of the magnitude and function of these cells. Different research groups 
reported protective level of CMV–specific CD8+ T-cells which ranged from 7x103/ml 
(Gratama et al., 2010) to 20x10
3
/ml (Aubert et al., 2001). Additionally, HLA-multimers 
have helped scientists to obtain valuable information on immunology of viral specific 
CD8
+ 
T-cells (Appay et al., 2002). Their utility in clinical practice remains to be 
established, but they have facilitated the development of adoptive cellular 
immunotherapy through the direct selection of CMV-specific T- cells from the 
transplant donor (Chapter 3) (Cobbold et al., 2005).  
Despite these studies, little is known regarding the nature of the CMV-specific CD4
+
 T-
cell immune response, partly due to the lack of experimental tools for direct study of 
them. They appear important in sustaining a functional virus-specific CD8
+
 immune 
response (Walter et all, 1995) and in renal transplantation they have been shown to 
protect against primary CMV infection (Gamadia et al., 2004). CD4
+
 T-cells have also 
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been implicated in the success of adoptive immunotherapy for EBV-associated PTLD 
(Haque et al., 2007).  However, the kinetics and role of CMV-specific CD4
+ 
T-cells 
following HSCT is not well defined (Widmann et al., 2008; Eid et al., 2009; 
Pourgheysari et al., 2009; Tormo et al., 2010). Some authors have reported a fall in the 
virus-specific CD4
+
 T-cell response following viral reactivation whilst others have 
indicated the need for a minimum threshold to control viraemia (Eid et al., 2009; Tormo 
et al., 2010). However, most of this information regarding CMV-specific CD4
+
 T-cells 
was acquired using indirect functional interferon-γ secretion assays which only detect 
cells that are capable of producing cytokine in response to antigen. These assays require 
antigenic stimulation of the virus-specific population, routinely overnight incubation, 
and cannot provide an accurate phenotype of the cells when taken directly from blood or 
lymphoid tissue. In an attempt to overcome this issue and establish a rapid assay, 
Sester’s group introduced an indirect phenotyping method. They used effector memory 
CD4
+
 T-cells with the phenotype of CD27
-
 CD28
-
 as a bio-marker of CMV-specific 
CD4
+
 T-cells and showed association of CD4
+ 
CD27
-
 CD28
-
 PD-1
+ 
with viraemia in 
transplant recipients (Dirks et al., 2013). The identification of antigen-specific T-cells 
with HLA-tetramers is a direct method for visualising antigen specific T-cells and is 
based on HLA-peptide specificity and independent of the functional viability of the 
cells. 
The observation of CD4
+
 T-cell co-evolvement with CD8
+
 T-cells in the clinical trial 
samples, persuaded another study with more focus on CMV-specific CD4
+
 T-cell 
response following viraemia in HSCT patients. In addition, the presence of quality 
controlled HLA- class I multimer staining which had been developed for the trial, 
helped to design and conduct a HLA-class II multimer staining assay. The only 
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available HLA-class II multimer specific for CMV was found as HLA-DRB1*0701 
restricted tetramer with CMV derived peptide: DYSNTHSTRYV. It has been shown 
that this peptide provokes a strong CD4 response (Crompton et al., 2008).Therefore, 
HSCT patients with HLA-DRB1*0701 were chosen for this study. The frequency of 
this HLA-class II is around 10% in the UK population and it became possible to study 
frozen PBMCs from 20 non-trial CMV sero-positive HSCT patients. These samples had 
been collected from 2003 to 2013. 
The objective of the presented study in this chapter, was to use HLA-class II peptide-
tetramers for the first time to interrogate the reconstitution of CMV-specific CD4
+
 T- 
cells following transplantation. This information was used to examine the relative 
kinetics and phenotype of the CMV-specific CD4
+
 alongside of CD8
+ 
T-cell immune 
response and to relate these findings to the clinical control of viraemia in order to 
inform clinical practice.  
 
4.2 Results 
4.2.1 CMV reactivation was common and over 40% of patients suffered from 
multiple episodes of viraemia   
This study recruited 20 HSCT patients with 18 of them received a reduced-intensity 
conditioned transplant which incorporated TCD using either intravenous Alemtuzumab 
(CD52-specific monoclonal antibody) or ATG (Table 4.1). Two patients (04, 13) 
received myeloablative transplants without TCD. Patient 04 did not suffer from viral 
reactivation and patient 13 reactivated whilst receiving steroids for gut GVHD. 
In 15 out of 19 patients with the CMV reactivation, viraemia occurred early and became 
apparent within 6 weeks. Of these 19, ten patients (53%) displayed only a single 
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episode of viral reactivation whereas the other nine (47%) suffered from multiple 
viremic relapses (Table 4.2). Examples of the viral reactivation patterns observed in the 
patient cohort are shown in Figure 4.1. Within the group which suffered from multiple 
viral reactivations, patients 05 and 06 had prolonged episodes of viraemia refractory to 
anti-viral treatment lasting 210 days and 77 days respectively. Patient 11 and 16 had 
three episodes of viral reactivation whereas patient 12 had four.  Importantly, 8 out of 9 
of this group had late recurrent reactivations beyond 100 days post-transplant (Table 
4.2).  
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Table 4.1 Characteristics of HSCT patients. 
UPN Age Gender Diagnosis Conditioning/
Donor 
T-Cell 
Depletion 
D/R 
(CMV 
serology) 
HLA-class I 
restriction of 
HLA-
multimers  
 
01 56 M NHL RIC-Sib C +/+ B*0702 
02 43 M NHL RIC-MUD C +/+ A*0202 
03 49 M NHL RIC-Sib C +/+ B*0801 
04 46 M Myeloma MA-Sib N +/+ A*1101 
05 44 F NHL MA-MUD C +/+ A*0201 
06 55 M NHL RIC-MUD C -/+ A*0201 
07 64 F MDS RIC-Sib C +/+ A*0201 
08 63 M AML RIC-MUD C +/+ A*0201 
09 48 F NHL RIC-MUD C +/+ A*0201 
10 54 M AML RIC-Sib C +/+ B*0702 
11 68 M AML RIC-MUD C +/+ B*0801 
12 74 M AML RIC-MUD C +/+ A*0101 
13 27 M AML MA-Sib N -/+ A*0101 
14 55 M CLL RIC-MUD C +/+ B*0801 
15 44 F MDS RIC-MUD C +/+ A*0201 
16 56 M CLL RIC-MUD ATG -/+ A*0201 
17 57 M MDS RIC-Sib C +/+ A*0201 
18 66 M AML RIC-MUD C -/+ A*0201 
19 71 M AML RIC-MUD          C +/+ A*0201 
20 61 M AML/MD
S 
RIC-MUD ATG +/+ A*0201 
 
UPN: Unique patient Number, NHL:Non Hodgkin Lymphoma, AML: Acute Myeloid 
Lymphoma,  MDS:  Myelodysplastic Syndrome, CLL: Chronic Lymphocytic 
Leukaemia, RIC-Sib: reduced intensity conditioning, Sib: Sibling, MA: Myeloablative 
conditioning, MUD: Matched unrelated donor transplant, T-Cell Depletion: N: none, C: 
Alemtuzumab (Campath), ATG: anti-thymocyte globulins 
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Table 4.2 Summary of CMV reactivation and magnitude of CMV specific T-cell 
responses in HSCT patients. 
 
UPN No. CMV 
episodes 
Duration 
of 
viraemia 
(days post-
HSCT) 
Maximum 
viral load 
(copies/ml 
Maximum 
CMV-
specific 
CD4+ T-
cells* 
(% CD4) 
Maximum 
CMV 
specific 
CD8+ T-
cells* 
(% CD8) 
Log 
expansion of 
CMV-
specific 
CD4+ T-
cells 
Log 
expansion of 
CMV- 
specific 
CD8+ T-
cells** 
01 1 
 
63-78 
 
900 50(15) 370(9.7) 3.07 1.36 
02 2 
 
21-28 
100-120 
 
2600 1.5(5.2) 7(10) 1.2 2.40 
03 1 
 
28-70 
 
700 17(7.5) 448(25) 2.03 3.04 
04 0 
 
0 
 
- 28.7(3.5) ND 0.17 ND 
05 2 
 
28-238 
308-322 
 
191633 ND ND ND ND 
06 2 
 
27-54 
97-174 
 
7100 ND 1.9(0.5) ND 3.5 
07 1 
 
24-50 
 
11650 15.5(10) 82(9.4) 1.49 1.79 
08 2 
 
34-41 
126-147 
 
1400 1.2(1.4) 76(8) 3.07 1.94 
09 1 
 
35-56 
 
1269 6.4(4) 146(12) 1.34 1.61 
10 1 
 
41-62 
 
3500 0.5(0.23) 54(6.1) 0.17 0.77 
11 3 
 
63-91 
144-164 
203-224 
 
16800 ND 297(36) ND 3.14 
12 4 
 
25-46 
83-114 
127-141 
195-226 
 
15400 0.46 
(0.35) 
390(17) 1.60 2.57 
13 2 
 
17-39 
77-84 
 
15760 2.9(4.1) 15(2) 1.89 1.04 
14 1 
 
26-47 
 
31000 ND 25(1.2) ND 2.77 
15 1 
 
47-68 
 
600 ND 37(13) ND ND 
16 3 43-78 
100-120 
280-295 
23000 30(25) ND 3 ND 
17 1 22-50 2155 
 
ND 8.7(1.3) ND 0.53 
18 1 22-43 5100 
 
ND ND ND ND 
19 1 28-56 1100 
 
ND 20(5) ND 4.75 
20 2 27-62 
99-118 
600 ND ND ND ND 
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Table 4.2 (continued)* Figures are cell numbers x10
3
/ml peripheral blood, Figures in 
the brackets are percent of specific cells in whole CD4
+
 or CD8 
+ 
T-cells, **There was 
no statistically significant difference in expansion from baseline between CMV-specific 
CD4
+
 and CD8
+
 T-cells (median:1.7 log and 2.2log, respectively. p=0.54).  ND; not 
detected 
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Figure 4.1 Pattern of reconstitution of CMV-specific CD4
+
 and CD8
+
 T-cells after 
transplantation in relation to episodes of CMV reactivation.  
 
Graphs showing reconstitution of CMV-specific T-cells in (A) a patient with single 
episode of CMV viraemia, (B) a patient with multiple episodes of viraemia and (C) a 
patient with no CMV reactivation (due to lack of HLA-class I multimer-stainable cells 
for this patient, only total CD8 
+
T-cell levels are available). The frequency of DYS-
specific CD4
+ 
T-cells in this patient was high (15 x 10
3
/ml) and stable post-HSCT. 
Dashed line shows CMV copy number/ml.  
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4.2.2 Monitoring of CMV-specific CD4
+
 T-cells using HLA-peptide tetramers 
showed that CD4
+
 T- cells reconstituted with similar kinetics to virus-specific CD8
+
 
T-cells  
The HLA-DRB1*0701-DYS tetramer was used in combination with a range of CMV-
specific HLA-class I multimers (Table 2.2) to characterise CMV-specific CD4
+
 and 
CD8
+
 T-cell reconstitution (Figure 4.2A). DYS-specific CD4
+
 T-cells were detected in 
11 out of 20 HLA-DRB1*0701 HSCT patients and the frequency of tetramer-staining 
cells ranged at baseline from 0% to 4% of the CD4
+
 T-cell pool (median: 0.11%) with 
absolute numbers ranging from 0 to 0.5x10
3
 /ml (median: 0.15x10
3
/ml) before first viral 
reactivation. The DYS-specific CD4
+
 T-cell population expanded markedly after viral 
reactivation and reached a median peak of 4.8% of the CD4
+
 T-cell pool (range 0.23% 
to 25%) corresponding to an absolute median count of 5.20 x10
3 
/ml (range 0.46 to 
50x10
3 
/ml). In comparison, the peak aggregate levels of tetramer-staining CMV-
specific CD8
+ 
T-cells were markedly higher, with a median value over 14 fold higher at 
76 x10
3 
/ml (range 8.70 x10
3 
/ml - 448x10
3 
/ml).  However, the kinetics of reconstitution 
of both CMV-specific CD4
+
 and CD8
+
 T-cells were comparable expanding by 
approximately 2 logs (Table 4.2 and Figure 4.2 B-C). Monitoring was continued until 
36 weeks post-transplant in nine patients with detectable levels of both CMV-specific 
CD4
+ 
and CD8
+ 
T-cells. A very strong correlation was found between the magnitude of 
the CD4
+
 and CD8
+
 CMV-specific immune response following CMV reactivation 
(r=0.75, p<0.0001) (Figure 4.2D).  
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Figure 4.2 Longitudinal analysis of reconstitution of CMV-specific T-cells following 
HSCT. 
(A) Flow cytometry dot plots of CMV-specific CD4
+
 T-cells visualised using HLA-
DRB1*0701 tetramers with CMV-derived DYS peptide. HLA-DRB1*0701 tetramers loaded 
with irrelevant peptides were used as negative control.  x-axis, CD4 staining; y-axis, staining 
with tetramer.(B) Longitudinal monitoring of DYS-specific CD4
+
 T- cells and (C) CMV-
specific CD8
+
 T-cells after HSCT. Thick black lines represent median cell numbers of CMV-
specific T-cells. (D) Correlation between the number of CMV-specific CD4
+
 and CD8
+
 T-cells 
during immune reconstitution post-HSCT (r=0.75, p<0.0001). 
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4.2.3 T-cell responses before and after clearance of viraemia indicate a minimum 
threshold of CMV-specific T-cell immune response is required for viral control 
Prior to reactivation, CMV-specific T-cells were detectable only at very low levels 
within peripheral blood. Although a difference in baseline CMV-specific CD4
+
 T-cell 
levels  between patients with single (median 0.25x10
3 
/ml) and multiple viremic 
episodes (median0.05x10
3 
/ml) was observable, it was not statistically significant 
(p=0.12). This was also true for CMV-specific CD8
+ 
T-cells (Figure 4.3A, B). The 
expansion of CMV-specific immune response is usually triggered by CMV reactivation. 
HLA-class II tetramers were used to assess if the magnitude of the CMV-specific CD4
+
 
T-cell response after the first reactivation was predictive of sustained viral control. 
Indeed, patients who experienced only a single viraemic episode showed a median peak 
CMV-specific CD4
+
 level of 6.2 x10
3 
/ml and cleared the virus without later relapses 
(Figure 4.3D). In contrast, patients who went on to experience multiple episodes of 
viraemia had a median CMV-specific CD4 
+
 T-cell level of only 0.04x10
3
/ml after the 
first reactivation (p=0.02). A similar pattern was seen with CMV-specific CD8
+
 T-cells, 
where the count after resolution of viraemia was 41.10 x10
3
/ml in patients with single 
reactivation compared to 4.30x10
3 
/ml in patients with multiple reactivations (p=0.049) 
(Figure 4.3E). The peak CMV-specific T-cell count after the initial viraemic episode is 
therefore predictive of the ability to maintain control of further reactivations. We 
estimated the minimum thresholds of CMV-specific T-cell counts predictive of long-
term viral control based on the median peak T-cell level following the last episode of 
viraemia. A median level of >0.7x10
3 
/ml CMV-specific CD4
+ 
and >20x10
3
/ml specific 
CD8
+
 T-cells after clearance of CMV was associated with absence of further 
reactivations. This magnitude of CMV specific CD8
+
T-cells is consistent with 
previously reported protective levels (Cwynarski et al., 2001; Aubert et al., 2001).  
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Figure 4.3 Frequencies of CMV specific T-cells before and after viraemia in relation 
to occurrence of single or recurrent episodes of reactivations.  
 
(A)Number of CMV-specific CD4
+ 
T-cells, (B) CMV-specific CD8
+
 T-cells and (C) 
CD4
+
CD57
+
  T-cells before the onset of initial CMV viraemia in patients who underwent single 
or multiple episodes of viral reactivation.(D) Number of CMV-specific CD4
+ 
T- cells , (E) 
CMV-specific CD8
+
 T-cells and (F) CD4
+
CD57
+
 T-cells after clearance of viraemia in patients 
with single of reactivation, or after first and final episode of reactivation in patients who 
suffered from multiple episodes of CMV reactivation. Patients with a single episode of CMV 
reactivation had higher numbers of all cell subsets after the first episode of viraemia compared 
to patients with multiple reactivations (p=0.02).  
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4.2.4 Expansion of CD4
+
CD57
+
 T-cells during viral reactivation indicates a 
broader CMV-specific CD4
+
 T-cell response  
As the level of DYS-specific CD4
+
 T-cells was predictive of control for viral 
reactivation following the first episode of viraemia, it became important to ascertain 
how this correlated with the total CMV-specific CD4
+
 T-cell immune response. CD4
+ 
CD57
+
 T-cells are present almost exclusively in CMV-seropositive patients (next 
chapter) and CD57 is present in CMV-specific CD4
+
 T-cells (van Leeuwen et al., 2005; 
Crompton et al., 2008; Strioga et al., 2011). Indeed, the number of tetramer-binding 
CMV-specific CD4
+
 T-cells correlated strongly with the CD4
+ 
CD57
+
 T-cell count 
(r=0.93, p<0.0001) (Figure 4.4).  Similar to DYS-specific CD4
+
 T-cells, there was a 
statistically significant difference in CD4
+ 
CD57
+
 T-cell peak levels after first CMV 
reactivation between patients with single reactivation (median 19 x10
3
/ml)  and those 
who went on to develop multiple reactivations (median 4 x10
3
/ml) (p=0.02) (Figure 
4.3F). The median level of protective number of CD4
+ 
CD57
+
 T-cells after final viral 
clearance in multiply reactivated patients was 11.5 x 10
3
/ml (Figure 4.3F).   
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Figure 4.4 Correlation between the number of CMV-specific CD4
+
 T-cells and number of 
CD4
+
 CD57
+
 T-cells during T-cell reconstitution post-HSCT. 
 
Reconstitution of CD4+ CD57+ T-cell correlates strongly with appearance of CMV-specific 
CD4
+
 T-cells and therefore could serve as a surrogate marker for detection of CMV-specific 
CD4
+
 T-cells. 
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4.2.5 Diagnostic value of CMV-specific T-cell quantification 
 
To address whether measuring the frequency of CMV-specific T-cells or CD4
+
 CD57
+
 
T-cells could be used as a diagnostic test in predicting recurrent CMV reactivations 
after the first episode of viraemia, ROC (Receiver Operating Characteristic) analysis 
was performed. Due to the low number of samples with the measurable frequencies of 
CMV-specific CD4
+
 T-cells, this analysis was only performed for CMV-specific CD8
+
 
and CD4
+
 CD57
+
 T-cells. Furthermore, in order to increase the number of samples with 
detectable CMV-specific CD8
+
 T-cells, additional data from 14 HSCT patients were 
kindly provided by Dr David Lewis (School of Cancer Sciences, University of 
Birmingham, submitted paper). These data and data from 15 patients (presented in 
Figure 4.3) (in total 29 patients) were analysed by ROC test. This analysis showed that 
the presence of lower than 7.22x10
3
/ml CMV-specific CD8
+
 T-cells after the clearance 
of first episode of viraemia, could predict the recurrent CMV reactivation with a 
sensitivity of 84.56% and specificity of 75.00%. The area under the curve (AUC) was 
82% and the test was statistically significant at p=0.003 (Figure 4.5A). These values for 
specificity and sensitivity were also found by X square analysis which is presented in 
the next pages. Figure 4.5B shows the comparison between CMV-specific CD8
+
 T-cells 
after the clearance of first viral reactivation in 29 patients with single or multiple 
episode(s) of viraemia. Similar to Figure 4.3E which illustrated the data from 15 
patients, Figure 4.5B confirms a median frequency of CMV-specific CD8
+
 T-cells after 
first episode of viraemia in patients with single episode of 20x10
3
/ml. However, 
according to the ROC analysis, this level of CMV-specific CD8
+
 T-cell frequency gives 
a sensitivity of 92.34% and a specificity of 50.10% specificity for detecting patients 
with multiple episodes.  
                                                                    127 
 
ROC analysis of CD4
+
 CD57
+
 T-cell frequencies in 14 HSCT patients (7 with single 
episode and 7 with multiple episodes of CMV viraemia), also showed that CD4
+
CD57
+
 
T-cell levels can be used as a reliable surrogate marker for predicting recurrent 
reactivation.  This analysis showed that after the resolution of the first episode of 
viraemia, a level of CD4
+
 CD57
+
 T-cells below 5x10
3
/ml is associated with patients 
suffering from further reactivations (85.70% sensitivity and 85.70% specificity , 
AUC=86% , p-0.022) (Figure 4.5C). Additionally, X square analysis confirmed these 
sensitivity and specificity values.  
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Figure 4.5 ROC analysis of CMV-specific T-cell numbers in HSCT patients with 
single or multiple episode(s) of CMV reactivation. 
 
 (A) CMV-specific CD8
+
 T-cell levels were analysed in 29 HSCT patients with single 
or multiple CMV viraemia by ROC analysis test or (B) compared by Mann Whitney 
test. (C) ROC analysis of CD4
+
 CD57
+ 
T-cells in 14 HSCT patients with single or 
multiple episodes of CMV reactivation. (D) Comparison of CD4
+
 CD57
+ 
T-cell levels. 
This figure is part of Figure 4.3F.   
 
Despite the small number of patients analysed by ROC test, the results clearly show the 
potential advantage of quantifying the frequency of CMV-specific T-cells, especially 
after a first episode of viraemia, for identifying patients at risk of recurrent viraemia. 
The CMV-specific T-cells can thus be used to risk-stratify HSCT patients into those at 
high risk of recurrent reactivation and those at low risk. This can help to guide clinical 
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decision making on how frequently the individual patient should be monitored for CMV 
reactivation, and possibly on when to use salvage CMV-specific therapy. The data 
support a role for CMV immunotherapy as salvage therapy in this setting, rather than as 
first line prophylactic or pre-emptive therapy.  
 
HLA-class I tetramer (CMV/CD8
+
 T-cells)                              CD4
+
 CD57
+
 T-cells 
multiple react.   single react 
 
 
 
 
 
 
4.2.6 CMV-specific CD4
+
 T-cells exhibit an effector phenotype 
To assess the functionality of CMV-specific CD4
+
 T-cells in the post-transplant setting,  
HLA-class II tetramers were co-stained with a range of different antibodies against cell 
surface or intracellular molecules (Figure 4.6). Longitudinal monitoring demonstrated 
largely stable CMV-specific CD4
+
 and CD8
+
 T-cell phenotypes throughout the period 
of viraemia (Figure 4.7A, B). The majority of CMV-specific CD4
+
 T-cells maintained a 
CCR7
- 
CD45RA
-
 effector memory phenotype (EM) (median 82%), whereas a mean of 
77% CMV-specific CD8
+
 T-cells skewed towards a CCR7
- 
CD45RA
+
 (EMRA 
phenotype) and a mean of 21% towards EM phenotype. CMV-specific CD8
+
 T-cells 
exhibited an increase in EMRA phenotype during viraemia. No naïve or central memory 
subsets were detected in this population. This indicates that following CMV-
reactivation in HSCT patients, CMV-specific CD4
+
 and CD8
+
 T-cells do not express 
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lymph node chemokine receptor CCR7. Despite this similar phenotype, most of CMV-
specific CD4
+
 T-cells do not re-express CD45RA whilst CD8
+
 T-cell undergo further 
cell differentiation and regain CD45RA molecule.  
 
 
 
 
 
Figure 4.6 Immunophenotyping of CMV specific T-cells by flow cytometry. 
 
CMV-specific T-cells were co-stained with antibodies against cell surface molecules of 
CD45RA, CCR7 and intracellular perforin, granzyme B and T-bet. The percentages show the 
frequency of cells expressing a particular phenotype among CMV-specific CD4
+ 
(HLA-
DR7/DYS tetramer) and CD8
+ 
(HLA-class I multimers) cells.  
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Figure 4.7 Immune phenotype of reconstituting CMV-specific T-cells post-HST. 
(A, B) Frequencies of T-cell subsets; naïve, central memory, effector memory (EM) and 
revertant EM (EMRA) during T-cell reconstitution (pre, during and post cell expansion). (C) 
Frequencies of perforin expressing CMV-specific CD4 (CMV-CD4) and CD8 (CMV-CD8) T-
cells post-HSCT. These figures are median frequencies of positive cells from 4 HSCT patients. 
A 
B 
C 
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4.2.7 Helper and Cytotoxic potential of CMV specific CD4
+ 
T-cells  
Several studies have shown that a considerable percentage of CMV-specific CD4
+
 T-
cells from healthy individuals display cytotoxic activity, a property that is less 
commonly observed in other antigen-specific CD4
+
 T-cells (Casazza et al., 2006). 
Indeed, perforin and granzyme B expression was observed in 32% and 22% of patients’ 
CMV-specific CD4
+
 T-cells, respectively, clearly demonstrating the cytotoxic potential 
of some of these cells (Figures 4.6-8). However, the expression level of T-bet within 
CMV-specific T-cells was similar in specific CD4
+ 
and CD8
+ 
T-cells, present at a 
median of 62% of the antigen-specific subset (Figures 4.6-8). T-bet is a T-box 
transcription factor with an important role in development of Th1 cells (Edwards et al., 
2014) and the proportion of T-bet positive cells within the CMV-specific CD4
+ 
T-cell 
population was significantly higher compared to the global CD4
+
 T-cell repertoire 
(p<0.03), supporting the predominant Th1 profile of CMV-specific CD4
+
 T-cell pool.  
On the other hand, the T-bet expression by CMV-specific CD8
+
 T-cells supports anti-
viral activity. T-bet expression by CMV-specific CD8
+
 T-cells after primary infection 
has been reported to predict control of recurrent pulmonary CMV viraemia in lung 
transplant patients
 
(Pipeling et al., 2011). 
 
As anticipated of CMV-specific CD8
+
 T-cells, 
being professional cytotoxic cells, the expression of perforin and granzyme B was much 
higher within 85% and 61% of the population, respectively. This remained largely 
stable during and after cell expansion in response to CMV (Figure 4.7C).  
Analysis of CD57 expression by CMV-specific CD4
+
 T-cells revealed that up to 65% of 
these cells expressed CD57. Interestingly, co-staining of CMV-specific T-cells with 
anti-CD57 and anti-perforin Abs showed that in both total and CMV-specific CD4
+
 T-
cells, perforin expression is much higher in the cells expressing CD57 molecule (Figure 
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4.9).This is in accordance with a previous finding on CD8
+ 
population showing that 
CD57 expression represents perforin positive cytotoxic T-cells (Chattopadhyay et al., 
2009).  
 
 
 Figure 4.8 Expression levels of perforin, granzyme B and T-bet in CMV-specific 
T- cells. 
 Percentages of CMV-specific T-cells with intracellular expression of perforin, 
granzyme B and T-bet during immune reconstitution in 4 HSCT patients. Expression of 
perforin and granzyme B were higher in CMV-specific CD8
+
 compared to CMV-
specific CD4
+
 T-cells (p<0.0001, p<0.002, respectively).  
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Figure 4.9 Perforin expression in total CD4
+
 population, CD4
+
CD57
+
 and CD57
+
 
DYS -specific T-cells.  
 
Higher perforin expression in CD4
+
CD57
+
 and CD57
+
 DYS-specific CD4
+ 
T-cells in 
comparison to total CD4
+ 
population. The perforin expression profile of CD4
+ 
CD57
+ 
cells was very similar to the expression profile of CMV-specific CD4
+ 
CD57
+ 
T-cells. 
 
 
4.2.8 Cytokine receptor expression in the reconstituting CMV-specific T-cells 
Cytokines play a major role in post-transplant immune reconstitution. We therefore co-
stained tetramer-positive cells with anti-CD25 (IL-2Rα) and -CD127 (IL-7Rα), 
receptors for two key homeostatic cytokines. Neither was detected in CMV-specific 
CD8
+
 T-cells but a mean 46% of CMV-specific CD4
+
 T-cells retained stable expression 
of IL-7Rα but not IL-2Rα (Figure 4.10), suggesting that CD4+ cells have the potential to 
respond to local IL-7 production, and to provide help to CD8
+
 T-cells. The absence of 
CD25 expression indicated that CD25
+
 T-regulatory cells were absent amongst CMV-
specific CD4
+
 T-cells. 
TNF-α is produced rapidly following HSCT and as it is discussed in the next chapter, 
there are two receptors for this cytokine which only one of them (TNFR2) is detectable 
on cell surface by using flow cytometry based cell staining. Co-staining with anti-
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TNFR2 (CD120b) antibody showed that all CMV-specific T-cells expressed CD120b 
after CMV viraemia. The expression level of CD120b per cell (as determined by mean 
fluorescent intensity (MFI) of stained cells) increased rapidly during viraemia (MFI 
from 3000 to 10500) and decreased following viral clearance (Figure 4.11).This finding 
may indicate an important role for TNF-α in the process of T-cell response to antigens 
(next chapter).  
 
 
 
 
Figure 4.10 Flow cytometry dot plots of cytokine receptor expression in CMV-specific 
T-cells. 
 
Co-staining of CMV-specific T-cells with IL-7Rα and IL-2Rα showed that these 
receptors were almost absent in CMV-specific CD8
+
 T-cells whilst the majority of 
CMV-specific CD4
+ 
T-cells expressed IL-7Rα with no IL-2Rα expression.  
 
 
 
 
CMV specific CD8                                            (CMV) DYS specific CD4 
3% 65% 
IL2Ra 
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Figure 4.11 TNFR2 (CD120b) expression by CMV-specific T-cells in response to 
CMV reactivation.  
 
CMV-specific T-cells expressed TNFR2 in different level per cell as measured by mean 
fluorescent intensity (MFI) (X axis). During cell response to CMV reactivation, TNFR2 
expression per cell increased considerably and returned to its steady level following 
viral clearance. Light green and red graphs show TNFR2 expression in whole peripheral 
and CMV-specific CD8
+
 T-cell populations, respectively.  
 
 
4.2.9 The CMV-specific humoral immune response correlates with the 
reconstitution of CMV-specific CD4
+
 T-cells  
As CD4
+
 T-cells are known to support antibody production through both Th1 and Th2 
help (Swain et al., 2012), it became interesting to study whether CMV-specific CD4
+
 T-
cells were involved in supporting anti-CMV humoral response. Longitudinal analysis of 
CMV-specific antibody titres showed correlation with the reconstitution of CMV-
specific CD4
+
 T-cells. This correlation was found between the magnitude of the CMV-
specific IgG and CMV-specific CD4
+ 
T-cells (r=0.45, p=0.01) (Figure 4.12).  
 
 
Days post HSCT:  
49(pre viraemia)      63(CMV viraemia)      91(CMV viraemia)     120(post viraemia)    150(post 
viraemia)  
 
 
MFI:3000  MFI:8600  MFI:10500  MFI:2800  MFI:3000  
CD120b 
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Figure 4.12 Coordinated humoral and cellular immune responses to CMV 
reactivation post-HSCT.  
 
There was a correlation between the number of DYS-specific CD4
+
 T- cells (x-axis) and 
anti CMV- IgG titre during immune reconstitution. 
 
 
4.3 Discussion   
Cytomegalovirus reactivation continues to be a considerable challenge in stem cell 
transplantation, and the risk is particularly high with non-myeloablative regimens that 
incorporate TCD (Chakrabarti et al., 2002). The management of viral reactivation has 
improved in recent years with use of QPCR for early detection of viral reactivation, 
guiding effective anti-viral medication and application of CMV-specific T-cell therapy. 
However, tests which can predict the onset of viraemia would be of considerable benefit 
in optimizing preventative therapies. 
The CMV-specific T-cell immune response is almost certainly the most important 
effector arm in the control of viral reactivation and studies have shown that regeneration 
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of a robust T-cellular response can predict effective viral control. The introduction of 
HLA-class I-peptide tetramers permitted the rapid assessment of the magnitude and 
phenotype of the CMV-specific CD8
+
 immune response. However, the lack of 
availability of CMV-specific HLA-class II tetramers has limited the incorporation of 
CMV-specific CD4
+
 immune response into management algorithms.  
This study used a CMV-specific HLA-class II tetramer for the first time to analyze the 
magnitude, kinetics and functional properties of regenerating CMV-specific CD4
+
 T-
cells in the post-transplant period. Three major findings were observed within the study: 
firstly, following the onset of CMV viraemia, CMV-specific CD4
+
 and CD8
+
 T-cells 
were found to expand in parallel and with similar kinetics. Both populations showed an 
average increase of around 2 logs over a period of 8 weeks. Rapid expansion of CMV-
specific T-cells following viral detection has been reported in many HSCT studies, and 
subclinical reactivation is thought to provide a basis for the high prevalence of CMV-
specific cells in healthy donors. These studies show that CMV-specific CD4
+
 T-cells 
have comparable proliferative capacity to their CD8
+
 counterparts, and demonstrate the 
importance of robust T-cellular expansion in the setting of viral replication. However, it 
was notable that the magnitude of and variation in the CMV-specific CD4
+
 T-cell 
response was much smaller than that of CMV-specific CD8
+
 T-cells. 
A second important finding was that we were able to use the peak CMV-specific T-cell 
response following initial viraemia to define a minimum number of CMV-specific 
CD4
+
 T-cells that was associated with protection from recurrent viral reactivations. A 
level of 0.7x10 
3
/ml CMV-specific CD4
+
 T-cells was required to provide long term 
control of viral reactivation. This level is comparable to protective value of 1x10
3
/ml 
previously reported using functional assays and confirms that reconstitution of CMV-
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specific CD4 T-cells is protective (Widmann et al., 2008; Pourgheysari et al., 2009; 
Tormo et al. 2010, Lilleri et al., 2008)
. 
 This estimate of minimum protective CMV-
specific CD8 T-cell level of 20x10
3
/ml is also comparable with previous reports of 
levels between 10 and 20 x10
3
/ml (Cwynarski et al., 2001; Aubert et al., 2001).
 
 Finally, the use of HLA-peptide tetramers allowed us to make a detailed phenotypic 
analysis of the CMV-specific CD4
+
 T-cell immune response in the post-transplant 
setting. This property is one of the most valuable aspects in the use of HLA-peptide 
multimers, as functional assays based on response to peptide stimulation, alter the 
membrane phenotype following cellular activation.  
Although, this study focused on a single glycoprotein B-derived epitope DYS with the 
available tetramer, the immune response to glycoprotein-B constitutes a large 
component of the overall CD4 and humoral response to CMV infection (Crompton et 
al., 2008).
 
Nevertheless, the total CMV-specific CD4 response is likely to be considerably larger 
as CD4 responses generally have a broad range of specificities, as seen in EBV-specific 
CD4 responses
 
(Long et al., 2013). Using CD4
+
 CD57
+
 T-cells as surrogate markers for 
CMV-specific CD4
+
 T-cells, it was estimated that the numbers of CD4
+
 CD57
+
 T-cells 
required for viral control were between 11.5 and 19 x10
3
/ml. These were the levels 
measured after resolution of viraemia in patients with single reactivation and after 
resolution of the last viraemic episode in patients with multiple reactivations, 
respectively (Figure 4.3F). Given the statistically significant difference in levels 
between single and multiply relapsed patients, it may be feasible to use CD4
+ 
CD57
+
 T-
cell levels to predict recurrent viraemia. 
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CD4
+
 T-cells contribute diverse functions to antiviral protection (Swain et al., 2012). 
The best known role of them is providing help to B-lymphocytes for antibody 
production, but it also mediates direct cytotoxicity as a number of studies of CMV-
specific CD4
+
 T-cells from healthy donors have shown (Casazza et al., 2006). In our 
cohort, cytotoxic molecules was observed in only up to 30% of CMV-specific CD4
+ 
T-
cells in contrast to CD8 counterparts that have much higher content . It is possible that 
exhaustion or selective migration from peripheral blood to the site of infection had 
taken place but the high expression of intracellular T-bet suggests that the predominant 
function of CMV-specific CD4
+
 T-cells is to provide Th1 support for CD8
+
 T-cells with 
only a minority component mediating cytotoxicity.
 
As nearly half of HSCT patients with high-risk CMV serology have been shown to go 
on to develop recurrent reactivations in this and previous studies (Chakrabarti et al., 
2002), using HLA-peptide tetramers to measure the CMV-specific T-cell response after 
resolution of the first CMV reactivation may allow the stratification of patients into high 
and low risk groups to guide the appropriate introduction of prophylactic CMV-specific 
adoptive T-cell immunotherapy or second line anti-viral drug therapy. 
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Chapter 5 
CYTOKINE RECEPTOR 
EXPRESSION PATTERN IN T-CELL 
SUBSETS AND FUNCTIONAL 
ACTIVITY OF TNFR2 
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5.1 Background 
Cytokines are vital mediators of a broad range of physiological processes including cell 
growth and differentiation, tissue formation and repair, inflammatory and anti-
inflammatory mechanisms and immune response. Cytokines’ activities are dependent 
on their interaction with specific receptors expressed by target cells. Cytokine receptors 
are grouped into six structurally related super-families. Among them are type I cytokine 
receptors and Tumour Necrosis Factor Receptor (TNFR) family (Wang et al. 2009;  
Hehlgans and Pfeffer, 2005).  The type I cytokine receptor family includes 3 subgroups: 
glycoprotein 130 (gp130), common beta and common gamma chain molecules. 
Cytokine receptors in this family mainly interact with cytokines that regulate a 
hematopoietic system and immune responses (Figure 5.1). Gp130 is a common signal 
transducing molecule in receptors for cytokines such as Interleukin 6 (IL-6) and IL-11 
(Taga, 1997). Common gamma chain is a signal transducing chain in receptors for 
cytokines such as IL-2, IL-7 and IL-15. Each of these cytokines has its own private 
receptor (IL-2Rα, IL-7Rα and IL-15Rα, respectively) which in combination with IL-2R- 
γ and beta receptor (in case of IL-2 and IL-15) make functional receptor complexes 
(Wang et al., 2009). Cytokines of the common gamma chain family are vital for the 
development of T cell memory. Antigenic stimulation of T- cells in the presence of IL-2 
leads to strong T-cell proliferation which is followed by IL-2 induced cell death during 
the contraction phase of the immune response. Activation-induced cell death is 
mediated through FAS/FASL and TNF/TNFR interactions (Grell et al., 1999; Green and 
Ware, 1997). In contrast, IL-7 and IL-15 are involved in the rescue of T-cells from 
apoptosis and induce cell growth which finally leads to the generation of memory T-cell 
pool (Schluns and Lefrancois, 2003). 
                                                                    143 
 
 
Figure 5.1 Cytokine-receptor interactions of type I family cytokine receptors. 
Type I family cytokine receptors include 3 subgroups; shared cytokine receptors βc (a) gp130 
(b) and γc (c) are represented schematically on a cell membrane. The respective interacting 
cytokines with known three-dimensional structures are shown with cylinder representations of 
the four-helix bundles. (CNTF: ciliary neurotrophic factor, LIF: leukemia inhibitory factor, 
OSM: oncostatin M, TCCR: T cell cytokine receptor, TSLPR: thymic stromal-derived 
lymphopoietin receptor) (Wang et al., 2009) 
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IL-15 interacts with the responding cells through a unique pathway of trans-presentation 
(Figure 5.2) which leads to the activation of Bcl-2 and Bcl- xL genes and therefore 
suppresses cell apoptosis (Malamut et al., 2010). IL-7 is also able to induce expression 
of anti-apoptotic Bcl-2 and Bcl-xl molecules.  
 
 
 
 
 
 
Figure 5.2 Trans-presentation of IL-15. 
The main pathway of IL-15 interaction with its receptor is trans-presentation which 
starts with binding to IL-15Rα in IL-15 producing cells and subsequently presentation 
to the responding cells bearing IL-15Rβγc complex on their cell surface. 
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The TNF superfamily includes 19 soluble and membrane-bound ligands and 32 
receptors. TNF superfamily ligands and receptors interact to regulate cell responses 
such as activation, proliferation, differentiation, and apoptosis (Aggarwal , 2003). Cell 
signalling through TNF superfamily members is a critical process in the regulation of 
immune responses and haematopoiesis, and is also implicated in tumorigenesis, 
transplant rejection, virus replication, and diabetes. Discovery of TNF/TNFR 
superfamily functions has led to successful development of multiple therapeutic 
interventions such as Infliximab (anti-TNF Ab) and Etanercept (consist of soluble 
TNFR2).  
Some TNFR family members such as 4-1BB (CD137, TNFRSF9), OX40 (CD134, 
TNFRSF4), CD27 (TNFRSF7), CD30 (TNFRSF8), CD40 (TNFRSF5), GITR (CD357, 
TNFRSF18), HVEM (TNFRSF14), and TACI (CD267, TNFRSF13B), have been 
studied widely for their roles as co-stimulatory molecules in T-cell activation (Figure 
5.3) (Croft, 2003 and 2009). Most of these molecules are not present in naïve T-cells 
and appear at high level following T-cell activation and differentiation toward effector 
T- cells. Generation of memory T-cells is accompanied by decrease in cell surface 
expression of TNF/TNFR members (Table 5.1) (Watts, 2005).  
Table 5.1 Expression properties of TNF/TNFR molecules by T-cells and APCs. 
 
Molecule                         T-cells                                                       APCs 
                            Naïve                Effector              Memory         Resting            Activated 
CD27 ++ +++ ++/- - B 
CD70(CD27L) - +++ - - B, DC, MØ 
HVEM +++ + +++ B, DC B, MØ 
OX40 - +++ +/- DC B, DC 
0X40L - +++ - - B, DC, MØ 
4-1BB - +++ +/- - B, DC 
4-1BBL - +++ - - B, DC, MØ 
CD30 - +++ +/- - - 
CD30L - +++ - - B, MØ 
Expression levels: -: absent, +: low level, ++: moderate level, +++: high level 
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Figure 5.3 TNF/TNFR family members with co-stimulatory roles. 
TNF ligands are shown as homotrimeric trans-membrane proteins. The TNFR family 
molecules are presented as monomers that are thought to associate in trimers when 
interacting with their ligands. The commonly used names are in bold, with alternate 
names and TNF/TNFR superfamily (SF) designation in parentheses. The total amino-
acid length and number of intracellular amino acids (parentheses) are also shown. Web 
access to TNF/TNFR nomenclature and sequence can be found at: 
http://www.gene.ucl.ac.uk/nomenclature/genefamily/tnftop.html.(Croft, 2003) 
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TNF has two receptors: TNFR1 (TNFRSF1A/CD120a) and TNFR2 
(TNFRSF1B/CD120b). TNFR1 is expressed by a wide array of cell types but TNFR2 
has restricted expression found in selective lymphoid, neuronal, mesenchymal and 
endothelial cells (Sedger et al., 2014). TNF as a pleiotropic cytokine induces both 
apoptotic and cell survival/proliferation signals (Brenner et al., 2015). Despite using 
different intracellular signalling pathways, both TNFR1 and TNFR2 promote cell 
survival through activation of NF-κB. The intracellular part of TNFR1 also contains a 
‘death domain’ which facilitates interaction with caspases molecules and consequently 
induces cell apoptosis. TNFR2 does not have a ‘death domain’, but can relay apoptotic 
signals through engagement of caspases (Depuydt et al., 2005). It is still not clear how 
TNFR1 and TNFR2 signalling are regulated. Most of immune cells express both 
TNFR2 and TNFR1 and it has been shown that the relative levels of TNFR1 and 
TNFR2 on the surface of immune cells and their activation status are vital factors in 
determining cell fate and in the regulation of survival versus cell death  (Pimentel-
Muinos et al., 1999).   
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Figure 5.4 TNF interaction with TNFR1 and TNFR2 induces two opposing 
signalling events.  
 TNFR signalling can result either in cell survival or apoptosis. This is dependent upon 
the cell type, the state of activation of the cell and the cell cycle. Engagement of both 
TNFR1 and TNFR2 can induce NF-ΚB activation which leads to cell survival through 
BCL-2 activation. In addition, binding of TNF of to its receptors could rely apoptotic 
signals through activation  of caspases. AP1, activator protein 1; cFLIP, cellular FLICE-
like inhibitory protein (also known as CFLAR); cIAP, cellular inhibitor of apoptosis 
protein; FADD, Fas-associated death domain; IKK, inhibitor of κB kinase; JNK, Jun N-
terminal kinase; MAPK, mitogen-activated protein kinase; MEKK, mitogen-activated 
protein kinase kinase kinase; MKK3, dual specificity mitogen-activated protein kinase 
kinase 3; NEMO, nuclear factor-κB (NF-κ B) essential modulator; RIP, receptor 
interacting protein; TRADD, TNFR1-associated death domain; TRAF, TNF receptor-
associated factor. (Faustman and Davis, 2010) 
 
. 
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CD8
+ 
and CD4
+
 T-cells are currently categorised into 4 main subsets based on the 
expression of lymph- node homing receptor CCR7 and membrane CD45RA molecule. 
These subsets represent T cells in their differentiation pathway following antigenic 
response: CD45RA
+ 
CCR7
+
 (Naïve), CD45RA
- 
CCR7
+
 (central memory, CM), 
CD45RA
- 
CCR7
- 
(effector memory, EM) and CD45RA
+ 
CCR7
- 
(effector memory 
CD45RA
+
, EMRA). Phenotypic analysis of T-cell subsets has shown distinct expression 
of functional molecules by naïve and memory T-cells (Mahnke et al., 2013). IL-7Rα is 
mainly expressed by naïve, CM and EM subsets and this serves IL-7 induced 
homeostatic expansion and survival of naïve and memory T-cells. IL-6R (gp130) is 
expressed by naïve and CM T-cells and its signalling leads to IL-7 production and 
consequently T- cell proliferation. In contrast, T-cells with late differentiation EMRA 
phenotype have less proliferation and survival potential, particularly in response to IL-7.  
In humans, infection with CMV has a profound effect on the frequency of T cell subsets 
in the peripheral blood (Wertheimer et al., 2014). The majority of CMV-specific T-cells 
have a late differentiation EM/EMRA phenotype and express CD57, discussed in 
chapter 4. It is well documented that the number of memory/effector memory cells is 
increased in whole T-cell population of CMV sero-positive elderly individuals. CMV 
infection is accompanied by production of Th1 derived cytokines such as IFN- γ and 
TNF-α which are made by differentiated T- cells (van de Berg et al., 2010).     
In this study, cytokine receptor expression was studied in T-cell subsets of CMV-sero-
positive and sero-negative healthy individuals, and found that the expression of TNFR2 
was uniquely skewed towards more differentiated cells. This observation was 
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investigated in more functional detail using a cognate ligand to stimulate peripheral 
blood CD8
+
 and CMV specific T-cells from healthy blood donors and HSCT patients. 
The results showed that CMV specific T-cells, which were predominantly differentiated 
effector memory T-cells, had high TNFR2 expression and that in vitro ligation of TNFR 
with a specific ligand led to the apoptosis of these cells. 
 
5.2 Results 
 
5.2.1 T-cell subset distribution and CMV infection 
First, the distribution of differentiation subsets was studied amongst CD4
+
 and CD8
+
 T-
cells derived from healthy blood donors. These were young and middle age individuals, 
with a mean age of 42 years. The blood donors were laboratory workers and platelet 
donors of the NHS Blood and Transplant Donor Centre, Birmingham, UK. 
CD4
+
 and CD8
+
 T-cells have different distribution patterns. Amongst CD4
+
 T-cells, the 
size of the differentiation subsets followed a decreasing trend from naïve to effector 
cells with the frequency of naïve cells (CCR7
+ 
CD45RA
+
) highest (median; 47.50%), 
followed by CM (CCR7
+ 
CD45RA
-
) (30.20%), EM (CCR7
- 
CD45RA
-
) (15.30%) and 
EMRA cells (CCR7
-
 CD45RA
+
) (4.15%) (Figure 5.5A). The pattern was different for 
CD8
+
 T-cells.  Naïve and EMRA cells occupied similar proportions with lower percent 
of EM and CM cells and the lowest frequency represented by CM cells (5.20%) (Figure 
5.5A). However, this is likely a reflection of the influence of exposure to CMV in a 
proportion of the donors. Previous reports have shown that CMV infection changes the 
T-cell subset frequencies in favour of more differentiated T-cells which become more 
prominent with ageing (Khan et al., 2002). By segregating the data according to their 
                                                                    151 
 
CMV sero-status we confirmed that the decreased frequency of naïve cells and 
corresponding increase in effector cells amongst both CD4
+
 and CD8
+
 T-cells were 
accentuated in the CMV sero-positive group (Figure 5.5B,C). The 2 groups of donors 
were CMV serostatus and age-matched (median age: 47.2 and 43.1 years). However, 
these differences did not reach statistically significant levels. CD57 is another marker of 
late T –cell differentiation and CD4+ and CD8+ CD57+ T-cells have been linked to 
CMV infection (discussed in chapter 4). When we analysed our healthy donors for 
CD57 expression, we found that the frequency of CD8
+ 
CD57
+
 T-cells were higher in 
CMV sero-positive compared to CMV sero-negative individuals, and this was 
statistically significant (p=0.01, Figure 5.5D). Importantly, CD4
+ 
CD57
+
 T-cells were 
barely detectable in CMV sero-negative donors, with median frequency of 0.4 percent, 
whilst the median frequency in CMV sero-positive blood donors was 12 percent 
(p<0.0001, Figure 5.5D). As presented in the chapter 4, this molecule could be used as a 
biomarker for clinical diagnostic purposes in the management of CMV reactivation. 
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Figure 5.5 Distribution of T-cell subsets in healthy individuals and CMV infection. 
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Figure 5.5 (continued). (A) Distribution of T-cell subsets in CD4
+
 and CD8
+ 
populations 
of healthy individuals (n=27) which shows statistically significant differences in their 
frequencies. Frequencies of CD4
+
 T-cell subsets in (B) and CD8
+  
(C) cells with respect 
to CMV infection which showed no difference in T-cell subset distribution in CMV
+
 
versus CMV
-
 healthy donors. D) Frequency of CD57
+
 T-cells in CMV
+
 versus CMV
-
 
individuals. CMV infection is associated with increase in the frequency of CD57
+ 
T-
cells. This was especially prominent in the CD4
+ 
population with a mean of less than 
1% frequency of CD4
+
 CD57
+
 T-cells in CMV
-
 donors. 
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5.2.2 Expression of IL-2Rα (CD25) in T cell subsets 
IL2 is a cytokine that promotes survival and homeostatic proliferation, so the presence 
of CD25 (IL2R) on T cell surface should be an indicator of the survival and 
proliferative capacity of the cells. Therefore, the overall frequency of CD25 positive 
cells was determined within the CD4
+
 and CD8+ populations and found this receptor 
was more abundant amongst CD4
+
 (median: 12.43%) than CD8
+
 T-cells (median: 
2.59%) (p=0.001) (Figure 5.6A). However, when segregated according to 
differentiation subsets,  CD25 expression was found to increase from a low base in 
naïve cells to a median of 21.50% amongst CM cells, and reaching a peak in the EM 
subset (median: 37.41%).  Further differentiation toward EMRA, however, led to a 
decrease in CD25
+
 expressing T-cells. Amongst CD8
+
 T cells, CD25 expression 
increased following cell differentiation and had its highest level in the CM subset 
(5.55%) and its frequency decreased with increasing differentiation (Figure 5.6B).The 
frequency of CD25
+
 cells was higher amongst CMV
+
 individuals (Figure 5.6C), despite 
the higher proportion of highly differentiated cells. Nevertheless, the frequency of 
CD25 expression was lower in CD57
+
 when compared to CD57
-
 T-cells (Figure 5.6D), 
in line with low CD25 expression amongst highly differentiated T-cells. 
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Figure 5.6 CD25 expression in T-cell subsets of healthy blood donors.   
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Figure 5.6 (continued). (A) Higher prevalence of CD25 expression in CD4
+ 
T-cells in 
comparison to CD8
+
 population. (B) In both CD4
+
 and CD8
+
 T-cells, all the subsets 
expressed CD25 and this expression increased following cell differentiation with the 
highest level of CD25
+
 cells were observed in EM and CM subsets of CD4
+
 and CD8
+
 
T-cells, though less pronounced amongst CD8. (C) Increase in the frequency of CD25
+
 
T-cells was a global effect of CMV infection in healthy individuals. (D) A low number 
of CD57
+
 T-cells expressed CD25. 
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5.2.3 Expression of IL-7Rα (CD127) in T-cell subsets 
IL7 is a key cytokine responsible for the maintenance and survival of T cells and it was  
observed that how the cognate receptor is mainly expressed by early differentiated T 
cells. 
Overall, fewer CD8
+
 T-cells expressed IL-7Rα (38.23%) in comparison to CD4+ T- 
cells (61.20%) (p=0.003) (Figure 5.7A). In the naïve subsets of CD4
+
 and CD8
+
 T-cells, 
around half of the cells expressed IL-7Rα and this frequency increases in CM cells to 
62.55% and 68.00% for CD4
+
 and CD8
+
 T-cell, respectively (Figure 5.7B), but then 
diminishes following  further differentiation with medians of 28% and 17% for EMRA 
subsets of CD4
+
 and CD8
+
 T-cells, respectively. Our results showed no statistically 
significant differences in the overall frequency of IL-7Rα positive T-cells between 
CMV
+
 versus CMV
- 
individuals (Figure 5.7C), but highly significant when we 
compared IL7Rα expression between CD57+ with CD57- T cells. Similar to the low 
expression of IL-2Rα by CD57+ T-cells, IL-7Rα was also low in CD57+ cells. The 
median frequencies of CD4
+ 
CD57
+ 
CD127
+
 and CD8
+ 
CD57
+ 
CD127
+
 were 34.10% 
and 15.00%, respectively in CMV sero-positive individuals (Figure 5.7D).  
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Figure 5.7 CD127 (IL7Rα) expression in T-cell subsets of healthy blood donors.   
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Figure 5.7 (continued). (A) Higher prevalence of CD127 expression in CD4
+ 
T-cells in 
comparison to CD8
+
 population. (B) In both CD4
+
 and CD8
+
 T-cells, all the subsets 
expressed CD127 and this expression increased following cell differentiation with the 
highest level of CD127
+
 cells was observed in CM subsets of CD4
+
 and CD8
+
 T-cells. 
Expression of this cytokine receptor decreased in fully differentiated CD4
+
 and CD8
+
 T-
cells. (C) CMV infection did not have any effect on the frequency of CD127
+ 
CD4
+
 and 
CD8
+
 T-cells. (D) In comparison to CD57
- 
T-cells, significantly lower number of 
CD57
+
 T-cells expressed CD127. 
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5.2.4 Expression pattern of IL-15Rα 
Detection of IL-15Rα positive T-cells was inefficient due to the trans-presentation of 
this receptor (Figure 5.2). The method used in this study detected low level of IL-15Rα 
in all T-cell subsets of CD4
+
 and CD8
+
 cells with no statistically significant difference 
between them (Figure 5.8A). In CD4
+
 T-cells, naïve and EMRA cells had slightly 
higher frequencies of IL-15Rα positive cells (medians: 3.50% and 8.55%, respectively). 
In CD8
+
 T-cells, detectable level of IL-15Rα was lower but the highest frequency was 
observed in CM cells with median of 2.50% (Figure 5.8B). Co-staining of cells with 
anti IL-15Rα and CD57 antibodies revealed higher expression of IL-15Rα in CD4+ 
CD57
+
 and CD8
+ 
CD57
+
 T-cells in comparison to CD57
-
 T cells (Figure 5.8C). This is 
in keeping with previous report showing important role of IL-15 in the proliferation of 
late differentiated T-cells (Broux et al., 2015; Picker et al., 2006).  
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Figure 5.8 IL-15Rα expression in T-cell subsets of healthy blood donors.   
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Figure 5.8 (continued). (A) IL-15Rα expression was more frequent in CD4+ T-cells in 
comparison to CD8
+
 population. (B) In CD4
+
 and CD8
+
 T-cells, frequencies of 
detectable IL-15Rα+ T-cells were low and in CD4+ T-cells, EMRA cells had the highest 
frequency of T-cell subsets expressing IL-15Rα. (C) In comparison to CD57- T-cells, 
IL-15Rα expression was more frequent in CD57+ T-cells. 
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5.2.5 Expression pattern of CD130 (IL-6Rα) 
IL-6 is a potent inflammatory cytokine. The frequency of its cognate receptor CD130 
expression was considerably higher in CD4
+ 
(median: 47.10%) than in CD8
+
 T cells 
(median:7.22%) (p=0.0001, Figure 5.9A), although its distribution amongst the 
differentiation subsets is comparable (Figure 5.9B). Unlike IL-2, IL-7 and IL-15 
receptors, CD130 expression was highest in the naïve T-cell population. In CD4
+
 and 
CD8
+
 T cells, the median CD130 frequency amongst naïve cells were 74.10% and  
24.20% for CD4
+
 and CD8
+
 T-cells, respectively, and decreased rapidly with 
differentiation, reaching its lowest level in EM/EMRA cells (medians: 11.22% and 
1.20% , in CD4
+
 and CD8
+
 T-cells, respectively) (Figure 5.9B). 
The CD130 expression was independent of CMV status (Figure 5.9C). CD57
+
 T-cells 
had much lower CD130 frequency (medians: 8.10% and 4.15%, respectively) than 
CD57
- 
T cells (medians: 58.45% and 18.12%) (p=0.0009, p=0.006, respectively) (Figure 
5.9D). This finding supports the previous observation of preferential CD130 expression 
amongst naïve and less differentiated cells.  
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Figure 5.9 CD130 (IL-6Rα) expression in T-cell subsets of healthy blood donors.   
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Figure 5.9 (continued). (A) Higher prevalence of CD130 expression in CD4
+ 
T-cells in 
comparison to CD8
+
 population. (B) In both CD4
+
 and CD8
+
 T-cells, the highest 
frequency of CD130
+
 cells belonged to naïve T-cell subsets and cell differentiation led 
to the rapid decrease in the expression of this receptor. In this line, very low percent of 
EMRA cells expressed CD130. (C) CMV infection did not have any effect on the 
frequency of CD130
+ 
CD4
+
 and CD8
+
 T-cells. (D) Frequency of CD57
+
 CD130
+ 
T-cells 
was very low whilst considerable percent of CD57
-
 T-cells expressed CD130. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                    166 
 
5.2.6 Expression pattern of CD120b (TNFR2) 
Another commonly studied inflammatory cytokine is TNF which interacts with two 
receptors: TNFR1 and TNFR2. TNFR1 was not detectable in T-cell through flow 
cytometry method used in this study. TNFR2 was easily detectable in T-cell subsets. 
Peripheral blood CD4
+
 and CD8
+
 T-cells had similar frequencies of TNFR2 (CD120b) 
expression (medians: 15.60% and 21.00%, respectively) (Figure 5.10A). However, 
opposite to CD130 and uniquely different from other cytokine receptors, TNFR2 
expression increased with T-cell differentiation (Figure5.10B). The lowest CD120b 
expression was detected in naïve T cells (medians: 4.50% and 4.00% in CD4
+
 and CD8
+
 
T-cells, respectively) and this expression gradually increased through CM, EM and 
reached its highest level amongst EMRA cells, with medians of 45.50% and 48.00%  
for CD4
+
 and CD8
+
 T-cells, respectively) (Figure 5.10B). CMV infected individuals 
showed even higher frequency of TNFR2 positive T-cells (Figure 5.10C). This is the 
first report of a possible effect of CMV infection on TNFR2 expression by peripheral 
blood T-cells. Accordingly, CD4
+ 
CD57
+
 and CD8
+ 
CD57
+
 T-cells also had 
significantly higher frequencies of TNFR2 expression in comparison with CD57
-
 T-
cells (Figure 5.10D). Nearly all CD57
+ 
T-cells expressed TNFR2 whilst only 25.15% 
CD4
+ 
CD57
- 
T-cells expressed this receptor, suggesting a close relationship of TNFR2 
expression with late T-cell differentiation. 
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Figure 5.10 CD120b (TNFR2) expression in T-cell subsets of healthy blood donors.   
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Figure 5.10 (continued). (A) In overall, frequency of CD120b
+
 cells was similar in 
CD4
+ 
and CD8
+
 populations. (B) In CD4
+
 and CD8
+
 T-cells, the highest frequency of 
CD120b0
+
 cells belonged to the fully differentiated cells whilst naïve T-cell subsets had 
the lowest frequency of cells expressing CD120b. (C) CMV infection had significant 
effect on CD120b expression. CMV sero-positive blood donors had statistically 
significant higher levels of circulating CD4
+
 CD120b
+
 and CD8
+
 CD120b
+
 cells. (D)  
Nearly all CD57
+
 T-cells expressed CD120b whilst less than half of CD57
-
 T-cells 
expressed this receptor. 
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5.2.7 TNFR2 expression in CMV-specific T-cells 
Increased frequency of TNFR2 positive cells amongst highly differentiated CD57
+
 T- 
cell populations persuaded the analysis of TNFR2 expression in CMV specific CD8
+
 T-
cells of healthy blood donors and stem cell transplant patients. Using CMV-specific 
HLA-tetramers, the peripheral blood lymphocytes from 6 CMV sero-positive healthy 
individuals were studied. This showed that a range of 28-100% of CMV-specific CD8
+
 
T-cells expressed TNFR2. Due to low number of samples, it was not possible to draw 
any conclusion on reason(s) behind this wide range of TNFR2
+ 
expression levels 
amongst CMV-specific T-cells. As described in the chapter 4, longitudinal analysis of 
PBMCs collected from 4 HSCT patients up to 21 months post-transplant, showed that 
TNFR2 was expressed by nearly all CMV-specific CD4
+ 
and CD8
+
 T-cells at all studied 
time points with the exception of one sample (below). During CMV reactivation which 
induces CMV-specific T-cell expansion (inflation phase), the density of TNFR2 
expression at the single cell level increased sharply as demonstrated by the increase in 
the median fluorescence intensity of TNFR2 staining (Figures 4.11 and 5.11). This is 
possibly due to increase in TNFR2 expression in activated or recently activated cells. 
In patient 1, where 92% of CMV specific CD8
+
 T-cells had an EMRA phenotype, 
CD120b was strongly expressed. At the single cell level, the MFI of CD120 expression 
increased during T-cell expansion, and then decreased to reach a new low steady state 
level following CMV viral clearance and contraction of T-cell response (monitored up 
to 6 months post transplant). A sample obtained 21 months post transplant, long after 
the resolution of CMV reactivation, revealed that around 30% of CMV specific CD8
+
 
T-cells still expressed CD120b, but with considerably diminished MFI (Figure 5.11A). 
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CMV-specific CD4
+
 T-cells also expressed CD120b (90%) and alongside this, their 
MFI also changed during its response to CMV with the highest level of MFI observed at 
peak level of cell expansion, and reached its lowest level 21 months post transplant. 
 In patient 2, CMV-specific T-cells expressed CD120b and its expression level 
increased during T-cell expansion and decreased during the contraction phase of T-cell 
response to CMV (Figure 5.11B). CD120b expression in CMV-specific CD8
 + 
T-cells of 
patients 3 and 4 peaked during cell expansion in response to CMV and decreased 
following viral clearance and decrease in T-cell number (Figure 5.11 C-D). Comparison 
of CD120b levels during (median MFI: 7500) and after CMV viraemia (median MFI: 
3200) in these patients showed statistically significant difference in the expression level 
of this cytokine receptor in CMV-specific T-cells (p=0.03) (Figure 5.12). These results 
are in line with the previous data on increased expression of TNFR family members 
following T-cell activation (Table 5.1) (Watts, 2005). 
These results suggest that CD120b up-regulation is a response to T cell activation by 
antigens. We therefore activated PBMCs from healthy blood donors with IL-2 and anti-
CD3 Abs for 3 days, and observed the increased CD120b expression in T-cells (Figure 
5.13). 
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Figure 5.11 CD120b (TNFR2) expression level of CMV-specific T-cells in response to 
CMV viraemia. 
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Figure 5.11 (continued) CD120b expression in CMV-specific CD8
+
 T-cells of 4 HSCT 
patients (A-D) was studied up to 21 months post transplantation. Following viraemia 
and during inflation phase of T-cell response, CD120b expression per cell increased 
rapidly. In 3 patients (A, C, D), CMV–specific T-cell numbers decreased (contraction 
phase) shortly after reduction in CD120b expression level. In overall, there were parallel 
changes in the level of CD120b expression and T-cell frequencies. 
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Figure 5.12 Comparison of CD120b expression level in CMV-specific T-cells  
of HSCT patients. 
 
Significant increase in the density of CD120b expression at the single cell level (as 
detected by MFI) during T-cell response to CMV viraemia. 
 
 
                                                        CD120b 
Figure 5.13 CD120b expression and in vitro T-cell activation. 
T-cell activation with anti-CD3 and IL-2 Abs led to increase in CD120b (TNFR2) 
expression. Top and bottom histograms show CD120b expression (dark area) before 
and after T-cell activation, respectively. 
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5.2.8 Ligation of TNFR2 with a specific agonist induces cell apoptosis 
In order to study what purpose the increased expression of TNFR2 in differentiated cells 
may serve, PBMCs isolated from healthy individuals and HSCT patients were incubated 
with a custom-made TNFR2 agonist, called Flag-TNC-scTNF (143N/145R) (Fischer et 
al., 2011) (Figure 5.14). TNFR2 preferentially binds to membrane TNF (Grell et al., 
1995) and ligation of soluble Flag-TNC scTNF (143N/145R) mimics binding of TNFR2 
to membrane TNF (m TNF). 
 
 
Figure 5.14 Interaction of TNFR2 and its soluble agonist (Flag-TNC- scTNF 
(143N/145R) which mimics TNFR2 binding to membrane TNF (main ligand for 
TNFR2). (Bremer et al., 2013) 
  
Experiments were first conducted to determine the optimal concentration of the ligand. 
PBMC were incubated with the ligand at concentrations of 50, 100 and 200 ng/ml of 
Flag-TNC-scTNF (143N/145R).  T-cell numbers, mainly CD8
+
 CD3
+
 population 
(Figure 5.15) decreased with increasing concentration. CD8
+
 T-cell number dropped 
from 272 cells/µl (un-stimulated cells) to 194/µl, 142/µl and 142/µl following cell 
incubation with 50, 100 and 200 ng/ml of Flag-TNC-scTNF (143N/145R), respectively.  
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Figure 5.15 Titration of Flag-TNC-scTNF (143N/145R) for study of TNFR2 ligation. 
 
In order to determine the working concentration of Flag-TNC-scTNF (143N/145R), 
PBMCs from healthy lab workers were stimulated with 50, 100 and 200 ng/ml of this 
reagent for 3 days. Following incubation and in comparison to the control (cells with no 
added ligand), a reduction in the CD8 T-cell number was observed. The biggest cell loss 
occurred in the presence of either 100 or 200ng/ml of Flag-TNC-scTNF (143N/145R). 
 
Next, PBMCs from 3 healthy CMV sero-positive individuals were incubated with Flag-
TNC-scTNF (143N/145R) in order to analyse cell loss in detail. This experiment was 
repeated 3 times for each individual. Phenotypic analysis showed that in all 3 samples, 
cell loss was restricted to EM/EMRA T-cell subsets (Figure 5.16). As the Figure 5.16 
with data from one of the donors shows, the number of naïve (N) (beige bars) and CM 
subsets (red bars) did not change following cell incubation with different concentrations 
of Flag-TNC-scTNF (143N/145R). On the other hand, this incubation caused up to  
60% and 34%  cell loss in EM (green bars) and EMRA (blue bars) subsets, respectively. 
It has been mentioned in the section 5.2.6 that EM/EMRA T-cell populations were the 
main subsets of T-cells expressing TNFR2 and accordingly, engagement of TNFR2 
with Flag-TNC-scTNF (143N/145R) resulted in the cell loss of only TNFR2
+
 
EM/EMRA cells. Analysis of data obtained from 3 blood donors showed that the 
percentages of cell loss in TNFR2
+
 populations were significantly higher than in 
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TNFR2 negative cells (Figure 5.17). Following TNFR2 ligation, the average reduction 
in the number of CD8
+
 TNFR2
+
 T-cells was 50.33% in comparison to 2.00% in CD8
+
 
TNFR2
-
 T-cells (p=0.001). Also, the median reduction in EM/EMRA TNFR2
+
 T-cell 
subsets was 54.66% in comparison to 6.30% in EM/EMRA TNFR2
-
 cells (p=0.004). 
Therefore, incubation with Flag-TNC-scTNF (143N/145R) specifically targeted 
TNFR2
+
 cells and reduced their frequency. 
The cell loss in CD57
+ 
T-cells was also observed following TNFR2 ligation in 3 healthy 
individuals. The percentages of reduction in CD57
+ 
CD57
+ 
T-cells were 74.41%, 
33.12% and 34.00% in those individuals.  
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Figure 5.16 Effect of TNFR2 ligation on the frequency of CD8
+
 T-cell subsets. 
PBMCs from healthy blood donors were incubated with 50, 100 and 200 ng/ml of 
Flag-TNC-scTNF (143N/145R). The Figure represents data obtained from one of 
donors and shows reduction in the number of EM and EMRA CD8
+
 T-cells following 
TNFR2 ligation whilst the number of naïve (N) and CM subsets did not change. 
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Figure 5.17 TNFR2 ligation and cell loss in TNFR2 positive population. 
Analysis of data from 3 healthy blood donors showed that TNFR2 ligation caused 
statistically significant cell loss only in TNFR2 positive cells. 
 
 
5.2.8A TNFR2 ligation associated with apoptosis  
To investigate the mechanism of cell loss following TNFR2 ligation, TNFR2-PE 
labelled CD8
+
 cells were isolated from a healthy blood donor by using anti-PE labelled 
magnetic beads. The immunomagnetically selected cells were 91% pure for CD8
+ 
TNFR2 pos cells. The negative fraction was used as a control for this experiment. The 
cells in positive and negative fractions were then incubated with Flag-TNC- scTNF 
(143N/145R) for 21 hrs. After the incubation, cells were stained with anti Annexin-V 
antibody and PI (Propium Iodyte) to demonstrate whether cell loss was due to apoptosis 
or necrosis. Indeed, the cells stained positively for Annexin V but with less frequency 
for PI (marker of necrotic death or late apoptosis). The presence of CD8
+
 cells (Annexin 
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V positive and PI negative) confirmed the presence of apoptosis  (Figure 5.18). Table 
5.2 shows the frequencies of necrotic and apoptotic cells in positive (TNFR2 pos) and 
negative fractions (TNFR2 neg) following isolation of TNFR2 positive cells and 
incubation with different concentrations of Flag-TNC-scTNF (143N/145R). The highest 
frequency of stained cells belonged to Annexin V stained cells in the positive fraction 
which ranged form 13.70% to 16.20% depending on the concentration of Flag-TNC- 
scTNF (143N/145R). These frequencies for TNFR2 ligation of the negative fraction 
ranged from 1.90% to 3.90%. In TNFR2 positive fraction, frequencies of necrotic cells 
following TNFR2 ligation was two times less than the percent of apoptotic cells and 
ranged from 2.30% to 3.60%. 
 
 
 
Figure 5.18 Induction of apoptosis following TNFR2 ligation. 
Following separation of TNFR2
+ 
and TNFR2
-
 CD8 T-cells and overnight incubation 
with Flag-TNC-scTNF (143N/145R), CD8
+ 
cells were stained with PI-PE and Annexin 
V-FITC in order to detect necrotic (Annexin V and PI positive) and apoptotic cells 
(Annexin V positive, PI negative). The left and right FACS panel show necrotic and 
apoptotic cells in the CD8
+
 TNFR2
-
 and CD8
+ 
TNFR2
+ 
T-cells, respectively. 
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Table 5.2 Frequencies of apoptotic and necrotic cells following TNFR2 ligation in 
TNFR2 positive and negative fractions of isolated CD8
+ 
cells 
 
Condition % necrotic cells % apoptotic cells 
positive fraction negative faction positive fraction negative faction 
Untreated 2.3* 2.1 4.1 1.3 
Flag-TNC 
50ng/ml 
2.3 3.3 16.2 2.7 
Flag-TNC 
100ng/ml 
2.4 2.2 13.7 3.9 
Flag-TNC 
200ng/ml 
3.6 3.1 15.1 1.9 
* These frequencies are mean frequencies of two experiments. 
 
 
5.2.8B Ligation of TNFR2 in CMV-specific T-cells 
The expression of TNFR2 by CMV-specific T-cells and the increase in its expression at 
single cell level during T-cell response to CMV reactivation have been discussed in this 
chapter and chapter 4). In this regard, it became important to study the possible effects 
of TNFR2 ligation on CMV-specific T-cells. For this study, blood samples from 3 
HSCT patients with high frequency CMV-specific T-cells were used. These samples 
were collected longitudinally and cryopreserved until it was possible to assay them 
simultaneously. Ligation of TNFR2 with Flag-TNC-scTNF (143N/145R) caused a 
decrease in the number of CMV-specific CD8
+
 T-cells in 2 out of 3 patients. In the first 
patient, cells were taken during and after CMV reactivation, which occurred between 
days 46 to 67 post HSCT. The cells were incubated with the TNFR2 ligand which led to 
a similar decrease in the number of CMV-specific T-cells in all samples. The 
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frequencies of cell loss were 66.66%, 58.00%, 58.60% and 70.20% for samples 
collected at: 56, 105, 148 and 252 days post HSCT.  Although the TNFR2 expression 
was at its highest on day 56, there was no difference in ligand-induced cell loss at 
different time points. 
In the second HSCT patient, CMV reactivated from days 21 to 100 and TNFR2 had its 
highest expression level at day 90. Incubation of samples collected during the time of 
active infection from days 56, 70, 98 and 112 with TNFR2 ligand did not cause cell loss 
in CMV-specific T-cells. However, 48.10% and 42.00% ligand-induced cell losses were 
seen in samples taken on days 168 and 420 after resolution of CMV viraemia. These 
experiments showed the possibility of cell death in CMV-specific T-cells following 
TNFR2 ligation. It should be noted that there was no any relation between the 
expression level of TNFR2 and apoptosis of CMV-specific CD8
+
 T-cells following 
TNFR2 ligation. No cell death due to TNFR2 ligation in CMV-specific T-cells was 
observed in the third HSCT patient.  These experiments need further investigations with 
more patient samples in order to precisely clarify the susceptibility of TNFR2 
expressing CMV-specific T-cells to cell death from ligand induction. 
                                                                                                                                                                                                                         
5.3 Discussion 
 
This chapter discussed cytokine receptor expression patterns in CD4
+
 and CD8
+
 T-cell 
subsets in order to explore the role of cytokines in T-cell development. Following 
HSCT, massive cytokine production (cytokine storm) governs the reconstitution and 
homeostasis of lymphocytes. Among highly produced cytokines post HSCT, are IL-6 
and IL-15 (first wave of cytokine storm) and TNF-α, IL-7 and IL-2 (second wave of 
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cytokine storm) (Melenhorst et al., 2012). Therefore, receptors for these cytokines were 
chosen for the study of cytokine receptor expression in whole T-cell population and in 
antigen specific T-cells of healthy individuals and HSCT patients. In healthy 
individuals, the frequencies of IL-2Rα, IL-7Rα, IL-15Rα and IL-6Rα expressing CD4+ 
T-cells were higher than the frequencies of CD8
+ 
T-cells bearing these receptors. 
However, when the analysis was segregated according to differentiation subsets, the 
pattern of cytokine receptor expression was similar for CD4
+
 and CD8
+
 T-cells. 
Importantly, each differentiation subset from healthy steady state lymphocytes had a 
unique pattern of cytokine receptor expression. Of the common gamma chain cytokine 
receptors, IL-7Rα is predominantly expressed by naïve and CM cells with peak 
expression amongst the latter population. IL2Rα was predominantly expressed by CM 
and EM peaking in the EM subset. Both IL-2Rα and IL-7Rα expression were steeply 
reduced in the EMRA subset.  Detection of IL-15Rα in CD4+ and CD8+ T-cells was 
challenging, and only a small fraction of T-cells showed Il-15Rα expression and CD4+ 
EMRA cells had highest frequencies of IL-15Rα positive cells. This may be in keeping 
with the previous reports of IL-15 being important for the maintenance of differentiated 
cells (Chiu et al., 2006), although the true expression may be masked by the trans-
expression of IL-15R. IL-6Rα expression was heavily skewed towards naïve cells with 
minimal expression in the EMRA cells. In contrast, TNFR2 was skewed towards 
EMRA and nearly absent in the naïve population. Further cell differentiation and 
activation caused rapid expression of this cytokine receptor which reached to its highest 
frequency in EM, EMRA and CD57
+ 
T-cells. This suggests that the receptor is 
associated with highly differentiated cells. TNFR2 expression is more selective to 
lymphocytes than TNFR1. Indeed TNFR1, although considered to be ubiquitously 
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expressed, was not detectable on lymphocytes using surface staining with antibodies in 
our experiments, and confirms previous reports (Zola et al., 1995). 
Considerable differences in the T-cell subset distribution were observed between CD4
+
 
and CD8
+
 T-cells. Amongst CD4
+
 T-cells, the most frequent subset was naïve cells 
followed by CM, EM and EMRA subsets, whereas amongst CD8
+
 T-cells, the highest 
frequency belonged to the EMRA subset, followed by naïve, EM and CM cells. This is 
likely to have been skewed by previous CMV exposure. All the studied cytokine 
receptors demonstrated higher expression amongst CD4
+
 than CD8
+ 
cells, except for 
TNFR2 which had highest frequency amongst CD8
+
 EM and EMRA cells. 
 CMV infection is known to induce changes in T-cell subset distribution in the elderly 
in favour of late differentiated cells (EM/EMRA) (Di Benedetto et al, 2015). In our 
CMV sero-positive group, the frequency of EMRA subset of CD4
+
 T-cells (median: 
12.53%) was much higher than in CMV sero-negative individuals (median: 2.12%). 
However, in our data, this difference did not reach to a statistically significant level 
(p=0.091). This is in accordance with the recent finding that CD4
+
 EMRA subset 
presents only in CMV sero-positive individuals and is independent of age (Di Benedetto 
et al, 2015). . This supports our data that CD4
+
 CD57
+
 T-cells were found almost 
exclusively in CMV sero-positive individuals. However, it should be mentioned that the 
healthy individuals in the current study were mostly in their middle age and the impact 
of CMV on T-cell subset distribution is more profound in the elderly.  
CMV infected individuals had higher frequencies of TNFR2 and IL-2Rα positive cells. 
This may represent one of the early impacts of CMV infection on the T-cell 
compartment which leads to the increase in the percent of activated cells. The presented 
data demonstrated that cell activation increased TNFR2 expression. CD57 molecule is 
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expressed by highly differentiated cells, and by many CMV-specific T-cells alongside 
TNFR2,  but not IL-2Rα, IL-7Rα-, IL-6Rα, that are primarily associated with less 
differentiated cells. Taken together, TNFR2 appears to be associated with highly 
differentiated cells.  
To my knowledge, this study was the first to investigate the profile of cytokine receptor 
expression amongst steady state T-cell subsets in a group of healthy adult blood donors 
by flow cytometry. H.Zola and colleagues (1995) published the first paper on cytokine 
receptor expression in PBMCs of adult and cord blood. Their finding showed lower 
frequencies of IL-2Rα, IL-7Rα and TNFR2 positive T-cells in cord blood in comparison 
to adult cells. This is in accordance with the fact that the majority of cord blood T-cells 
are antigen inexperienced cells (Frumento et al., 2013) and cell activation increased the 
frequencies of cells bearing cytokine receptors (Zola et al., 1995). Interestingly, they 
reported that IL-6Rα was the only cytokine receptor which had similar frequency in 
adult and cord blood cells, indicating its utility as another marker for identifying naïve 
cells.  
M.Callan’s group investigated the molecular signatures of CD8+ T-cell subsets and 
focused on cytokine receptor expression pattern at mRNA level (Willinger et al., 2005). 
This group found differential expression of cytokine receptors mRNA that supports the 
present findings. Naïve T-cells were shown to have higher mRNA expression of IL-6R 
and IL-7Rα. Cell activation and differentiation led to increase in the mRNA for 
receptors of Th1 related cytokines including: TNFR2, IL-12RB1, IL-18R and IFNγR1. 
Functional analysis of cytokine receptor signalling pathways showed naïve, CM and 
EM subsets responded to IL-7 through STAT-3 phosphorylation, and TNFR2 signalling 
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induced higher NF-κB expression in EM/EMRA subsets in comparison to the other 
subsets (Willinger et al., 2005).  
Taken together, all these data support the role of common gamma chain receptors and 
their ligands in the differentiation and homeostasis of T-cells. IL-7 is important for cell 
survival and proliferation of naïve and CM cells and IL2 has fundamental role in T-cell 
proliferation. The increased frequency of IL-7Rα in CM subset may explain their 
greater expansion potential than effector memory cells. 
It has been shown that IL-15 induces generation and growth of EMRA cells (Chiu et al., 
2006) which is consistent with the limited observation of increased frequencies of IL-
15Rα within the EMRA subset. In addition it has been documented that IL-15 increases 
expression of cytotoxic molecules, granzyme B and perforin in EMRA subset of CD4
+
 
T-cells (Alonso-Arias et al., 2011).  
TNFR2 expression is limited to certain cell types including lymphocytes and believed, 
sometimes controversially, to mediate a broad range of activities. There are multiple 
reports on the role of TNFR2 in the induction of apoptosis in lymphocytes. Zheng and 
colleagues (1995) were the first to show that TNFR2 ligation was involved in cell 
apoptosis of CD8
+
 T-cells following T-cell receptor activation. Then, it was shown that 
TNFR2 deficient CD8
+
 (and not CD4
+
 T-cells) were resistant to Fas/FasL induced 
apoptosis (Teh et al., 2000). This group also reported that TNFR2 lowered the T-cell 
activation threshold, and as one of the earliest co-stimulatory molecules of TNFR 
family, help T-cell proliferation alongside CD28 for optimal IL-2 production and T-cell 
survival (Kim et al., 2001, 2004 and 2006). Interestingly, in murine models, TNFR2
-/-
 
CD8
+ 
T-cells had superior anti-tumour activity due to their resistance to activation 
induced cell death (Kim et al., 2009). Therefore, TNFR2 has a role in providing initial 
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activation signals for T-cells and is also important for limiting the duration of T-cell 
responses by promoting activation induced cell death (AICD) (Twu et al., 2011). Based 
on the observation made by Teh’s group, a model has been proposed to explain the 
opposing activities of TNFR2. The model proposes that TNFR2 activation leads to the 
consumption of TRAF2 (Figure 5.4) which connects TNFR2 to the apoptosis 
machinery. In conditions with high level of TRAF2 (such as in TNFR2
-/-
 cell lines), 
TNFR1 signalling pathway interacts with this molecule and activates the canonical NF-
κB pathway and induce cell survival (Twu et al., 2011). This model suggests a cross 
talk between TNFR1 and TNFR2 and in addition, TNFR1 can induce a pro-survival 
signal. 
The current study had access to a special ligand for TNFR2 (Flag-TNC-scTNF 
(143N/145R) which mimicked membrane TNF. T-cell culture in the presence of this 
ligand caused cell death through induction of apoptosis.  This research was the first that 
show a link between TNFR2 expression in EM/EMRA subsets of T-cells and induction 
of apoptosis in these highly differentiated subsets of CD8
+
 T-cells. Preliminary 
experiments did not show CD4
+
 T-cell death following TNFR2 ligation, which is likely 
explained by the low frequency of EM/EMRA subsets amongst CD4
+
 and hence 
absence or low frequency of CD4
+
 T-cells expressing TNFR2. The induction of cell 
death through TNFR2 primarily in CD8
+ 
and not CD4
+ 
T-cells has been previously 
reported (Zheng et al., 1995).  
The possible function of TNFR2 molecule in CMV–specific T-cells is not clear but it 
has been reported that in HIV infection CD8
+
 T-cell loss is due to cell apoptosis which 
in turn is mediated by the interaction between mTNF in macrophages and TNFR2 
                                                                    187 
 
expressed by CD8
+
 T-cells. Expression of these cell surface proteins is up-regulated by 
lymphocytes in HIV sero-positive individuals (Herbein et al., 1998).The findings of this 
chapter contribute towards the understanding of the possible role of TNFR2 in inducing 
apoptosis of antigen specific T-cells in humans. In an interesting observation, 
stimulation of TNFR2 specifically killed autoreactive insulin specific CD8
+
 T-cells in 
type I diabetes, as well as autoreactive cells in multiple sclerosis, Graves, and Sjogren’s 
disease (Ban et al., 2008). TNFR2 stimulation did not induce loss of non-autoreactive 
T-cells. Although the authors did not look for TNFR2 expression in the autoreative T-
cells, we speculate whether these autoreactive cells, which are continuously activated in 
autoimmune disorders, express high levels of TNFR2 and go through apoptosis process 
following TNFR2 ligation. In another recent study, TNFR2 expression was shown to be 
the key molecule in the induction of apoptosis in inflammatory T-cells (Punit et al., 
2015; Dube et al., 2015). In a mouse model of inflammatory bowel disease where CD8
+
 
T-cells played an essential role in the immunopathogenesis of IBD, the presence of 
TNFR2 was associated with the mouse’s ability to inhibit the function and expansion of 
these inflammatory cells, whereas the absence of TNFR2 drove the aggressive 
inflammation by CD8
+
 T-cells. Therefore, approaches that can increase the expression 
of TNFR2 or agents such as ligands or antibodies that can interact with TNFR2 
expressing cells may provide new ways of treating inflammatory conditions caused by 
CD8
+
 T-cells and their Th1 related cytokines. 
 In this work, a significant increase in the levels of TNFR2 in CMV-specific T-cells 
following CMV viraemia was observed. This is in line with well documented increase 
in the levels of other TNFR family molecules after cell activation (Table 5.1). Although 
this study did not define the physiological role of TNFR2 in T-cell activation, it was 
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demonstrated how TNFR2 engagement could induce apoptosis in EM/EMRA subsets of 
CD8
+
 T-cells as well as CMV-specific CD8
+
 T-cells. Pathophysiologically, cell death 
due to TNFR2 ligation could be a putative mechanism for reducing the number of 
lymphocytes following massive cell expansion in response to CMV reactivation, thus 
limiting CTL toxicity. Expansion of inflationary T-cells with late differentiated 
phenotype (CCR7
 - 
CD45RA
-
 CD27
-/+
 CD28
-/+
 IL-7R
-
) is one of the main features of the 
immune response to CMV reactivation. These cells undergo apoptosis as part of their 
rapid turnover (Klenerman and Dunbar, 2008). The results of this chapter suggest that 
TNFR2 may be important for the homeostasis of expanded T-cells and controls the 
inflation of antigen-specific T-cells through induction of apoptosis. 
The number of inflammatory diseases that CMV infection might exacerbate their 
inflammatory conditions,  grows continuously (chapter 1) (Halenius and Hengel, 2014). 
A common feature of several inflammatory diseases such as IBD, RA and CVID, is the 
accumulation of late differentiated T-cells (EM/EMRA subsets). Some of these T-cells 
are CMV-specific (Domènech et al., 2008; Rothe et al., 2015; Marashi at al., 2011). 
Deficiency in TNFR2 signalling pathway has been described in some of inflammatory 
diseases (Faustman and Davis, 2013). It is possible that the accumulation of terminally 
differentiated T-cells in these diseases may be due patly to dysfunctional TNFR2 
signalling and consequently, disruption of cell apoptosis. Molecules such as Flag-TNC-
scTNF (143N/145R) that targets TNFR2 or its signalling pathway, could potentially be 
used for therapeutic purposes in Th1 mediated inflammatory conditions to control these 
responses. In conclusion, study of cytokine receptor expression pattern may become 
useful in clarifying physiological properties of T-cell subsets in more detail and apply 
the relevant information in management of broad range of human diseases. 
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CMV disease resulting from the progression of CMV reactivation is a major cause of 
infection-related morbidity and mortality in the HSCT setting (Ljungman et al., 2011). 
The probability of CMV reactivation is approximately 85% in the reduced intensity 
conditioning allogeneic HSCT patients with ‘high risk CMV serology’ (D/R CMV+/+ 
and -/+) (Chakrabarti et al., 2002). CMV viraemia is the consequence of the 
immunosuppression that these patients receive as part of transplant conditioning 
chemoimmunotherapy, and of the delayed immune reconstitution following 
transplantation. T-cell immunity is essential for controlling CMV reactivation and 
recovery of CMV-specific T-cells in the early post-transplant period abrogates the 
development of CMV-related disease. In the current study, most of patients underwent 
reduced intensity conditioning HSCT. With the use of reduced-intensity conditioning 
transplant regimens which incorporate Alemtuzumab, the probabilities of multiple 
reactivations before and after 100 days post transplant are 53.6% and 46.6%, 
respectively (Chakrabarti et al., 2002). Antiviral drug therapy is highly effective in 
controlling CMV viraemia in the majority of patients, but its prolonged use in patients 
with long period of viraemia or recurrent reactivations is associated with renal toxicity 
and myelosuppression. This leads to increased morbidity and management complexity 
of these patients. There is also evidence that first line antivirals such as ganciclovir and 
foscarnet may not be effective in the complete absence of CMV-specific T-cells (D. 
Lewis et al., submitted paper to BMT, 2016). There is therefore an unmet need for more 
effective and less toxic therapy for these more complex cases. Amongst different 
strategies for controlling CMV reactivation, adoptive cellular therapy with CMV-
specific T-cells aims to restore the CMV-specific T-cell immunity in HSCT patients. To 
date, there are 11 published reports on phase I/II single armed clinical trials of cellular 
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therapy with CMV-specific CD4
+
 and/or CD8
+
 T-cells (chapter 1). These studies have 
demonstrated safety and provided evidence of efficacy for CMV-specific cellular 
therapy.  
This PhD project comprised three experimental chapters. In chapter 3, CMV-specific T-cell 
responses were analysed following the randomised controlled phase II adoptive cellular 
therapy (ACE-ASPECT trial) of T-cell depleted allogeneic HSCT patients. This trial was 
one of the first randomised controlled cell therapy for CMV-specific T-cells and the 
primary end point was reconstitution of CMV-specific CD8
+
 T-cells rather than viral 
control as this is covered by another ongoing trial. The primary end point was the recovery 
of CMV-specific CD8+ T-cells to 1x104 cells/ml of peripheral blood by 2 months post 
cellular therapy. Adoptive CMV-specific CD8
+
 T-cell immunotherapy led to the rapid 
reconstitution of CMV-specific CD8
+
 T-cells within 2 months post-ACT in 8 out of 17 
patients (47.1%). In these patients, the mean frequency of CMV-specific CD8
+
 T-cells 
within 2 months post-ACT was 35x10
3 
cells/ml, above the trial end point level of 
1x10
4
/ml. The trial end point was achieved in 37% of the control group who were on the 
best available anti-viral drugs. Further analysis of the infused cell dose and serum 
Alemtuzumab levels by the clinical trial sponsor identified these as the two main factors 
influencing the reconstitution of immunotherapeutic cells. The failure to achieve the 
pre-specified trial end point (CMV- specific T-cell level) was related to the low number 
of infused cells (below 1x10
3
/kg) and high levels of Alemtuzumab (>0.15mg/ml). There 
were no statistically significant differences between the trial arms with regard to the 
frequency of patients who achieved the trial end point level and to the absolute number 
of CMV-specific CD8
+
 T-cells at their peak. However, the rate of cell expansion shortly 
after cell infusion was considerably higher in the ACT group. At one month post-ACT, 
a greater cell expansion from baseline to peak was observed in the ACT group. These 
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data clearly showed that early cell expansion was more rapid in the ACT arm. 
Interestingly, T-cell expansion was not restricted to the specificity of the infused cells. 
Non-infused CMV-specific CD8
+
 T-cells and CMV-specific CD4
+
 T-cells also 
expanded alongside the whole CD4
+
 and CD8
+
 populations in the ACT group. This 
thesis is the first to report the boosting and supportive effects of the therapeutic cells in 
the reconstitution of non-infused CD4
+
 and CD8
+
 T-cells following adoptive cellular 
therapy. Although the trial’s aim was not to explore the possible factors involved in the 
broader expansion of non-infused T-cells in the ACT group, it is reasonable to speculate 
on a number of possible mechanisms. 
One explanation for the expansion of non-infused cells may relate to antigen spreading, 
which has been reported in other immunotherapy trials such as in vaccination of 
melanoma antigens which generated T-cells against non-vaccine tumour antigens and 
contributed to the regression of melanoma metastases (Corbiere et al., 2011).  
CD8
+
 T-cells have also been found to support the proliferation of CD4
+
 T-cells in vitro 
through CD40 Ligand on activated CD8
+
 T-cells (Xydia et al., 2011; Romagnoli et. al, 
2013). It is possible to speculate that a similar scenario existed in vivo where the infused 
CMV-specific CD8
+
 T-cells helped the CD4
+
 T-cells response within the first month 
post ACT which led to the greater fold increase in the number of CD4
+
 T-cells in 
comparison to the control group.  
Cytokines and co-stimulatory molecules in the presence of CMV-derived antigens 
govern T-cell reconstitution post-HSCT. Following HSCT, high levels of cytokines 
such as IL-7, IL-15 and TNF-α are present (William and Gress, 2008). It is possible that 
because of the low number of CMV-specific T-cells at the beginning of the immune 
response in the control patients, other cells out-competed them in the consumption of 
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cytokines, whereas in the therapeutic arm, the larger number of infused CMV-specific 
T-cells dominated the consumption of cytokines and expanded rapidly.  
Finally, it is possible that there were contaminating cells in the selected CMV-specific 
CD8
+
 T-cell population that expanded following cell therapy. It should be mentioned 
that the purity of isolated CMV-specific T-cells was considerably less than 100% and 
therefore, contaminated cells might have contributed in the greater cell expansion 
observed in the ACT group.   
The rapid cell expansion of CMV-specific T-cells within the first month after cell 
therapy was followed by a subsequent  retraction in cell number. This phenomenon 
differed from the reconstitution pattern in the control arm. The reason for this is not 
clear. T-regulatory cells have important role in the control of cell reconstitution post-
HSCT (William and Gress, 2008). Alongside the global cellular reconstitution, the 
generation of T-reg may have also been quicker in the ACT arm, which in turn induced 
a sharp retraction phase.   
At the time of writing this thesis, there were no further data regarding the secondary 
objectives of ACE-ASPECT trial including evaluation of the potential clinical benefit of 
cell therapy as measured by reduction in CMV, anti-viral drug treatment and number of 
in-patient days. However, the incidence of new onset grade II-IV GVHD after therapy 
did not differ significantly between the cellular therapy and control arms (17.6% vs 
27.3% respectively) (Chen et al., 2014). Taken together, this first randomized trial of 
CMV- specific T-cell therapy post-HSCT proved that cell therapy was safe and resulted 
in the earlier and greater expansion of CMV-specific T cells. Further investigation is 
underway to determine if the observed increase in CMV-specific cells translates to 
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clinical benefit. Some of the results obtained in ACE-ASPECT trial published as an 
abstract (Chen et al., 2014). 
The observation of concomitant CMV-specific CD4
+
 and CD8
+
 T-cells reconstitution 
warranted a more detailed analysis of CMV-specific CD4
+
 T-cells through the usage of 
a novel HLA-class II restricted tetramer. Chapter 4 presented the results of first direct 
visualization of CMV-specific CD4
+
 T-cells in human responses to CMV infection. In a 
cohort of non-trial HSCT patients, co-expansion of CMV-specific T-cells was observed 
and it was possible to directly quantify CMV-specific CD4
+
 T-cells conferring 
protection against CMV reactivation. In line with some of the previously published data 
using indirect methods of CMV-specific CD4
+
 T-cell detection (Lilleri et al., 2008), the 
minimum level of CD4
+
 cells required for clearance of CMV viraemia, determined as 
0.7x10
3
 cells/ml.  The frequency of cells at levels lower than this resulted in multiple 
episodes of CMV reactivations. In this chapter, the frequency of CMV-specific CD8
+
 T-
cells was also studied. Despite having a relatively small cohort of patients, analysis of 
the data on CMV-specific CD8
+
 T-cell numbers from 29 patients clearly showed the 
potential of HLA tetramer/multimers to identify patients who are able to control CMV 
viraemia versus those who cannot and end up suffering from multiple episodes of 
viraemia. These data showed that HLA-tetramers could be used as a clinical diagnostic 
assay where a CMV-specific CD8
+
 T-cell level below 7.22x10
3
/ml after resolution of 
first CMV reactivation can predict recurrent CMV reactivations with sensitivity of 
85.46% and specificity of 75.00%. Based on the previous data from the non-trial 
patients, this suggests that patients with more than 7.22x10
3
/ml CMV-specific T–cells 
would probably not have benefited from ACT. Therefore, in future trials, it would be 
important to stratify patients into high and low risk groups according to the level of 
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CMV-specific T-cells, and ACT offered only to those who have CMV-specific T-cells 
below the threshold level and thus at high risk of multiple CMV reactivations. The 
majority of patients develop CMV reactivation within 28 days of transplant. However, 
only half will go on to develop recurrent reactivations. This group of patients have low 
recovery of CMV-specific T-cells following the first episode of viraemia, and are at 
high risk of transplant-related morbidity. This group of patients are the ones most at 
need of nontoxic antiviral therapy, and adoptive cell therapy should in the future be 
targeted at this group. Risk-assessment of these patients based on immune monitoring of 
CMV-specific T-cell levels would help to select the most appropriate patients for ACT. 
 
 
The study identified CD57 as a possible surrogate marker for CMV-specific CD4
+ 
T-
cells. CD4
+
 CD57
+ 
T-cells presented only in CMV-seropositive individuals and 
expanded in response to CMV reactivation in parallel with class II tetramer-staining 
CMV-specific CD4
+
 T and CD8
+
 T-cells. As such they were found to be as informative 
as tetramers in identifying patients with recurrent CMV reactivation, and thus be used 
as a biomarker for risk stratifying patients. As a diagnostic assay, CD4
+ 
CD57
+
 T-cell  
level lower than 5x10
3
/ml can identify patients suffering from multiple reactivations 
1
st
 CMV 
reactivation 
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with 85% sensitivity and 85% specificity. For a diagnostic assay, these are good 
discriminatory values. Importantly, CD4
+ 
CD57
+
 T-cell quantification, unlike tetramers, 
is independent of HLA restrictions. Therefore, CD57 expression could potentially serve 
as universal biomarker usable in assessment of CMV immunity in all patients. Further 
prospective studies will be required to validate its clinical utility.  
The use of HLA-class I and II tetramers in this thesis permitted the immunophenotyping 
of antigen specific T-cells for additional information on their quality and function.  
Of interest, CD4
+
 T-cells were found to have an earlier differentiation phenotype 
(CCR7
- 
CD45RA
-
, EM phenotype) than CMV-specific CD8
+ 
T-cells which had mostly a 
highly differentiated ‘exhausted‘ phenotype (CCR7- CD45RA+ , EMRA phenotype). In 
keeping with this, IL-7Rα (CD127) was down regulated in CMV-specific CD8+ T-cells, 
though a considerable proportion of CMV-specific CD4
+
 T-cells did express it, possibly 
indicating their better  proliferative and survival potential over the CD8
+
 counterparts.  
T-bet was expressed by the majority of CMV-specific CD4
+
 and CD8
+
 T-cells, 
demonstrating the Th1 profile. Additionally, up to one third of CMV-specific CD4
+
 T-
cells expressed both perforin and granzyme B, supporting a cytotoxic role for this 
subgroup of CMV-specific CD4
+
 T-cells (Casazza et al., 2006). The frequency of these 
cytotoxic cells were significantly higher in the CMV-specific CD4
+
 T-cells expressing 
CD57. This relation between CD57 expression and cytotoxic activity has also been 
described for CD8 population (Chattopadhyay et al., 2009). 
As the reconstitution of T-cells following HSCT is dependent on exogenous factors 
such as cytokines (Melenhorst et al., 2012), it is important to examine the role of 
cytokine receptors on T cells, as their expression or non-expression provide an 
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indication of their function and responsiveness to the cognate cytokines, whether in 
terms of proliferation, apoptosis or effector function.   
In this thesis, first, the baseline expression of cytokine receptors to IL-2, IL-7, IL-15, 
TNFR2 and IL-6, were analyzed in T-cells from healthy individuals (data presented in 
chapter 5). Distinct and stable patterns of cytokine receptor expression were found in 
each differentiation subset. Of interest, IL-7Rα was found to be expressed 
predominantly by naïve and early differentiated cells as previously demonstrated, 
whereas in a direct contrast, TNFR2 was uniquely found in late differentiated cells.  
Then, in HSCT patients (Chapter 4), the cytokines receptors on reconstituting CMV-
specific T-cells were investigated in greater detail. In these patients, CMV-specific 
CD8
+ 
T-cells showed low IL-2Rα, IL-7Rα expression and high levels of CD57, in 
keeping with highly differentiated T cells. A high proportion of cells also expressed 
TNFR2, but importantly there was also a rapid increase in the density (MFI) of TNFR2 
expression at the single cell level during CMV reactivation. Following   in vitro ligation 
of these cells with TNFR2 ligand, they went through apoptosis, suggesting that the 
increased TNFR2 expression by expanded cells in response to CMV reactivation could 
be a mechanism by which expanded and activated cells deflate following resolution of 
the infection, a phenomenon often referred to as Activation-induced Cell death (AICD). 
The importance of TNFR2 function in the contraction of activated T-cells will need 
further research, not only in the HSCT setting but also in other conditions where there is 
a chronic immune stimulation. In this regard, TNFR2 ligation might be important in the 
apoptosis of CMV-specific and other Th1 cells (with EM/EMRA phenotype) present in 
many inflammatory diseases like type I diabetes and IBD (Faustman and Davis, 2013; 
Punit et al., 2015).  
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In summary, studying cytokine receptor expression can help identify fundamental 
aspects of cytokine function involved in the expansion, survival and contraction of T-
cell subsets, whilst providing critical information on the physiological and pathological 
properties of T-cells in disease states. The current study suggests a potential role of 
TNFR2 in the termination of terminal effector T-cells (CCR7
-
 CD45RA
-
 CD57
+
 IL-
7Rα- TNFR2+) following immune response to antigens (following figure). 
Different phases of an immune response to a virus which leads to the T-cell memory 
generation and effector T-cell retraction (from Kaech and Cui, 2012). Effector (IL-7Rα 
low
, BCL-2 
low
) and memory precursor T-cells (IL-7Rα high, BCL-2 high) are shown as 
blue and red cells, respectively. Populations in other colours are T-cells with 
intermediate differentiation state with mixed phenotypes.  
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